[gpt3]
Your sole task is to transform the raw text provided in
Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233–54.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
Van der Jeught K, Xu H-C, Li Y-J, Lu X-B, Ji G. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol. 2018;24(34):3834.
Shinji S, Yamada T, Matsuda A, Sonoda H, Ohta R, Iwai T, et al. Recent advances in the treatment of colorectal cancer: a review. J Nippon Med Sch. 2022;89(3):246–54.
Haider T, Pandey V, Banjare N, Gupta PN, Soni V. Drug resistance in cancer: mechanisms and tackling strategies. Pharmacol Rep. 2020;72(5):1125–51.
Sheikhnia F, Maghsoudi H, Majidinia M. The critical function of MicroRNAs in developing resistance against 5- fluorouracil in cancer cells. Mini Rev Med Chem. 2024;24(6):601–17.
Zhou J, Ji Q, Li Q. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. J Exp Clin Cancer Res. 2021;40:1–17.
Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016;8(1):57–84.
Sharifi-Azad M, Fathi M, Cho WC, Barzegari A, Dadashi H, Dadashpour M, et al. Recent advances in targeted drug delivery systems for resistant colorectal cancer. Cancer Cell Int. 2022;22(1):196.
Khosravi M, Poursaleh A, Ghasempour G, Farhad S, Najafi M. The effects of oxidative stress on the development of atherosclerosis. Biol Chem. 2019;400(6):711–32.
Basak D, Uddin MN, Hancock J. The role of oxidative stress and its counteractive utility in colorectal cancer (CRC). Cancers. 2020;12(11):3336.
Yang L, Fang C, Zhang R, Zhou S. Prognostic value of oxidative stress-related genes in colorectal cancer and its correlation with tumor immunity. BMC Genomics. 2024;25(1):8.
Briffa R, Langdon SP, Grech G, Harrison DJ. Acquired and intrinsic resistance to colorectal cancer treatment. Colorectal Cancer-Diagnosis. Screening and Management: Intech Open London; 2018. pp. 57–81.
To KK, Wu M, Tong CW, Yan W. Drug transporters in the development of multidrug resistance in colorectal cancer. Drug resistance in colorectal cancer: molecular mechanisms and therapeutic strategies. Elsevier; 2020. pp. 35–55.
Maali A, Sarfi M, Mirzakhani M, Goodarzi G, Maghsoudi H, Maniati M, et al. Peaceful existence of tumor cells with their non-malignant neighbors: the trade of tumor cells with tumor microenvironment. Curr Chem Biol. 2020;14(4):228–39.
Zafari N, Khosravi F, Rezaee Z, Esfandyari S, Bahiraei M, Bahramy A, et al. The role of the tumor microenvironment in colorectal cancer and the potential therapeutic approaches. J Clin Lab Anal. 2022;36(8): e24585.
Chen Y, Zheng X, Wu C. The role of the tumor microenvironment and treatment strategies in colorectal cancer. Front Immunol. 2021;12:792691.
Liu K, Gao L, Ma X, Huang J-J, Chen J, Zeng L, et al. Long non-coding RNAs regulate drug resistance in cancer. Mol Cancer. 2020;19(1):1–13.
Sheikhnia F, Fazilat A, Rashidi V, Azizzadeh B, Mohammadi M, Maghsoudi H, et al. Exploring the therapeutic potential of Quercetin in cancer treatment: targeting long non-coding RNAs. Pathology. 2024;260: 155374.
Mohammadi F, Nejatollahi M, Sheikhnia F, Ebrahimi Y, Mohammadi M, Rashidi V, et al. MiRNAs: main players of cancer drug resistance target ABC transporters. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2025. https://doi.org/10.1007/s00210-024-03719-y.
Alizadeh-Fanalou S, Khosravi M, Alian F, Rokhsartalb-Azar S, Nazarizadeh A, Karimi-Dehkordi M, et al. Dual role of microRNA-1297 in the suppression and progression of human malignancies. Biomed Pharmacother. 2021;141: 111863.
Tajik F, Alian F, Yousefi M, Azadfallah A, Hoseini A, Mohammadi F, et al. MicroRNA-372 acts as a double-edged sword in human cancers. Heliyon. 2023;9(5):e15991. https://doi.org/10.1016/j.heliyon.2023.e15991.
Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669–85.
Yau TO. Precision treatment in colorectal cancer: now and the future. JGH Open. 2019;3(5):361–9.
McNair AG, Whistance RN, Forsythe RO, Macefield R, Rees J, Pullyblank AM, et al. Core outcomes for colorectal cancer surgery: a consensus study. PLoS Med. 2016;13(8): e1002071.
Vennix S, Bakker OJ, Prins HA, Lips DJ. Re-interventions following laparoscopic surgery for colorectal cancer: data from 818 individuals from the Dutch surgical colorectal audit. Journal of Laparoendoscopic & Advanced Surgical Techniques. 2014;24(11):751–5.
Ammerata G, Filippo R, Laface C, Memeo R, Solaini L, Cavaliere D, et al. Hyperthermic intraperitoneal chemotherapy and colorectal cancer: from physiology to surgery. World J Clin Cases. 2022;10(30):10852.
McQuade M, Stojanovska R, Bornstein VC, Nurgali J. Colorectal cancer chemotherapy: the evolution of treatment and new approaches. Curr Med Chem. 2017;24(15):1537–57.
Xie Y-H, Chen Y-X, Fang J-Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5(1): 22.
Sakata S, Larson DW. Targeted therapy for colorectal cancer. Surg Oncol Clin N Am. 2022;31(2):255–64.
Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–75.
Golshani G, Zhang Y. Advances in immunotherapy for colorectal cancer: a review. Therapeutic Adv Gastroenterol. 2020;13:1756284820917527.
Boushey R, Williams LJ, Weiser M, Chen W. Management of anastomotic complications of colorectal surgery. 2017.
Köhne C. Current stages of adjuvant treatment of colon cancer. Ann Oncol. 2012;23:x71–6.
Sheikhnia F, Rashidi V, Maghsoudi H, Majidinia M. Potential anticancer properties and mechanisms of thymoquinone in colorectal cancer. Cancer Cell Int. 2023;23(1): 320.
Hossain MS, Karuniawati H, Jairoun AA, Urbi Z, Ooi DJ, John A, et al. Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers. 2022;14(7):1732.
Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2(2):141.
Fu J, Xu Y, Yang Y, Liu Y, Ma L, Zhang Y. Aspirin suppresses chemoresistance and enhances antitumor activity of 5-Fu in 5-Fu-resistant colorectal cancer by abolishing 5-Fu-induced NF-κB activation. Sci Rep. 2019;9(1):16937.
Wawro ME, Sobierajska K, Ciszewski WM, Niewiarowska J. Nonsteroidal anti-inflammatory drugs prevent vincristine-dependent cancer-associated fibroblasts formation. Int J Mol Sci. 2019;20(8): 1941.
Esra’a IK, Ismail WW, Mhaidat NM, Alqudah MA. Effect of metformin on irinotecan-induced cell cycle arrest in colorectal cancer cell lines HCT116 and SW480. Int J Health Sci. 2021;15(5):34.
Zhang P, Zhao S, Lu X, Shi Z, Liu H, Zhu B. Metformin enhances the sensitivity of colorectal cancer cells to cisplatin through ROS-mediated PI3K/Akt signaling pathway. Gene. 2020;745:144623.
Maghsoudi H, Sheikhnia F, Sitarek P, Hajmalek N, Hassani S, Rashidi V, et al. The potential preventive and therapeutic roles of NSAIDs in prostate cancer. Cancers. 2023;15(22):5435.
Hassani S, Maghsoudi H, Fattahi F, Malekinejad F, Hajmalek N, Sheikhnia F, et al. Flavonoids nanostructures promising therapeutic efficiencies in colorectal cancer. Int J Biol Macromol. 2023;241: 124508.
Wu S, Wen F, Li Y, Gao X, He S, Liu M, et al. PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma. Tumor Biol. 2016;37:8799–809.
Xia Z, Zhang L, Chen Q, Royal C, Yu Z, Liu Z, et al. Stable reversal of multidrug resistance in colon cancer cells by RNA interference targeting the MDR1 gene. Mol Med Rep. 2009;2(4):579–84.
Ma SC, Zhang JQ, Yan TH, Miao MX, Cao YM, Cao YB, et al. Novel strategies to reverse chemoresistance in colorectal cancer. Cancer Med. 2023;12(10):11073–96.
Singh D, Khan MA, Siddique HR. Emerging role of long non-coding RNAs in cancer chemoresistance: unravelling the multifaceted role and prospective therapeutic targeting. Mol Biol Rep. 2020;47(7):5569–85.
Mahato RK, Bhattacharya S, Khullar N, Sidhu IS, Reddy PH, Bhatti GK, et al. Targeting long non-coding RNAs in cancer therapy using CRISPR-Cas9 technology: a novel paradigm for precision oncology. J Biotechnol. 2024;379:98–119. https://doi.org/10.1016/j.jbiotec.2023.12.003.
Wang X, Zhao X, Zhong Y, Shen J, An W. Biomimetic exosomes: a new generation of drug delivery system. Front Bioeng Biotechnol. 2022;10:865682.
Chabria Y, Duffy GP, Lowery AJ, Dwyer RM. Hydrogels: 3d drug delivery systems for nanoparticles and extracellular vesicles. Biomedicines. 2021;9(11): 1694.
Sui H, Zhou S, Wang Y, Liu X, Zhou L, Yin P, et al. COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer. Carcinogenesis. 2011;32(5):667–75.
Kim S-H, Kim S-C, Ku J-L. Metformin increases chemo-sensitivity via gene downregulation encoding DNA replication proteins in 5-Fu resistant colorectal cancer cells. Oncotarget. 2017;8(34):56546.
Zhang C, Wang Y. Metformin attenuates cells stemness and epithelial–mesenchymal transition in colorectal cancer cells by inhibiting the Wnt3a/β–catenin pathway. Mol Med Rep. 2019;19(2):1203–9.
Liang Y, Hou L, Li L, Li L, Zhu L, Wang Y, et al. Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway. Oncogene. 2020;39(2):469–85.
Liang Y, Zhu D, Hou L, Wang Y, Huang X, Zhou C, et al. MiR-107 confers chemoresistance to colorectal cancer by targeting calcium-binding protein 39. Br J Cancer. 2020;122(5):705–14.
Yang Y, Ma L, Xu Y, Liu Y, Li W, Cai J, et al. Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins. Cell Death Dis. 2020;11(6):477.
Jiang L, Wang P, Sun Y-J, Wu Y-J. Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway. J Exp Clin Cancer Res. 2019;38(1):1–18.
Li S, Tian J, Zhang H, Zhou S, Wang X, Zhang L, et al. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer. Apoptosis. 2018;23:356–74.
Sakatani A, Sonohara F, Goel A. Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells. Carcinogenesis. 2019;40(3):422–31.
Mosca L, Pagano M, Borzacchiello L, Mele L, Russo A, Russo G, et al. S-adenosylmethionine increases the sensitivity of human colorectal cancer cells to 5-fluorouracil by inhibiting P-glycoprotein expression and NF-κB activation. Int J Mol Sci. 2021;22(17): 9286.
Pires AS, Marques CR, Encarnação JC, Abrantes AM, Marques IA, Laranjo M, et al. Ascorbic acid chemosensitizes colorectal cancer cells and synergistically inhibits tumor growth. Front Physiol. 2018;9:911.
Liu G, Hu X, Chakrabarty S. Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor‐dependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5‐FU. Int J Cancer. 2010;126(3):631–9.
Taghizadeh F, Tang MJ, Tai IT. Synergism between vitamin D and secreted protein acidic and rich in cysteine–induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy. Mol Cancer Ther. 2007;6(1):309–17.
Wang Z, Sun X, Feng Y, Wang Y, Zhang L, Wang Y, et al. Dihydromyricetin reverses MRP2-induced multidrug resistance by preventing NF-κB-Nrf2 signaling in colorectal cancer cell. Phytomedicine. 2021;82:153414.
Fan Y, Abulimiti P, Zhang H, Zhou Y, Zhu L. Mechanism of reversal of multidrug resistance by curcumin in human colorectal cancer cell line HCT-8/5-FU. Genet Mol Res. 2017;16(2): 16029414.
Lu Y, Zhang R, Zhang X, Zhang B, Yao Q. Curcumin may reverse 5-fluorouracil resistance on colonic cancer cells by regulating TET1-NKD-Wnt signal pathway to inhibit the EMT progress. Biomed Pharmacother. 2020;129: 110381.
Buhrmann C, Shayan P, Kraehe P, Popper B, Goel A, Shakibaei M. Resveratrol induces chemosensitization to 5-fluorouracil through up-regulation of intercellular junctions, epithelial-to-mesenchymal transition and apoptosis in colorectal cancer. Biochem Pharmacol. 2015;98(1):51–68.
Zhang R, Pan T, Xiang Y, Zhang M, Feng J, Liu S, et al. Β-elemene reverses the resistance of p53-deficient colorectal cancer cells to 5-fluorouracil by inducing pro-death autophagy and cyclin D3-dependent cycle arrest. Front Bioeng Biotechnol. 2020;8:378.
Li T, Si W, Zhu J, Yin L, Zhong C. Emodin reverses 5-Fu resistance in human colorectal cancer via downregulation of PI3K/Akt signaling pathway. Am J Transl Res. 2020;12(5):1851.
Hu T, Wang L, Zhang L, Lu L, Shen J, Chan RL, et al. Sensitivity of apoptosis-resistant colon cancer cells to Tanshinones is mediated by autophagic cell death and p53-independent cytotoxicity. Phytomedicine. 2015;22(5):536–44.
Zhang Y, Ge T, Xiang P, Zhou J, Tang S, Mao H, et al. Tanshinone IIA reverses oxaliplatin resistance in human colorectal cancer via Inhibition of erk/akt signaling pathway. OncoTargets Therapy. 2019;12:9725.
Lin S, Lei K, Du W, Yang L, Shi H, Gao Y, et al. Enhancement of oxaliplatin sensitivity in human colorectal cancer by hypericin mediated photodynamic therapy via ROS-related mechanism. Int J Biochem Cell Biol. 2016;71:24–34.
Sui H, Zhou LH, Zhang YL, Huang JP, Liu X, Ji Q, et al. Evodiamine suppresses ABCG2 mediated drug resistance by inhibiting p50/p65 NF-κB pathway in colorectal cancer. J Cell Biochem. 2016;117(6):1471–81.
Liu GW, Liu YH, Jiang GS, Ren WD. The reversal effect of ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism. Hum Cell. 2018;31(3):189–98.
Wang Z, Zhan Y, Xu J, Wang Y, Sun M, Chen J, et al. β-Sitosterol reverses multidrug resistance via BCRP suppression by inhibiting the p53-MDM2 interaction in colorectal cancer. J Agric Food Chem. 2020;68(12):3850–8.
Guo P, Wang S, Liang W, Wang W, Wang H, Zhao M, et al. Salvianolic acid B reverses multidrug resistance in HCT–8/VCR human colorectal cancer cells by increasing ROS levels. Mol Med Rep. 2017;15(2):724–30.
Al Bitar S, El-Sabban M, Doughan S, Abou-Kheir W. Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: updates and beyond. World J Gastroenterol. 2023;29(9):1395.
Ahmadi D, Zarei M, Rahimi M, Khazaie M, Asemi Z, Mir SM, et al. Preparation and in-vitro evaluation of pH-responsive cationic cyclodextrin coated magnetic nanoparticles for delivery of methotrexate to the Saos-2 bone cancer cells. J Drug Deliv Sci Technol. 2020;57:101584.
Kist M, Vucic D. Cell death pathways: intricate connections and disease implications. EMBO J. 2021;40(5): e106700.
Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011;30:1–14.
Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B, et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 2012;45(6):487–98.
Wang H, Liu H, Zheng Z-M, Zhang K-B, Wang T-P, Sribastav S-S, et al. Role of death receptor, mitochondrial and endoplasmic reticulum pathways in different stages of degenerative human lumbar disc. Apoptosis. 2011;16:990–1003.
Cavalcante GC, Schaan AP, Cabral GF, Santana-da-Silva MN, Pinto P, Vidal AF, et al. A cell’s fate: an overview of the molecular biology and genetics of apoptosis. Int J Mol Sci. 2019;20(17):4133.
Neophytou CM, Trougakos IP, Erin N, Papageorgis P. Apoptosis deregulation and the development of cancer multi-drug resistance. Cancers (Basel). 2021;13(17):4363.
Berindan-Neagoe I, Braicu C, Pileczki V, Petric RC, Miron N, Balacescu O, et al. 5-Fluorouracil potentiates the anti-cancer effect of oxaliplatin on Colo320 colorectal adenocarcinoma cells. J Gastrointestin Liver Dis. 2013;22(1):37–43.
Silke J, Vince J. IAPs and cell death. In: Nagata S, Nakano H, editor. Apoptotic and non-apoptotic cell death. Current topics in microbiology and immunology, vol. 403. Springer, Cham; 2016. https://doi.org/10.1007/82_2016_507.
Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov. 2012;11(2):109–24.
Meyer M. Pre-Clinical application of inhibitor of apoptosis protein (IAP) antagonists in colorectal cancer (CRC). Royal College of Surgeons in Ireland; 2022.
Knoll G, Ehrenschwender M. The non-peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis. FEBS Open Bio. 2021;11(3):714–23.
Enoch T, Norbury C. Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. Trends Biochem Sci. 1995;20(10):426–30.
Yao J, Huang A, Zheng X, Liu T, Lin Z, Zhang S, et al. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM–CHK2–P53 pathway. J Cancer Res Clin Oncol. 2017;143:419–31.
Xie Q, Wu M-Y, Zhang D-X, Yang Y-M, Wang B-S, Zhang J, et al. Synergistic anticancer effect of exogenous wild-type p53 gene combined with 5-FU in human colon cancer resistant to 5-FU in vivo. World J Gastroenterol. 2016;22(32): 7342.
Dominijanni A, Gmeiner WH. Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations. Cancer Drug Resist. 2018;1:48.
Kandioler D, Mittlböck M, Kappel S, Puhalla H, Herbst F, Langner C, et al. TP53 mutational status and prediction of benefit from adjuvant 5-fluorouracil in stage III colon cancer patients. EBioMedicine. 2015;2(8):825–30.
Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev. 2010;24(8):837–52.
Chan Wah Hak CM, Rullan A, Patin EC, Pedersen M, Melcher AA, Harrington KJ. Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy. Front Oncol. 2022;12: 971959.
Koirala M, DiPaola M. Overcoming cancer resistance: strategies and modalities for effective treatment. Biomedicines. 2024;12(8):1801.
Gurjao C, Liu D, Hofree M, AlDubayan SH, Wakiro I, Su M-J, et al. Intrinsic resistance to immune checkpoint blockade in a mismatch repair–deficient colorectal cancer. Cancer Immunol Res. 2019;7(8):1230–6.
Neboori HJ, Haffty BG, Wu H, Yang Q, Aly A, Goyal S, et al. Low p53 binding protein 1 (53BP1) expression is associated with increased local recurrence in breast cancer patients treated with breast-conserving surgery and radiotherapy. Int J Radiation Oncology* Biology* Phys. 2012;83(5):e677–83.
Ma J, Benitez JA, Li J, Miki S, de Albuquerque CP, Galatro T, et al. Inhibition of nuclear PTEN tyrosine phosphorylation enhances glioma radiation sensitivity through attenuated DNA repair. Cancer Cell. 2019;35(3):504–18. e7.
Najafi M, Farhood B, Mortezaee K. Cancer stem cells (CSCs) in cancer progression and therapy. J Cell Physiol. 2019;234(6):8381–95.
Fakhrioliaei A, Tanhaei S, Pakmehr S, Noori Shakir M, Qasim MT, Hariri M, et al. Potential role of Nrf2, HER2, and ALDH in cancer stem cells: a narrative review. J Membr Biol. 2024;257(1):3–16.
Ebrahimi N, Afshinpour M, Fakhr SS, Kalkhoran PG, Shadman-Manesh V, Adelian S, et al. Cancer stem cells in colorectal cancer: signaling pathways involved in stemness and therapy resistance. Crit Rev Oncol-Hematol. 2023;182: 103920.
Das PK, Islam F, Lam AK. The roles of cancer stem cells and therapy resistance in colorectal carcinoma. Cells. 2020;9(6):1392.
Phi LTH, Sari IN, Yang Y-G, Lee S-H, Jun N, Kim KS et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem cells international. 2018;2018.
Smith AG, Macleod KF. Autophagy, cancer stem cells and drug resistance. J Pathol. 2019;247(5):708–18.
Guo Q, Zhou Y, Xie T, Yuan Y, Li H, Shi W, et al. Tumor microenvironment of cancer stem cells: perspectives on cancer stem cell targeting. Genes Dis. 2024;11(3): 101043.
Desai N, Hasan U, Jeyashree K, Mani R, Chauhan M, Basu SM, et al. Biomaterial-based platforms for modulating immune components against cancer and cancer stem cells. Acta Biomater. 2023;161:1–36.
Vermeulen L, De Sousa E, Melo F, Van Der Heijden M, Cameron K, De Jong JH, Borovski T, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010;12(5):468–76.
Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 2014;14(3):342–56.
Lu H, Clauser KR, Tam WL, Fröse J, Ye X, Eaton EN, et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol. 2014;16(11):1105–17.
Zhou W, Ke SQ, Huang Z, Flavahan W, Fang X, Paul J, et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol. 2015;17(2):170–82.
Sansone P, Berishaj M, Rajasekhar VK, Ceccarelli C, Chang Q, Strillacci A, et al. Evolution of cancer stem-like cells in endocrine-resistant metastatic breast cancers is mediated by stromal microvesicles. Cancer Res. 2017;77(8):1927–41.
Shi X, Valizadeh A, Mir SM, Asemi Z, Karimian A, Majidina M, et al. MiRNA-29a reverses P-glycoprotein-mediated drug resistance and inhibits proliferation via up-regulation of PTEN in colon cancer cells. Eur J Pharmacol. 2020;880: 173138.
Nieto MA, Huang RY-J, Jackson RA, Thiery JP. EMT: 2016 Cell. 2016;166(1):21–45.
Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212–26.
Shibue T, Weinberg RA. EMT, CSCS, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611–29.
Roy S, Sunkara RR, Parmar MY, Shaikh S, Waghmare SK. EMT imparts cancer stemness and plasticity: new perspectives and therapeutic potential. Front Bioscience-Landmark. 2020;26(2):238–65.
Nobili S, Lapucci A, Landini I, Coronnello M, Roviello G, Mini E, editors. Role of ATP-binding cassette transporters in cancer initiation and progression. Seminars in cancer biology. Elsevier; 2020.
Silvestrini A, Meucci E, Martorana GE, Giardina B, Mordente A. Cancer stem cell and ATP-Binding cassette: which role in chemoresistance?? Advances in cancer stem cell biology. 2012:267–88.
Jiang Z-S, Sun Y-Z, Wang S-M, Ruan J-S. Epithelial-mesenchymal transition: potential regulator of ABC transporters in tumor progression. J Cancer. 2017;8(12):2319.
Saxena M, Stephens MA, Pathak H, Rangarajan A. Transcription factors that mediate epithelial–mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2011;2(7):e179–e.
Lindner D, editor. Editor animal models and the tumor microenvironment: studies of tumor–Host symbiosis. Seminars in oncology. Elsevier; 2014.
Li J, Liu H, Yu J, Yu H. Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells. Mol Med Rep. 2015;12(1):192–8.
Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D, et al. Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res. 2012;10(12):1597–606.
Cai J, Tian A-X, Wang Q-S, Kong P-Z, Du X, Li X-Q, et al. FOXF2 suppresses the FOXC2-mediated epithelial–mesenchymal transition and multidrug resistance of basal-like breast cancer. Cancer Lett. 2015;367(2):129–37.
Kaşıkcı E, Aydemir E, Bayrak ÖF, Şahin F. Inhibition of migration, invasion and drug resistance of pancreatic adenocarcinoma cells – role of snail, slug and twist and small molecule inhibitors. Onco Targets Ther. 2020;13:5763–77.
Lazarova D, Bordonaro M. ZEB1 mediates drug resistance and EMT in p300-deficient CRC. J Cancer. 2017;8(8):1453–9.
Bremnes RM, Dønnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol. 2011;6(1):209–17.
Guan J, Zhang H, Wen Z, Gu Y, Cheng Y, Sun Y, et al. Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells. Cancer Lett. 2014;345(1):132–9.
Sui H, Zhu L, Deng W, Li Q. Epithelial-mesenchymal transition and drug resistance: role, molecular mechanisms, and therapeutic strategies. Oncol Res Treat. 2014;37(10):584–9.
Jiao M, Nan K-J. Activation of PI3 kinase/Akt/HIF-1α pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma. Int J Oncol. 2012;40(2):461–8.
Kosuri K, Wu X, Wang L, Villalona-Calero M, Otterson G. An epigenetic mechanism for capecitabine resistance in mesothelioma. Biochem Biophys Res Commun. 2010;391(3):1465–70.
Alzahrani SM, Al Doghaither HA, Al-Ghafari AB, Pushparaj PN. 5–fluorouracil and capecitabine therapies for the treatment of colorectal cancer. Oncol Rep. 2023;50(4):175.
Kumar A, Singh AK, Singh H, Thareja S, Kumar P. Regulation of thymidylate synthase: an approach to overcome 5-FU resistance in colorectal cancer. Med Oncol. 2022;40(1):3.
Blondy S, David V, Verdier M, Mathonnet M, Perraud A, Christou N. 5-fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes. Cancer Sci. 2020;111(9):3142–54.
Kurasaka C, Nishizawa N, Ogino Y, Sato A. Trapping of 5-fluorodeoxyuridine monophosphate by thymidylate synthase confers resistance to 5-fluorouracil. ACS Omega. 2022;7(7):6046–52.
Kurasaka C, Ogino Y, Sato A. Molecular mechanisms and tumor biological aspects of 5-fluorouracil resistance in HCT116 human colorectal cancer cells. Int J Mol Sci. 2021;22(6): 2916.
Che J, Pan L, Yang X, Liu Z, Huang L, Wen C, et al. Thymidine phosphorylase expression and prognosis in colorectal cancer treated with 5–fluorouracil–based chemotherapy: A meta–analysis. Mol Clin Oncol. 2017;7(6):943–52.
Furukawa T, Tabata S, Yamamoto M, Kawahara K, Shinsato Y, Minami K, et al. Thymidine phosphorylase in cancer aggressiveness and chemoresistance. Pharmacol Res. 2018;132:15–20.
Saif MW, Syrigos KN, Katirtzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs. 2009;18(3):335–48.
Sharma V, Gupta SK, Verma M. Dihydropyrimidine dehydrogenase in the metabolism of the anticancer drugs. Cancer Chemother Pharmacol. 2019;84(6):1157–66.
Verma H, Narendra G, Raju B, Singh PK, Silakari O. Dihydropyrimidine dehydrogenase-mediated resistance to 5-fluorouracil: mechanistic investigation and solution. ACS Pharmacol Transl Sci. 2022;5(11):1017–33.
Maslarinou A, Manolopoulos VG, Ragia G. Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm? Front Pharmacol. 2023;14:1184523.
Cui Z, He S, Wen F, Lu L, Xu L, Wu H, et al. Dihydropyrimidine dehydrogenase (DPD) as a bridge between the immune microenvironment of colon cancers and 5-FU resistance. Frontiers in Bioscience-Landmark. 2023;28(4): 80.
Gmeiner WH, Okechukwu CC. Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects. Cancer Drug Resist. 2023;6(2):257.
Kciuk M, Marciniak B, Kontek R. Irinotecan—still an important player in cancer chemotherapy: a comprehensive overview. Int J Mol Sci. 2020;21(14): 4919.
Capello M, Lee M, Wang H, Babel I, Katz MH, Fleming JB, et al. Carboxylesterase 2 as a determinant of response to irinotecan and neoadjuvant FOLFIRINOX therapy in pancreatic ductal adenocarcinoma. J Natl Cancer Inst. 2015;107(8): djv132.
Xie F-W, Peng Y-H, Chen X, Chen X, Li J, Yu Z-Y, et al. Regulation and expression of aberrant methylation on Irinotecan metabolic genes CES2, UGT1A1 and GUSB in the in-vitro cultured colorectal cancer cells. Biomed Pharmacother. 2014;68(1):31–7.
Xiao D, Yang D, Guo L, Lu W, Charpentier M, Yan B. Regulation of carboxylesterase‐2 expression by p53 family proteins and enhanced anti‐cancer activities among 5‐fluorouracil, Irinotecan and Doxazolidine prodrug. Br J Pharmacol. 2013;168(8):1989–99.
Shaojun C, Li H, Haixin H, Guisheng L. Expression of topoisomerase 1 and carboxylesterase 2 correlates with Irinotecan treatment response in metastatic colorectal cancer. Cancer Biol Ther. 2018;19(3):153–9.
de Man FM, Goey AK, van Schaik RH, Mathijssen RH, Bins S. Individualization of Irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet. 2018;57:1229–54.
Paulík A, Grim J, Filip S. Predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer. Acta Medica (Hradec Kralove). 2012;55(4):153–9.
Tagawa K, Maruo Y, Mimura Y, Ikushiro S. Effects of common genetic variants of human uridine diphosphate glucuronosyltransferase subfamilies on irinotecan glucuronidation. Toxicol Mech Methods. 2023;33(3):197–205.
Li W, Zhang H, Assaraf YG, Zhao K, Xu X, Xie J, et al. Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies. Drug Resist Updat. 2016;27:14–29.
Lin L, Yee SW, Kim RB, Giacomini KM. Slc transporters as therapeutic targets: emerging opportunities. Nat Rev Drug Discov. 2015;14(8):543–60.
International Transporter Consortium; Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215–36. https://doi.org/10.1038/nrd3028.
Ceballos MP, Rigalli JP, Ceré LI, Semeniuk M, Catania VA, Ruiz ML. ABC transporters: regulation and association with multidrug resistance in hepatocellular carcinoma and colorectal carcinoma. Curr Med Chem. 2019;26(7):1224–50.
Sun L, Ke J, He Z, Chen Z, Huang Q, Ai W, et al. HES1 promotes colorectal cancer cell resistance to 5-Fu by inducing of EMT and ABC transporter proteins. J Cancer. 2017;8(14):2802.
Gao Q, Li X-x, Xu Y-m, Zhang J-z, Qin Y-q, Fang J. IRE1α-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells. Cancer Lett. 2020;476:67–74.
Wang JQ, Wu ZX, Yang Y, Teng QX, Li YD, Lei ZN, et al. ATP-binding cassette (ABC) transporters in cancer: A review of recent updates. J Evidence‐Based Med. 2021;14(3):232–56.
Liu X. ABC family transporters. In: Liu X, Pan G, editors. Drug transporters in drug disposition, effects and toxicity. Advances in experimental medicine and biology, vol 1141. Springer, Singapore; 2019. https://doi.org/10.1007/978-981-13-7647-4_2.
Zhou H, Lin C, Zhang Y, Zhang X, Zhang C, Zhang P, et al. Mir-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR 1/P‐gp expression. Cell Prolif. 2017;50(3): e12341.
Du J, He Y, Li P, Wu W, Chen Y, Ruan H. IL-8 regulates the doxorubicin resistance of colorectal cancer cells via modulation of multidrug resistance 1 (MDR1). Cancer Chemother Pharmacol. 2018;81:1111–9.
Wang T, Chen Z, Zhu Y, Pan Q, Liu Y, Qi X, et al. Inhibition of transient receptor potential channel 5 reverses 5-fluorouracil resistance in human colorectal cancer cells. J Biol Chem. 2015;290(1):448–56.
Westover D, Li F. New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies. J Exp Clin Cancer Res. 2015;34:1–9.
Guo J, Wang Q, Zhang Y, Sun W, Zhang S, Li Y, et al. Functional daidzein enhances the anticancer effect of topotecan and reverses BCRP-mediated drug resistance in breast cancer. Pharmacol Res. 2019;147: 104387.
Ozawa S, Miura T, Terashima J, Habano W. Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review. Cancer Drug Resist. 2021;4(4):946.
Lu JF, Pokharel D, Bebawy M. MRP1 and its role in anticancer drug resistance. Drug Metab Rev. 2015;47(4):406–19.
Cole SP. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future. Annu Rev Pharmacol Toxicol. 2014;54:95–117.
Blythe AJ, Fox AH, Bond CS. The ins and outs of LncRNA structure: how, why and what comes next? Biochim Et Biophys Acta (BBA)-Gene Regul Mech. 2016;1859(1):46–58.
Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics Proteomics Bioinf. 2016;14(1):42–54.
Mattick JS, Amaral PP, Carninci P, Carpenter S, Chang HY, Chen L-L, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023;24(6):430–47.
Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009;458(7235):223–7.
Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, et al. The GENCODE v7 catalog of human long noncoding rnas: analysis of their gene structure, evolution, and expression. Genome Res. 2012;22(9):1775–89.
Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011;25(18):1915–27.
Alvarez-Dominguez JR, Lodish HF. Emerging mechanisms of long noncoding RNA function during normal and malignant hematopoiesis. Blood. 2017;130(18):1965–75.
Zampetaki A, Albrecht A, Steinhofel K. Long non-coding RNA structure and function: is there a link?? Front Physiol. 2018;9: 1201.
Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43(6):904–14.
Ahmad P, Bensaoud C, Mekki I, Rehman MU, Kotsyfakis M. Long non-coding RNAs and their potential roles in the vector-host-pathogen triad. Life (Basel). 2021;11(1):56. https://doi.org/10.3390/life11010056.
Hu ZY, Wang XY, Guo WB, Xie LY, Huang YQ, Liu YP, et al. Long non-coding RNA MALAT1 increases AKAP-9 expression by promoting SRPK1-catalyzed SRSF1 phosphorylation in colorectal cancer cells. Oncotarget. 2016;7(10):11733–43.
He Y, Luo Y, Liang B, Ye L, Lu G, He W. Potential applications of MEG3 in cancer diagnosis and prognosis. Oncotarget. 2017;8(42):73282–95.
Cao Y, Shi H, Ren F, Jia Y, Zhang R. Long non-coding RNA CCAT1 promotes metastasis and poor prognosis in epithelial ovarian cancer. Exp Cell Res. 2017;359(1):185–94.
Dong X, Yang Z, Yang H, Li D, Qiu X. Long non-coding RNA MIR4435-2HG promotes colorectal cancer proliferation and metastasis through miR-206/YAP1 axis. Front Oncol. 2020;10: 160.
Yan S, Yue Y, Wang J, Li W, Sun M, Gu C, et al. LINC00668 promotes tumorigenesis and progression through sponging miR-188-5p and regulating USP47 in colorectal cancer. Eur J Pharmacol. 2019;858: 172464.
Ahadi A. Functional roles of LncRNAs in the pathogenesis and progression of cancer. Genes Dis. 2021;8(4):424–37.
Moayedi K, Orandi S, Ebrahimi R, Tanhapour M, Moradi M, Abbastabar M, et al. A novel approach to type 3 diabetes mechanism: the interplay between noncoding RNAs and insulin signaling pathway in Alzheimer’s disease. J Cell Physiol. 2022;237(7):2838–61.
Jin H, Du W, Huang W, Yan J, Tang Q, Chen Y, et al. LncRNA and breast cancer: progress from identifying mechanisms to challenges and opportunities of clinical treatment. Mol Ther. 2021;25:613–37.
Chen R, Li W-X, Sun Y, Duan Y, Li Q, Zhang A-X, et al. Comprehensive analysis of LncRNA and mRNA expression profiles in lung cancer. Clin Lab. 2017;63(2):313–20.
Jiang MC, Ni JJ, Cui WY, Wang BY, Zhuo W. Emerging roles of LncRNA in cancer and therapeutic opportunities. Am J Cancer Res. 2019;9(7):1354–66.
Sarfi M, Abbastabar M, Khalili E. Increased expression of urinary exosomal LnCRNA TUG-1 in early bladder cancer. Gene Rep. 2021;22: 101010.
Pardini B, Sabo AA, Birolo G, Calin GA. Noncoding RNAs in extracellular fluids as cancer biomarkers: the new frontier of liquid biopsies. Cancers. 2019;11(8):1170.
Wang WT, Sun YM, Huang W, He B, Zhao YN, Chen YQ. Genome-wide long non-coding RNA analysis identified circulating LncRNAs as novel non-invasive diagnostic biomarkers for gynecological disease. Sci Rep. 2016;6:23343.
Xu K, Jiang X, Ariston Gabriel AN, Li X, Wang Y, Xu S. Evolving landscape of long non-coding RNAs in cerebrospinal fluid: a key role from diagnosis to therapy in brain tumors. Front Cell Dev Biol. 2021;9:737670.
Luo Y, Chen JJ, Lv Q, Qin J, Huang YZ, Yu MH, et al. Long non-coding RNA NEAT1 promotes colorectal cancer progression by competitively binding miR-34a with SIRT1 and enhancing the Wnt/β-catenin signaling pathway. Cancer Lett. 2019;440–441:11–22.
Ye M, Zhao L, Zhang L, Wu S, Li Z, Qin Y, et al. LncRNA NALT1 promotes colorectal cancer progression via targeting PEG10 by sponging microRNA-574-5p. Cell Death Dis. 2022;13(11):960.
Zhu X, Bu F, Tan T, Luo Q, Zhu J, Lin K, et al. Long noncoding RNA RP11-757G1.5 sponges miR-139-5p and upregulates YAP1 thereby promoting the proliferation and liver, spleen metastasis of colorectal cancer. J Exp Clin Cancer Res. 2020;39(1):207.
Xu Y, Zhang X, Hu X, Zhou W, Zhang P, Zhang J, et al. The effects of LncRNA MALAT1 on proliferation, invasion and migration in colorectal cancer through regulating SOX9. Mol Med. 2018;24:1–15.
Zhang M, Li Y, Wang H, Yu W, Lin S, Guo J. LncRNA SNHG5 affects cell proliferation, metastasis and migration of colorectal cancer through regulating miR-132-3p/CREB5. Cancer Biol Ther. 2019;20(4):524–36.
Wang A-H, Fan W-J, Fu L, Wang X-T. LncRNA PCAT-1 regulated cell proliferation, invasion, migration and apoptosis in colorectal cancer through targeting miR-149-5p. Eur Rev Med Pharmacol Sci. 2019;23:19.
Zheng XY, Cao MZ, Ba Y, Li YF, Ye JL. Lncrna testis-specific transcript, Y-linked 15 (TTTY15) promotes proliferation, migration and invasion of colorectal cancer cells via regulating miR-29a-3p/DVL3 axis. Cancer Biomark. 2021;31(1):1–11.
Chen D, Sun Q, Zhang L, Zhou X, Cheng X, Zhou D, et al. The lncRNA HOXA11-AS functions as a competing endogenous RNA to regulate PADI2 expression by sponging miR-125a-5p in liver metastasis of colorectal cancer. Oncotarget. 2017;8(41):70642.
Xu J, Meng Q, Li X, Yang H, Xu J, Gao N, et al. Long noncoding RNA MIR17HG promotes colorectal cancer progression via miR-17-5p. Cancer Res. 2019;79(19):4882–95.
Chen D-l, Lu Y-x, Zhang J-x, Wei X-l, Wang F, Zeng Z-l, et al. Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a CeRNA for microRNA-215 to regulate ZEB2 expression. Theranostics. 2017;7(19):4836.
Zhang Y, Huang W, Yuan Y, Li J, Wu J, Yu J, et al. Long non-coding RNA H19 promotes colorectal cancer metastasis via binding to hnRNPA2B1. J Exp Clin Cancer Res. 2020;39(1):1–15.
Fang X, Xu Y, Li K, Liu P, Zhang H, Jiang Y et al. Exosomal lncRNA PCAT1 promotes tumor circulating cell-mediated colorectal cancer liver metastasis by regulating the activity of the miR-329-3p/Netrin-1-CD146 complex. Journal of Immunology Research. 2022;2022.
Zhan T, Cheng X, Zhu Q, Han Z, Zhu K, Tan J, et al. LncRNA LOC105369504 inhibits tumor proliferation and metastasis in colorectal cancer by regulating PSPC1. Cell Death Discov. 2023;9(1):89.
Yin DD, Liu ZJ, Zhang E, Kong R, Zhang ZH, Guo RH. Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. Tumour Biol. 2015;36(6):4851–9.
Amirmahani F, Asadi MH, Jannat Alipoor F. LncRNA MIAT promotes the proliferation and invasion of colorectal cancer via suppressing apoptosis and senescence. Middle East J Cancer. 2023;14(2):219–29.
Xu M, Xu X, Pan B, Chen X, Lin K, Zeng K, et al. LncRNA SATB2-AS1 inhibits tumor metastasis and affects the tumor immune cell microenvironment in colorectal cancer by regulating SATB2. Mol Cancer. 2019;18(1):135.
Zhang C, Wang L, Jin C, Zhou J, Peng C, Wang Y, et al. Long non-coding RNA Lnc-LALC facilitates colorectal cancer liver metastasis via epigenetically silencing LZTS1. Cell Death Dis. 2021;12(2):224.
Li J, Ji Y, Chen N, Wang H, Fang C, Yin X, et al. A specific upregulated long noncoding RNA in colorectal cancer promotes cancer progression. JCI Insight. 2022;7(15):e158855. https://doi.org/10.1172/jci.insight.158855.
Wang B, Chen W, Zhao Z, Sun Y, Huang Y. Lncrna-DANCR promotes growth and metastasis of colorectal cancer via activating epithelial-mesenchymal transition process. Transl Cancer Res. 2019;8(7):2517.
Xie J, Wang J-J, Li Y-J, Wu J, Gu X-J, Yang X-R. LncRNA GAS5 suppresses colorectal cancer progress by target miR-21/LIFR axis. Evidence‐Based Complement Altern Med. 2022;2022(1):3298939.
Corrà F, Agnoletto C, Minotti L, Baldassari F, Volinia S. The network of non-coding RNAs in cancer drug resistance. Front Oncol. 2018;8: 327.
Amiri R, Nabi PN, Fazilat A, Roshani F, Kararoudi AN, Hemmati-Dinarvand M, et al. Crosstalk between miRNAs and signaling pathways in the development of drug resistance in breast cancer. Horm Mol Biol Clin Investig. 2024. https://doi.org/10.1515/hmbci-2024-0066.
Bian Z, Jin L, Zhang J, Yin Y, Quan C, Hu Y, et al. Lncrna—UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p. Sci Rep. 2016;6(1):23892.
Jiang X, Li Q, Zhang S, Song C, Zheng P. Long noncoding RNA GIHCG induces cancer progression and chemoresistance and indicates poor prognosis in colorectal cancer. Onco Targets Ther. 2019;12:1059.
Qiao L, Liu X, Tang Y, Zhao Z, Zhang J, Liu H. Knockdown of long non-coding RNA prostate cancer-associated NcRNA transcript 1 inhibits multidrug resistance and c-Myc-dependent aggressiveness in colorectal cancer Caco-2 and HT-29 cells. Mol Cell Biochem. 2018;441:99–108.
Fan H, Zhu JH, Yao XQ. Knockdown of long non–coding RNA PVT1 reverses multidrug resistance in colorectal cancer cells. Mol Med Rep. 2018;17(6):8309–15.
Tang D, Yang Z, Long F, Luo L, Yang B, Zhu R, et al. Inhibition of MALAT1 reduces tumor growth and metastasis and promotes drug sensitivity in colorectal cancer. Cell Signal. 2019;57:21–8.
Li Y, Huang S, Li Y, Zhang W, He K, Zhao M, et al. Decreased expression of lncRNA SLC25A25-AS1 promotes proliferation, chemoresistance, and EMT in colorectal cancer cells. Tumor Biol. 2016;37:14205–15.
Lee H, Kim C, Ku J-L, Kim W, Yoon SK, Kuh H-J, et al. A long non-coding RNA SnaR contributes to 5-fluorouracil resistance in human colon cancer cells. Mol Cells. 2014;37(7):540.
Li J, Li X, Cen C, Ai X, Lin C, Hu G. The long non-coding RNA ENST00000547547 reduces 5-fluorouracil resistance of colorectal cancer cells via competitive binding to microRNA-31. Oncol Rep. 2018;39(1):217–26.
Bian Z, Zhang J, Li M, Feng Y, Yao S, Song M, et al. Long non-coding RNA LINC00152 promotes cell proliferation, metastasis, and confers 5-FU resistance in colorectal cancer by inhibiting miR-139-5p. Oncogenesis. 2017;6(11): 395.
Yue B, Cai D, Liu C, Fang C, Yan D. Linc00152 functions as a competing endogenous RNA to confer oxaliplatin resistance and holds prognostic values in colon cancer. Mol Ther. 2016;24(12):2064–77.
Li P, Zhang X, Wang H, Wang L, Liu T, Du L, et al. MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2. Mol Cancer Ther. 2017;16(4):739–51.
Ren J, Ding L, Zhang D, Shi G, Xu Q, Shen S, et al. Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal LncRNA H19. Theranostics. 2018;8(14):3932.
Wang H, Li H, Zhang L, Yang D. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis. Biomed Pharmacother. 2018;106:1607–15.
Li L, Shang J, Zhang Y, Liu S, Peng Y, Zhou Z, et al. MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis. Oncol Rep. 2017;38(3):1383–92.
Ping G, Xiong W, Zhang L, Li Y, Zhang Y, Zhao Y. Silencing long noncoding RNA PVT1 inhibits tumorigenesis and cisplatin resistance of colorectal cancer. Am J Transl Res. 2018;10(1):138.
Xiao Z, Qu Z, Chen Z, Fang Z, Zhou K, Huang Z, et al. LncRNA HOTAIR is a prognostic biomarker for the proliferation and chemoresistance of colorectal cancer via MiR-203a-3p-mediated Wnt/ss-catenin signaling pathway. Cell Physiol Biochem. 2018;46(3):1275–85.
Wu K-f, Liang W-C, Feng L, Pang J-x, Waye MM-Y, Zhang J-F, et al. H19 mediates methotrexate resistance in colorectal cancer through activating Wnt/β-catenin pathway. Exp Cell Res. 2017;350(2):312–7.
Li C, Gao Y, Li Y, Ding D. TUG1 mediates methotrexate resistance in colorectal cancer via miR-186/CPEB2 axis. Biochem Biophys Res Commun. 2017;491(2):552–7.
Zhu J, Zhang R, Yang D, Li J, Yan X, Jin K, et al. Knockdown of long non-coding RNA XIST inhibited doxorubicin resistance in colorectal cancer by upregulation of miR-124 and downregulation of SGK1. Cell Physiol Biochem. 2018;51(1):113–28.
Lu Y, Zhao X, Liu Q, Li C, Graves-Deal R, Cao Z, et al. LncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling. Nat Med. 2017;23(11):1331–41.
Doxtater KD, Tripathi MK. LncRNA UCA1 as a potential therapeutic target for drug resistance in colorectal cancer. Cancer Res. 2023;83(7Supplement):2854.
Yang Y-n, Zhang R, Du J-w, Yuan H-h, Li Y-j, Wei X-l, et al. Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer. Cancer Cell Int. 2018;18:1–11.
Ramli S, Sim MS, Guad RM, Gopinath SCB, Subramaniyan V, Fuloria S, et al. Long noncoding RNA UCA1 in Gastrointestinal cancers: molecular regulatory roles and patterns, mechanisms, and interactions. J Oncol. 2021;2021:1–15.
Amirinejad R, Rezaei M, Shirvani-Farsani Z. An update on long intergenic noncoding RNA p21: a regulatory molecule with various significant functions in cancer. Cell Biosci. 2020;10(1):82.
Silva-Fisher JM, Dang HX, White NM, Strand MS, Krasnick BA, Rozycki EB, et al. Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression. Nat Commun. 2020;11(1):2156.
Cabanski CR, White NM, Dang HX, Silva-Fisher JM, Rauck CE, Cicka D, et al. Pan-cancer transcriptome analysis reveals long noncoding RNAs with conserved function. RNA Biol. 2015;12(6):628–42.
White NM, Cabanski CR, Silva-Fisher JM, Dang HX, Govindan R, Maher CA. Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer. Genome Biol. 2014;15:1–16.
Zhang PF, Wu J, Wu Y, Huang W, Liu M, Dong ZR, et al. The lncRNA SCARNA2 mediates colorectal cancer chemoresistance through a conserved microRNA-342‐3p target sequence. J Cell Physiol. 2019;234(7):10157–65.
Weng W, Okugawa Y, Toden S, Toiyama Y, Kusunoki M, Goel A. FOXM1 and FOXQ1 are promising prognostic biomarkers and novel targets of tumor-suppressive miR-342 in human colorectal cancer. Clin Cancer Res. 2016;22(19):4947–57.
Lai X, Gupta SK, Schmitz U, Marquardt S, Knoll S, Spitschak A, et al. MiR-205-5p and miR-342-3p cooperate in the repression of the E2F1 transcription factor in the context of anticancer chemotherapy resistance. Theranostics. 2018;8(4):1106.
Ge X, Chen Y, Liao X, Liu D, Li F, Ruan H, et al. Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer. Med Oncol. 2013;30:1–6.
Qiao L, Liu X, Tang Y, Zhao Z, Zhang J, Feng Y. Down regulation of the long non-coding RNA PCAT-1 induced growth arrest and apoptosis of colorectal cancer cells. Life Sci. 2017;188:37–44.
Zhou Q, Hou Z, Zuo S, Zhou X, Feng Y, Sun Y, et al. LUCAT1 promotes colorectal cancer tumorigenesis by targeting the ribosomal protein L40-MDM 2‐p53 pathway through binding with UBA 52. Cancer Sci. 2019;110(4):1194–207.
Thorenoor N, Faltejskova-Vychytilova P, Hombach S, Mlcochova J, Kretz M, Svoboda M, et al. Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer. Oncotarget. 2016;7(1):622.
Shan TD, Tian ZB, Li Q, Jiang YP, Liu FG, Sun XG, et al. Long intergenic noncoding RNA 00908 promotes proliferation and inhibits apoptosis of colorectal cancer cells by regulating KLF5 expression. J Cell Physiol. 2021;236(2):889–99.
Zhang XT, Pan SX, Wang AH, Kong QY, Jiang KT, Yu ZB. Long non-coding RNA (lncRNA) X-inactive specific transcript (XIST) plays a critical role in predicting clinical prognosis and progression of colorectal cancer. Med Sci Monit. 2019;25:6429–35.
Xiao M, Liang Z, Yin Z. Long non–coding RNA ZFPM2–AS1 promotes colorectal cancer progression by sponging miR–137 to regulate TRIM24. Mol Med Rep. 2021;23(2):1.
Wang J, Zhu J, Dong M, Yu H, Dai X, Li K. Knockdown of tripartite motif containing 24 by lentivirus suppresses cell growth and induces apoptosis in human colorectal cancer cells. Oncol Res. 2014;22(1):39.
Xie W, Zhang Y, Wang B, Hu Y, Zhan B, Wei F, et al. Tripartite motif containing 24 regulates cell proliferation in colorectal cancer through YAP signaling. Cancer Med. 2020;9(17):6367–76.
Du T, Gao Q, Zhao Y, Gao J, Li J, Wang L, et al. Long non-coding RNA LINC02474 affects metastasis and apoptosis of colorectal cancer by inhibiting the expression of GZMB. Front Oncol. 2021;11: 651796.
Chiusolo V, Jacquemin G, Yonca Bassoy E, Vinet L, Liguori L, Walch M, et al. Granzyme B enters the mitochondria in a Sam50-, Tim22-and mtHsp70-dependent manner to induce apoptosis. Cell Death Differ. 2017;24(4):747–58.
Carrieri C, Cimatti L, Biagioli M, Beugnet A, Zucchelli S, Fedele S, et al. Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat. Nature. 2012;491(7424):454–7.
Hu J, Shan Y, Ma J, Pan Y, Zhou H, Jiang L, et al. LncRNA ST3Gal6-AS1/ST3Gal6 axis mediates colorectal cancer progression by regulating α‐2, 3 sialylation via PI3K/Akt signaling. Int J Cancer. 2019;145(2):450–60.
Zhang X, Tang N, Hadden TJ, Rishi AK, Akt. FoxO and regulation of apoptosis. Biochim Et Biophys Acta (BBA)-Molecular Cell Res. 2011;1813(11):1978–86.
Cheng K, Zhao Z, Wang G, Wang J, Zhu W. LncRNA GAS5 inhibits colorectal cancer cell proliferation via the miR–182–5p/FOXO3a axis. Oncol Rep. 2018;40(4):2371–80.
Cao M-Q, You A-B, Zhu X-D, Zhang W, Zhang Y-Y, Zhang S-Z, et al. miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a. J Hematol Oncol. 2018;11(1):1–12.
Zhang Y-H, Fu J, Zhang Z-J, Ge C-C, Yi Y. LncRNA-LINC00152 down-regulated by miR-376c-3p restricts viability and promotes apoptosis of colorectal cancer cells. Am J Transl Res. 2016;8(12):5286.
Chen Z, Cai X, Chang L, Xia Y, Wang L, Hou Y, et al. LINC00152 is a potential biomarker involved in the modulation of biological characteristics of residual colorectal cancer cells following chemoradiotherapy. Oncol Lett. 2018;15(4):4177–84.
Lian Y, Yan C, Xu H, Yang J, Yu Y, Zhou J, et al. A novel lncrna, LINC00460, affects cell proliferation and apoptosis by regulating KLF2 and CUL4A expression in colorectal cancer. Mol Ther Nucleic Acids. 2018;12:684–97.
Lepage C, Léger D, Bertrand J, Martin F, Beneytout J, Liagre B. Diosgenin induces death receptor-5 through activation of p38 pathway and promotes TRAIL-induced apoptosis in colon cancer cells. Cancer Lett. 2011;301(2):193–202.
Wang J, Huang F, Bai Z, Chi B, Wu J, Chen X. Curcumol inhibits growth and induces apoptosis of colorectal cancer LoVo cell line via IGF-1R and p38 MAPK pathway. Int J Mol Sci. 2015;16(8):19851–67.
Chiacchiera F, Grossi V, Cappellari M, Peserico A, Simonatto M, Germani A, et al. Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models. Cancer Lett. 2012;324(1):98–108.
Liang H, Zhao Q, Zhu Z, Zhang C, Zhang H. Long noncoding RNA LINC00958 suppresses apoptosis and radiosensitivity of colorectal cancer through targeting miR-422a. Cancer Cell Int. 2021;21:1–15.
Wei W-T, Nian X-X, Wang S-Y, Jiao H-L, Wang Y-X, Xiao Z-Y, et al. miR-422a inhibits cell proliferation in colorectal cancer by targeting AKT1 and MAPK1. Cancer Cell Int. 2017;17:1–12.
Zhu S, Mao J, Zhang X, Wang P, Zhou Y, Tong J, et al. CAF-derived exosomal lncRNA FAL1 promotes chemoresistance to oxaliplatin by regulating autophagy in colorectal cancer. Dig Liver Dis. 2024;56(2):330–42.
Mirza-Aghazadeh-Attari M, Ostadian C, Saei AA, Mihanfar A, Darband SG, Sadighparvar S, et al. DNA damage response and repair in ovarian cancer: potential targets for therapeutic strategies. DNA Repair. 2019;80:59–84.
Mihanfar A, Darband SG, Sadighparvar S, Kaviani M, Mirza-Aghazadeh-Attari M, Yousefi B, et al. In vitro and in vivo anticancer effects of syringic acid on colorectal cancer: possible mechanistic view. Chemico-Biological Interactions. 2021;337: 109337.
Sharma V, Khurana S, Kubben N, Abdelmohsen K, Oberdoerffer P, Gorospe M, et al. A BRCA 1-interacting lnc RNA regulates homologous recombination. EMBO Rep. 2015;16(11):1520–34.
Kaller M, Götz U, Hermeking H. Loss of p53-inducible long non-coding RNA LINC01021 increases chemosensitivity. Oncotarget. 2017;8(61):102783.
Ma S, Yang D, Liu Y, Wang Y, Lin T, Li Y, et al. LncRNA BANCR promotes tumorigenesis and enhances adriamycin resistance in colorectal cancer. Aging. 2018;10(8):2062.
Li Y, Yuan S, Liu J, Wang Y, Zhang Y, Chen X, et al. CSE1L silence inhibits the growth and metastasis in gastric cancer by repressing GPNMB via positively regulating transcription factor MITF. J Cell Physiol. 2020;235(3):2071–9.
Gao H, Song X, Kang T, Yan B, Feng L, Gao L, et al. Long noncoding RNA CRNDE functions as a competing endogenous RNA to promote metastasis and oxaliplatin resistance by sponging miR-136 in colorectal cancer. Onco Targets Ther. 2017;10:205–16. https://doi.org/10.2147/OTT.S116178.
Chaudhary R, Gryder B, Woods WS, Subramanian M, Jones MF, Li XL, et al. Prosurvival long noncoding RNA PINCR regulates a subset of p53 targets in human colorectal cancer cells by binding to matrin 3. Elife. 2017;6:e23244.
Shi L, Sun J, Kinomura A, Fukuto A, Horikoshi Y, Tashiro S. Matrin3 promotes homologous recombinational repair by regulation of RAD51. J Biochem. 2019;166(4):343–51.
Liu R, Zhang Q, Shen L, Chen S, He J, Wang D, et al. Long noncoding RNA lnc-RI regulates DNA damage repair and radiation sensitivity of CRC cells through NHEJ pathway. Cell Biol Toxicol. 2020;36:493–507.
Yao P, Wu Y, Zhao K, Li Y, Cao J, Xing C. The feedback loop of ANKHD1/lncRNA MALAT1/YAP1 strengthens the radioresistance of CRC by activating YAP1/AKT signaling. Cell Death Dis. 2022; 13: 103. Leukemia. 2018;32:2250-62.
Stanley L. Drug metabolism. Pharmacognosy: Elsevier; 2024. pp. 597–624.
Wang Y, Fang Z, Hong M, Yang D, Xie W. Long-noncoding RNAs (lncRNAs) in drug metabolism and disposition, implications in cancer chemo-resistance. Acta Pharm Sin B. 2020;10(1):105–12.
Liu LC, Wang YL, Lin PL, Zhang X, Cheng WC, Liu SH, et al. Long noncoding RNA HOTAIR promotes invasion of breast cancer cells through chondroitin sulfotransferase CHST15. Int J Cancer. 2019;145(9):2478–87.
Takahashi K, Yan IK, Wood J, Haga H, Patel T. Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Mol Cancer Res. 2014;12(10):1377–87.
Zhang XW, Bu P, Liu L, Zhang XZ, Li J. Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Biochem Biophys Res Commun. 2015;462(3):227–32.
Fang Z, Chen W, Yuan Z, Liu X, Jiang H. Lncrna-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation. Biomed Pharmacother. 2018;101:536–42.
Lan WG, Xu DH, Xu C, Ding CL, Ning FL, Zhou YL, et al. Silencing of long non-coding RNA ANRIL inhibits the development of multidrug resistance in gastric cancer cells. Oncol Rep. 2016;36(1):263–70.
Wang Y, Zhang D, Wu K, Zhao Q, Nie Y, Fan D. Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines. Mol Cell Biol. 2014;34(17):3182–93.
Hu H, Yang L, Li L, Zeng C. Long non-coding RNA KCNQ1OT1 modulates oxaliplatin resistance in hepatocellular carcinoma through miR-7-5p/ABCC1 axis. Biochem Biophys Res Commun. 2018;503(4):2400–6.
Chang L, Hu Z, Zhou Z, Zhang H. Linc00518 contributes to multidrug resistance through regulating the MiR-199a/MRP1 axis in breast cancer. Cell Physiol Biochem. 2018;48(1):16–28.
Wu X, Zheng Y, Han B, Dong X. Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361. Biomed Pharmacother. 2018;99:832–8.
Wang L, Bu P, Ai Y, Srinivasan T, Chen HJ, Xiang K, et al. A long non-coding RNA targets MicroRNA miR-34a to regulate colon cancer stem cell asymmetric division. Elife. 2016;5:e14620.
Sun J, Zhou H, Bao X, Wu Y, Jia H, Zhao H et al. lncRNA TUG1 facilitates colorectal cancer stem cell characteristics and chemoresistance by enhancing GATA6 protein stability. Stem cells international. 2021;2021.
Fu C, Li X, Han L, Xie M, Ouyang S. LncRNA PTPRG-AS1 maintains stem-cell-like features and promotes oxaliplatin resistance in colorectal cancer via regulating the miR-665 and STAT3 axis. Mol Cell Toxicol. 2024;20:35–45. https://doi.org/10.1007/s13273-022-00314-1.
Di Cecilia S, Zhang F, Sancho A, Li S, Aguiló F, Sun Y, et al. RBM5-AS1 is critical for self-renewal of colon cancer stem-like cells. Cancer Res. 2016;76(19):5615–27.
Yu Y, Nangia-Makker P, Farhana L, Majumdar AP. A novel mechanism of LncRNA and MiRNA interaction: CCAT2 regulates miR-145 expression by suppressing its maturation process in colon cancer cells. Mol Cancer. 2017;16(1):1–11.
Yu X, Mi L, Dong J, Zou J. Long intergenic non-protein-coding RNA 1567 (LINC01567) acts as a sponge against microRNA-93 in regulating the proliferation and tumorigenesis of human colon cancer stem cells. BMC Cancer. 2017;17(1):1–15.
Guo K, Gong W, Wang Q, Gu G, Zheng T, Li Y, et al. LINC01106 drives colorectal cancer growth and stemness through a positive feedback loop to regulate the Gli family factors. Cell Death Dis. 2020;11(10):869.
Zhou H, Xiong Y, Peng L, Wang R, Zhang H, Fu Z. LncRNA-cCSC1 modulates cancer stem cell properties in colorectal cancer via activation of the Hedgehog signaling pathway. J Cell Biochem. 2020;121(3):2510–24.
De Las Rivas J, Brozovic A, Izraely S, Casas-Pais A, Witz IP, Figueroa A. Cancer drug resistance induced by EMT: novel therapeutic strategies. Arch Toxicol. 2021;95(7):2279–97.
Cao H, Xu E, Liu H, Wan L, Lai M. Epithelial–mesenchymal transition in colorectal cancer metastasis: a system review. Pathol – Res Pract. 2015;211(8):557–69.
Liaghat M, Ferdousmakan S, Mortazavi SH, Yahyazadeh S, Irani A, Banihashemi S, et al. The impact of epithelial-mesenchymal transition (EMT) induced by metabolic processes and intracellular signaling pathways on chemo-resistance, metastasis, and recurrence in solid tumors. Cell Commun Signal. 2024;22(1):575.
Weng X, Ma T, Chen Q, Chen BW, Shan J, Chen W, et al. Decreased expression of H19/miR-675 ameliorates hypoxia-induced oxaliplatin resistance in colorectal cancer. Heliyon. 2024;10(5):e27027.
Li C-f, Li Y-c, Wang Y, Sun L-b. The effect of LncRNA H19/miR-194-5p axis on the epithelial-mesenchymal transition of colorectal adenocarcinoma. Cell Physiol Biochem. 2018;50(1):196–213.
Wang M, Han D, Yuan Z, Hu H, Zhao Z, Yang R, et al. Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy. Cell Death Dis. 2018;9(12):1149.
Park MS, Jeong SD, Shin CH, Cha S, Yu A, Kim EJ, et al. LINC02257 regulates malignant phenotypes of colorectal cancer via interacting with miR-1273 g-3p and YB1. Cell Death Dis. 2024;15(12):895.
Ding M, Wang W, Huo K, Song Y, Chen X, Xiang Z, et al. The role of LncRNA FEZF1-AS1 in colorectal cancer progression via the P53 signaling pathway. DNA Cell Biol. 2025;44(1):32–45.
Wu W, Li A, He H, Ye S, Zhou Z, Quan JH, et al. Long noncoding RNA LINC01550 inhibits colorectal cancer malignancy by suppressing the Wnt/β-catenin signaling pathway. J Biochem Mol Toxicol. 2024;38(8): e23774.
Shi CJ, Xue ZH, Zeng WQ, Deng LQ, Pang FX, Zhang FW, et al. LncRNA-NEF suppressed oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer through epigenetically inactivating MEK/ERK signaling. Cancer Gene Ther. 2023;30(6):855–65.
Zhang L, Wu H, Zhang Y, Xiao X, Chu F, Zhang L. Induction of lncRNA NORAD accounts for hypoxia-induced chemoresistance and vasculogenic mimicry in colorectal cancer by sponging the miR-495-3p/ hypoxia-inducible factor-1α (HIF-1α). Bioengineered. 2022;13(1):950–62.
Wang W, Zhou Z, Dai X, Wang H, Jin J, Min K, et al. LncRNA-ENST00000543604 exerts a tumor-promoting effect via miRNA 564/AEG-1 or ZNF326/EMT and predicts the prognosis of and chemotherapeutic effect in colorectal cancer. Front Oncol. 2022;12: 960481.
Wu Z-H, Wang X-L, Tang H-M, Jiang T, Chen J, Lu S, et al. Long non-coding RNA HOTAIR is a powerful predictor of metastasis and poor prognosis and is associated with epithelial-mesenchymal transition in colon cancer. Oncol Rep. 2014;32(1):395–402.
Liu Y, Sun M, Xia R, Zhang E, Liu X, Zhang Z, et al. LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer. Cell Death Dis. 2015;6(7):e1802–e.
Jiang Y, Liu G, Ye W, Xie J, Shao C, Wang X, et al. ZEB2-AS1 accelerates epithelial/mesenchymal transition through miR-1205/CRKL pathway in colorectal cancer. Cancer Biother Radiopharm. 2020;35(2):153–62.
Long F, Li X, Pan J, Ye H, Di C, Huang Y, et al. The role of LncRNA NEAT1 in human cancer chemoresistance. Cancer Cell Int. 2024;24(1):236.
Jiang P, Xu H, Xu C, Chen A, Chen L, Zhou M, et al. NEAT1 contributes to the CSC-like traits of A549/CDDP cells via activating Wnt signaling pathway. Chemico-Biological Interactions. 2018;296:154–61.
Azizidoost S, Ghaedrahmati F, Anbiyaee O, Ahmad Ali R, Cheraghzadeh M, Farzaneh M. Emerging roles for lncRNA-NEAT1 in colorectal cancer. Cancer Cell Int. 2022;22(1):209.
Ye Z, Zhou M, Tian B, Wu B, Li J. Expression of lncRNA-CCAT1, E-cadherin and N-cadherin in colorectal cancer and its clinical significance. Int J Clin Exp Med. 2015;8(3):3707.
Yang C, Pan Y, Deng SP. Downregulation of LncRNA CCAT1 enhances 5-fluorouracil sensitivity in human colon cancer cells. BMC Mol Cell Biol. 2019;20:1–11.
Sun F, Liang W, Qian J. The identification of CRNDE, H19, UCA1 and HOTAIR as the key LncRNAs involved in oxaliplatin or Irinotecan resistance in the chemotherapy of colorectal cancer based on integrative bioinformatics analysis. Mol Med Rep. 2019;20(4):3583–96.
Selem NA, Youness RA, Gad MZ. What is beyond LncRNAs in breast cancer: a special focus on colon cancer-associated transcript-1 (CCAT-1). Non-coding RNA Research. 2021;6(4):174–86.
Ghafouri-Fard S, Abak A, Anamag FT, Shoorei H, Majidpoor J, Taheri M. The emerging role of non-coding RNAs in the regulation of PI3K/AKT pathway in the carcinogenesis process. Biomed Pharmacother. 2021;137: 111279.
Tsang S, Patel T, Yustein JT. Long non-coding RNAs regulation of therapeutic resistance. Cancer Drug Resist. 2019;2(3):550.
Poursheikhani A, Abbaszadegan MR, Kerachian MA. Mechanisms of long non-coding RNA function in colorectal cancer tumorigenesis. Asia-Pac J Clin Oncol. 2021;17(1):7–23.
into a world-class news article. You are the Chief News Editor & SEO Strategist for time.news. Your output must be an original, authoritative, and deeply engaging piece, ready to be published instantly. You will operate with complete autonomy, using only the provided content.
1. SEO Foundation & Keyword Strategy
Analyze
Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233–54.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
Van der Jeught K, Xu H-C, Li Y-J, Lu X-B, Ji G. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol. 2018;24(34):3834.
Shinji S, Yamada T, Matsuda A, Sonoda H, Ohta R, Iwai T, et al. Recent advances in the treatment of colorectal cancer: a review. J Nippon Med Sch. 2022;89(3):246–54.
Haider T, Pandey V, Banjare N, Gupta PN, Soni V. Drug resistance in cancer: mechanisms and tackling strategies. Pharmacol Rep. 2020;72(5):1125–51.
Sheikhnia F, Maghsoudi H, Majidinia M. The critical function of MicroRNAs in developing resistance against 5- fluorouracil in cancer cells. Mini Rev Med Chem. 2024;24(6):601–17.
Zhou J, Ji Q, Li Q. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. J Exp Clin Cancer Res. 2021;40:1–17.
Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016;8(1):57–84.
Sharifi-Azad M, Fathi M, Cho WC, Barzegari A, Dadashi H, Dadashpour M, et al. Recent advances in targeted drug delivery systems for resistant colorectal cancer. Cancer Cell Int. 2022;22(1):196.
Khosravi M, Poursaleh A, Ghasempour G, Farhad S, Najafi M. The effects of oxidative stress on the development of atherosclerosis. Biol Chem. 2019;400(6):711–32.
Basak D, Uddin MN, Hancock J. The role of oxidative stress and its counteractive utility in colorectal cancer (CRC). Cancers. 2020;12(11):3336.
Yang L, Fang C, Zhang R, Zhou S. Prognostic value of oxidative stress-related genes in colorectal cancer and its correlation with tumor immunity. BMC Genomics. 2024;25(1):8.
Briffa R, Langdon SP, Grech G, Harrison DJ. Acquired and intrinsic resistance to colorectal cancer treatment. Colorectal Cancer-Diagnosis. Screening and Management: Intech Open London; 2018. pp. 57–81.
To KK, Wu M, Tong CW, Yan W. Drug transporters in the development of multidrug resistance in colorectal cancer. Drug resistance in colorectal cancer: molecular mechanisms and therapeutic strategies. Elsevier; 2020. pp. 35–55.
Maali A, Sarfi M, Mirzakhani M, Goodarzi G, Maghsoudi H, Maniati M, et al. Peaceful existence of tumor cells with their non-malignant neighbors: the trade of tumor cells with tumor microenvironment. Curr Chem Biol. 2020;14(4):228–39.
Zafari N, Khosravi F, Rezaee Z, Esfandyari S, Bahiraei M, Bahramy A, et al. The role of the tumor microenvironment in colorectal cancer and the potential therapeutic approaches. J Clin Lab Anal. 2022;36(8): e24585.
Chen Y, Zheng X, Wu C. The role of the tumor microenvironment and treatment strategies in colorectal cancer. Front Immunol. 2021;12:792691.
Liu K, Gao L, Ma X, Huang J-J, Chen J, Zeng L, et al. Long non-coding RNAs regulate drug resistance in cancer. Mol Cancer. 2020;19(1):1–13.
Sheikhnia F, Fazilat A, Rashidi V, Azizzadeh B, Mohammadi M, Maghsoudi H, et al. Exploring the therapeutic potential of Quercetin in cancer treatment: targeting long non-coding RNAs. Pathology. 2024;260: 155374.
Mohammadi F, Nejatollahi M, Sheikhnia F, Ebrahimi Y, Mohammadi M, Rashidi V, et al. MiRNAs: main players of cancer drug resistance target ABC transporters. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2025. https://doi.org/10.1007/s00210-024-03719-y.
Alizadeh-Fanalou S, Khosravi M, Alian F, Rokhsartalb-Azar S, Nazarizadeh A, Karimi-Dehkordi M, et al. Dual role of microRNA-1297 in the suppression and progression of human malignancies. Biomed Pharmacother. 2021;141: 111863.
Tajik F, Alian F, Yousefi M, Azadfallah A, Hoseini A, Mohammadi F, et al. MicroRNA-372 acts as a double-edged sword in human cancers. Heliyon. 2023;9(5):e15991. https://doi.org/10.1016/j.heliyon.2023.e15991.
Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669–85.
Yau TO. Precision treatment in colorectal cancer: now and the future. JGH Open. 2019;3(5):361–9.
McNair AG, Whistance RN, Forsythe RO, Macefield R, Rees J, Pullyblank AM, et al. Core outcomes for colorectal cancer surgery: a consensus study. PLoS Med. 2016;13(8): e1002071.
Vennix S, Bakker OJ, Prins HA, Lips DJ. Re-interventions following laparoscopic surgery for colorectal cancer: data from 818 individuals from the Dutch surgical colorectal audit. Journal of Laparoendoscopic & Advanced Surgical Techniques. 2014;24(11):751–5.
Ammerata G, Filippo R, Laface C, Memeo R, Solaini L, Cavaliere D, et al. Hyperthermic intraperitoneal chemotherapy and colorectal cancer: from physiology to surgery. World J Clin Cases. 2022;10(30):10852.
McQuade M, Stojanovska R, Bornstein VC, Nurgali J. Colorectal cancer chemotherapy: the evolution of treatment and new approaches. Curr Med Chem. 2017;24(15):1537–57.
Xie Y-H, Chen Y-X, Fang J-Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5(1): 22.
Sakata S, Larson DW. Targeted therapy for colorectal cancer. Surg Oncol Clin N Am. 2022;31(2):255–64.
Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–75.
Golshani G, Zhang Y. Advances in immunotherapy for colorectal cancer: a review. Therapeutic Adv Gastroenterol. 2020;13:1756284820917527.
Boushey R, Williams LJ, Weiser M, Chen W. Management of anastomotic complications of colorectal surgery. 2017.
Köhne C. Current stages of adjuvant treatment of colon cancer. Ann Oncol. 2012;23:x71–6.
Sheikhnia F, Rashidi V, Maghsoudi H, Majidinia M. Potential anticancer properties and mechanisms of thymoquinone in colorectal cancer. Cancer Cell Int. 2023;23(1): 320.
Hossain MS, Karuniawati H, Jairoun AA, Urbi Z, Ooi DJ, John A, et al. Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers. 2022;14(7):1732.
Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2(2):141.
Fu J, Xu Y, Yang Y, Liu Y, Ma L, Zhang Y. Aspirin suppresses chemoresistance and enhances antitumor activity of 5-Fu in 5-Fu-resistant colorectal cancer by abolishing 5-Fu-induced NF-κB activation. Sci Rep. 2019;9(1):16937.
Wawro ME, Sobierajska K, Ciszewski WM, Niewiarowska J. Nonsteroidal anti-inflammatory drugs prevent vincristine-dependent cancer-associated fibroblasts formation. Int J Mol Sci. 2019;20(8): 1941.
Esra’a IK, Ismail WW, Mhaidat NM, Alqudah MA. Effect of metformin on irinotecan-induced cell cycle arrest in colorectal cancer cell lines HCT116 and SW480. Int J Health Sci. 2021;15(5):34.
Zhang P, Zhao S, Lu X, Shi Z, Liu H, Zhu B. Metformin enhances the sensitivity of colorectal cancer cells to cisplatin through ROS-mediated PI3K/Akt signaling pathway. Gene. 2020;745:144623.
Maghsoudi H, Sheikhnia F, Sitarek P, Hajmalek N, Hassani S, Rashidi V, et al. The potential preventive and therapeutic roles of NSAIDs in prostate cancer. Cancers. 2023;15(22):5435.
Hassani S, Maghsoudi H, Fattahi F, Malekinejad F, Hajmalek N, Sheikhnia F, et al. Flavonoids nanostructures promising therapeutic efficiencies in colorectal cancer. Int J Biol Macromol. 2023;241: 124508.
Wu S, Wen F, Li Y, Gao X, He S, Liu M, et al. PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma. Tumor Biol. 2016;37:8799–809.
Xia Z, Zhang L, Chen Q, Royal C, Yu Z, Liu Z, et al. Stable reversal of multidrug resistance in colon cancer cells by RNA interference targeting the MDR1 gene. Mol Med Rep. 2009;2(4):579–84.
Ma SC, Zhang JQ, Yan TH, Miao MX, Cao YM, Cao YB, et al. Novel strategies to reverse chemoresistance in colorectal cancer. Cancer Med. 2023;12(10):11073–96.
Singh D, Khan MA, Siddique HR. Emerging role of long non-coding RNAs in cancer chemoresistance: unravelling the multifaceted role and prospective therapeutic targeting. Mol Biol Rep. 2020;47(7):5569–85.
Mahato RK, Bhattacharya S, Khullar N, Sidhu IS, Reddy PH, Bhatti GK, et al. Targeting long non-coding RNAs in cancer therapy using CRISPR-Cas9 technology: a novel paradigm for precision oncology. J Biotechnol. 2024;379:98–119. https://doi.org/10.1016/j.jbiotec.2023.12.003.
Wang X, Zhao X, Zhong Y, Shen J, An W. Biomimetic exosomes: a new generation of drug delivery system. Front Bioeng Biotechnol. 2022;10:865682.
Chabria Y, Duffy GP, Lowery AJ, Dwyer RM. Hydrogels: 3d drug delivery systems for nanoparticles and extracellular vesicles. Biomedicines. 2021;9(11): 1694.
Sui H, Zhou S, Wang Y, Liu X, Zhou L, Yin P, et al. COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer. Carcinogenesis. 2011;32(5):667–75.
Kim S-H, Kim S-C, Ku J-L. Metformin increases chemo-sensitivity via gene downregulation encoding DNA replication proteins in 5-Fu resistant colorectal cancer cells. Oncotarget. 2017;8(34):56546.
Zhang C, Wang Y. Metformin attenuates cells stemness and epithelial–mesenchymal transition in colorectal cancer cells by inhibiting the Wnt3a/β–catenin pathway. Mol Med Rep. 2019;19(2):1203–9.
Liang Y, Hou L, Li L, Li L, Zhu L, Wang Y, et al. Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway. Oncogene. 2020;39(2):469–85.
Liang Y, Zhu D, Hou L, Wang Y, Huang X, Zhou C, et al. MiR-107 confers chemoresistance to colorectal cancer by targeting calcium-binding protein 39. Br J Cancer. 2020;122(5):705–14.
Yang Y, Ma L, Xu Y, Liu Y, Li W, Cai J, et al. Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins. Cell Death Dis. 2020;11(6):477.
Jiang L, Wang P, Sun Y-J, Wu Y-J. Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway. J Exp Clin Cancer Res. 2019;38(1):1–18.
Li S, Tian J, Zhang H, Zhou S, Wang X, Zhang L, et al. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer. Apoptosis. 2018;23:356–74.
Sakatani A, Sonohara F, Goel A. Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells. Carcinogenesis. 2019;40(3):422–31.
Mosca L, Pagano M, Borzacchiello L, Mele L, Russo A, Russo G, et al. S-adenosylmethionine increases the sensitivity of human colorectal cancer cells to 5-fluorouracil by inhibiting P-glycoprotein expression and NF-κB activation. Int J Mol Sci. 2021;22(17): 9286.
Pires AS, Marques CR, Encarnação JC, Abrantes AM, Marques IA, Laranjo M, et al. Ascorbic acid chemosensitizes colorectal cancer cells and synergistically inhibits tumor growth. Front Physiol. 2018;9:911.
Liu G, Hu X, Chakrabarty S. Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor‐dependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5‐FU. Int J Cancer. 2010;126(3):631–9.
Taghizadeh F, Tang MJ, Tai IT. Synergism between vitamin D and secreted protein acidic and rich in cysteine–induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy. Mol Cancer Ther. 2007;6(1):309–17.
Wang Z, Sun X, Feng Y, Wang Y, Zhang L, Wang Y, et al. Dihydromyricetin reverses MRP2-induced multidrug resistance by preventing NF-κB-Nrf2 signaling in colorectal cancer cell. Phytomedicine. 2021;82:153414.
Fan Y, Abulimiti P, Zhang H, Zhou Y, Zhu L. Mechanism of reversal of multidrug resistance by curcumin in human colorectal cancer cell line HCT-8/5-FU. Genet Mol Res. 2017;16(2): 16029414.
Lu Y, Zhang R, Zhang X, Zhang B, Yao Q. Curcumin may reverse 5-fluorouracil resistance on colonic cancer cells by regulating TET1-NKD-Wnt signal pathway to inhibit the EMT progress. Biomed Pharmacother. 2020;129: 110381.
Buhrmann C, Shayan P, Kraehe P, Popper B, Goel A, Shakibaei M. Resveratrol induces chemosensitization to 5-fluorouracil through up-regulation of intercellular junctions, epithelial-to-mesenchymal transition and apoptosis in colorectal cancer. Biochem Pharmacol. 2015;98(1):51–68.
Zhang R, Pan T, Xiang Y, Zhang M, Feng J, Liu S, et al. Β-elemene reverses the resistance of p53-deficient colorectal cancer cells to 5-fluorouracil by inducing pro-death autophagy and cyclin D3-dependent cycle arrest. Front Bioeng Biotechnol. 2020;8:378.
Li T, Si W, Zhu J, Yin L, Zhong C. Emodin reverses 5-Fu resistance in human colorectal cancer via downregulation of PI3K/Akt signaling pathway. Am J Transl Res. 2020;12(5):1851.
Hu T, Wang L, Zhang L, Lu L, Shen J, Chan RL, et al. Sensitivity of apoptosis-resistant colon cancer cells to Tanshinones is mediated by autophagic cell death and p53-independent cytotoxicity. Phytomedicine. 2015;22(5):536–44.
Zhang Y, Ge T, Xiang P, Zhou J, Tang S, Mao H, et al. Tanshinone IIA reverses oxaliplatin resistance in human colorectal cancer via Inhibition of erk/akt signaling pathway. OncoTargets Therapy. 2019;12:9725.
Lin S, Lei K, Du W, Yang L, Shi H, Gao Y, et al. Enhancement of oxaliplatin sensitivity in human colorectal cancer by hypericin mediated photodynamic therapy via ROS-related mechanism. Int J Biochem Cell Biol. 2016;71:24–34.
Sui H, Zhou LH, Zhang YL, Huang JP, Liu X, Ji Q, et al. Evodiamine suppresses ABCG2 mediated drug resistance by inhibiting p50/p65 NF-κB pathway in colorectal cancer. J Cell Biochem. 2016;117(6):1471–81.
Liu GW, Liu YH, Jiang GS, Ren WD. The reversal effect of ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism. Hum Cell. 2018;31(3):189–98.
Wang Z, Zhan Y, Xu J, Wang Y, Sun M, Chen J, et al. β-Sitosterol reverses multidrug resistance via BCRP suppression by inhibiting the p53-MDM2 interaction in colorectal cancer. J Agric Food Chem. 2020;68(12):3850–8.
Guo P, Wang S, Liang W, Wang W, Wang H, Zhao M, et al. Salvianolic acid B reverses multidrug resistance in HCT–8/VCR human colorectal cancer cells by increasing ROS levels. Mol Med Rep. 2017;15(2):724–30.
Al Bitar S, El-Sabban M, Doughan S, Abou-Kheir W. Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: updates and beyond. World J Gastroenterol. 2023;29(9):1395.
Ahmadi D, Zarei M, Rahimi M, Khazaie M, Asemi Z, Mir SM, et al. Preparation and in-vitro evaluation of pH-responsive cationic cyclodextrin coated magnetic nanoparticles for delivery of methotrexate to the Saos-2 bone cancer cells. J Drug Deliv Sci Technol. 2020;57:101584.
Kist M, Vucic D. Cell death pathways: intricate connections and disease implications. EMBO J. 2021;40(5): e106700.
Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011;30:1–14.
Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B, et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 2012;45(6):487–98.
Wang H, Liu H, Zheng Z-M, Zhang K-B, Wang T-P, Sribastav S-S, et al. Role of death receptor, mitochondrial and endoplasmic reticulum pathways in different stages of degenerative human lumbar disc. Apoptosis. 2011;16:990–1003.
Cavalcante GC, Schaan AP, Cabral GF, Santana-da-Silva MN, Pinto P, Vidal AF, et al. A cell’s fate: an overview of the molecular biology and genetics of apoptosis. Int J Mol Sci. 2019;20(17):4133.
Neophytou CM, Trougakos IP, Erin N, Papageorgis P. Apoptosis deregulation and the development of cancer multi-drug resistance. Cancers (Basel). 2021;13(17):4363.
Berindan-Neagoe I, Braicu C, Pileczki V, Petric RC, Miron N, Balacescu O, et al. 5-Fluorouracil potentiates the anti-cancer effect of oxaliplatin on Colo320 colorectal adenocarcinoma cells. J Gastrointestin Liver Dis. 2013;22(1):37–43.
Silke J, Vince J. IAPs and cell death. In: Nagata S, Nakano H, editor. Apoptotic and non-apoptotic cell death. Current topics in microbiology and immunology, vol. 403. Springer, Cham; 2016. https://doi.org/10.1007/82_2016_507.
Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov. 2012;11(2):109–24.
Meyer M. Pre-Clinical application of inhibitor of apoptosis protein (IAP) antagonists in colorectal cancer (CRC). Royal College of Surgeons in Ireland; 2022.
Knoll G, Ehrenschwender M. The non-peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis. FEBS Open Bio. 2021;11(3):714–23.
Enoch T, Norbury C. Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. Trends Biochem Sci. 1995;20(10):426–30.
Yao J, Huang A, Zheng X, Liu T, Lin Z, Zhang S, et al. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM–CHK2–P53 pathway. J Cancer Res Clin Oncol. 2017;143:419–31.
Xie Q, Wu M-Y, Zhang D-X, Yang Y-M, Wang B-S, Zhang J, et al. Synergistic anticancer effect of exogenous wild-type p53 gene combined with 5-FU in human colon cancer resistant to 5-FU in vivo. World J Gastroenterol. 2016;22(32): 7342.
Dominijanni A, Gmeiner WH. Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations. Cancer Drug Resist. 2018;1:48.
Kandioler D, Mittlböck M, Kappel S, Puhalla H, Herbst F, Langner C, et al. TP53 mutational status and prediction of benefit from adjuvant 5-fluorouracil in stage III colon cancer patients. EBioMedicine. 2015;2(8):825–30.
Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev. 2010;24(8):837–52.
Chan Wah Hak CM, Rullan A, Patin EC, Pedersen M, Melcher AA, Harrington KJ. Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy. Front Oncol. 2022;12: 971959.
Koirala M, DiPaola M. Overcoming cancer resistance: strategies and modalities for effective treatment. Biomedicines. 2024;12(8):1801.
Gurjao C, Liu D, Hofree M, AlDubayan SH, Wakiro I, Su M-J, et al. Intrinsic resistance to immune checkpoint blockade in a mismatch repair–deficient colorectal cancer. Cancer Immunol Res. 2019;7(8):1230–6.
Neboori HJ, Haffty BG, Wu H, Yang Q, Aly A, Goyal S, et al. Low p53 binding protein 1 (53BP1) expression is associated with increased local recurrence in breast cancer patients treated with breast-conserving surgery and radiotherapy. Int J Radiation Oncology* Biology* Phys. 2012;83(5):e677–83.
Ma J, Benitez JA, Li J, Miki S, de Albuquerque CP, Galatro T, et al. Inhibition of nuclear PTEN tyrosine phosphorylation enhances glioma radiation sensitivity through attenuated DNA repair. Cancer Cell. 2019;35(3):504–18. e7.
Najafi M, Farhood B, Mortezaee K. Cancer stem cells (CSCs) in cancer progression and therapy. J Cell Physiol. 2019;234(6):8381–95.
Fakhrioliaei A, Tanhaei S, Pakmehr S, Noori Shakir M, Qasim MT, Hariri M, et al. Potential role of Nrf2, HER2, and ALDH in cancer stem cells: a narrative review. J Membr Biol. 2024;257(1):3–16.
Ebrahimi N, Afshinpour M, Fakhr SS, Kalkhoran PG, Shadman-Manesh V, Adelian S, et al. Cancer stem cells in colorectal cancer: signaling pathways involved in stemness and therapy resistance. Crit Rev Oncol-Hematol. 2023;182: 103920.
Das PK, Islam F, Lam AK. The roles of cancer stem cells and therapy resistance in colorectal carcinoma. Cells. 2020;9(6):1392.
Phi LTH, Sari IN, Yang Y-G, Lee S-H, Jun N, Kim KS et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem cells international. 2018;2018.
Smith AG, Macleod KF. Autophagy, cancer stem cells and drug resistance. J Pathol. 2019;247(5):708–18.
Guo Q, Zhou Y, Xie T, Yuan Y, Li H, Shi W, et al. Tumor microenvironment of cancer stem cells: perspectives on cancer stem cell targeting. Genes Dis. 2024;11(3): 101043.
Desai N, Hasan U, Jeyashree K, Mani R, Chauhan M, Basu SM, et al. Biomaterial-based platforms for modulating immune components against cancer and cancer stem cells. Acta Biomater. 2023;161:1–36.
Vermeulen L, De Sousa E, Melo F, Van Der Heijden M, Cameron K, De Jong JH, Borovski T, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010;12(5):468–76.
Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 2014;14(3):342–56.
Lu H, Clauser KR, Tam WL, Fröse J, Ye X, Eaton EN, et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol. 2014;16(11):1105–17.
Zhou W, Ke SQ, Huang Z, Flavahan W, Fang X, Paul J, et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol. 2015;17(2):170–82.
Sansone P, Berishaj M, Rajasekhar VK, Ceccarelli C, Chang Q, Strillacci A, et al. Evolution of cancer stem-like cells in endocrine-resistant metastatic breast cancers is mediated by stromal microvesicles. Cancer Res. 2017;77(8):1927–41.
Shi X, Valizadeh A, Mir SM, Asemi Z, Karimian A, Majidina M, et al. MiRNA-29a reverses P-glycoprotein-mediated drug resistance and inhibits proliferation via up-regulation of PTEN in colon cancer cells. Eur J Pharmacol. 2020;880: 173138.
Nieto MA, Huang RY-J, Jackson RA, Thiery JP. EMT: 2016 Cell. 2016;166(1):21–45.
Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212–26.
Shibue T, Weinberg RA. EMT, CSCS, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611–29.
Roy S, Sunkara RR, Parmar MY, Shaikh S, Waghmare SK. EMT imparts cancer stemness and plasticity: new perspectives and therapeutic potential. Front Bioscience-Landmark. 2020;26(2):238–65.
Nobili S, Lapucci A, Landini I, Coronnello M, Roviello G, Mini E, editors. Role of ATP-binding cassette transporters in cancer initiation and progression. Seminars in cancer biology. Elsevier; 2020.
Silvestrini A, Meucci E, Martorana GE, Giardina B, Mordente A. Cancer stem cell and ATP-Binding cassette: which role in chemoresistance?? Advances in cancer stem cell biology. 2012:267–88.
Jiang Z-S, Sun Y-Z, Wang S-M, Ruan J-S. Epithelial-mesenchymal transition: potential regulator of ABC transporters in tumor progression. J Cancer. 2017;8(12):2319.
Saxena M, Stephens MA, Pathak H, Rangarajan A. Transcription factors that mediate epithelial–mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2011;2(7):e179–e.
Lindner D, editor. Editor animal models and the tumor microenvironment: studies of tumor–Host symbiosis. Seminars in oncology. Elsevier; 2014.
Li J, Liu H, Yu J, Yu H. Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells. Mol Med Rep. 2015;12(1):192–8.
Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D, et al. Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res. 2012;10(12):1597–606.
Cai J, Tian A-X, Wang Q-S, Kong P-Z, Du X, Li X-Q, et al. FOXF2 suppresses the FOXC2-mediated epithelial–mesenchymal transition and multidrug resistance of basal-like breast cancer. Cancer Lett. 2015;367(2):129–37.
Kaşıkcı E, Aydemir E, Bayrak ÖF, Şahin F. Inhibition of migration, invasion and drug resistance of pancreatic adenocarcinoma cells – role of snail, slug and twist and small molecule inhibitors. Onco Targets Ther. 2020;13:5763–77.
Lazarova D, Bordonaro M. ZEB1 mediates drug resistance and EMT in p300-deficient CRC. J Cancer. 2017;8(8):1453–9.
Bremnes RM, Dønnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol. 2011;6(1):209–17.
Guan J, Zhang H, Wen Z, Gu Y, Cheng Y, Sun Y, et al. Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells. Cancer Lett. 2014;345(1):132–9.
Sui H, Zhu L, Deng W, Li Q. Epithelial-mesenchymal transition and drug resistance: role, molecular mechanisms, and therapeutic strategies. Oncol Res Treat. 2014;37(10):584–9.
Jiao M, Nan K-J. Activation of PI3 kinase/Akt/HIF-1α pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma. Int J Oncol. 2012;40(2):461–8.
Kosuri K, Wu X, Wang L, Villalona-Calero M, Otterson G. An epigenetic mechanism for capecitabine resistance in mesothelioma. Biochem Biophys Res Commun. 2010;391(3):1465–70.
Alzahrani SM, Al Doghaither HA, Al-Ghafari AB, Pushparaj PN. 5–fluorouracil and capecitabine therapies for the treatment of colorectal cancer. Oncol Rep. 2023;50(4):175.
Kumar A, Singh AK, Singh H, Thareja S, Kumar P. Regulation of thymidylate synthase: an approach to overcome 5-FU resistance in colorectal cancer. Med Oncol. 2022;40(1):3.
Blondy S, David V, Verdier M, Mathonnet M, Perraud A, Christou N. 5-fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes. Cancer Sci. 2020;111(9):3142–54.
Kurasaka C, Nishizawa N, Ogino Y, Sato A. Trapping of 5-fluorodeoxyuridine monophosphate by thymidylate synthase confers resistance to 5-fluorouracil. ACS Omega. 2022;7(7):6046–52.
Kurasaka C, Ogino Y, Sato A. Molecular mechanisms and tumor biological aspects of 5-fluorouracil resistance in HCT116 human colorectal cancer cells. Int J Mol Sci. 2021;22(6): 2916.
Che J, Pan L, Yang X, Liu Z, Huang L, Wen C, et al. Thymidine phosphorylase expression and prognosis in colorectal cancer treated with 5–fluorouracil–based chemotherapy: A meta–analysis. Mol Clin Oncol. 2017;7(6):943–52.
Furukawa T, Tabata S, Yamamoto M, Kawahara K, Shinsato Y, Minami K, et al. Thymidine phosphorylase in cancer aggressiveness and chemoresistance. Pharmacol Res. 2018;132:15–20.
Saif MW, Syrigos KN, Katirtzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs. 2009;18(3):335–48.
Sharma V, Gupta SK, Verma M. Dihydropyrimidine dehydrogenase in the metabolism of the anticancer drugs. Cancer Chemother Pharmacol. 2019;84(6):1157–66.
Verma H, Narendra G, Raju B, Singh PK, Silakari O. Dihydropyrimidine dehydrogenase-mediated resistance to 5-fluorouracil: mechanistic investigation and solution. ACS Pharmacol Transl Sci. 2022;5(11):1017–33.
Maslarinou A, Manolopoulos VG, Ragia G. Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm? Front Pharmacol. 2023;14:1184523.
Cui Z, He S, Wen F, Lu L, Xu L, Wu H, et al. Dihydropyrimidine dehydrogenase (DPD) as a bridge between the immune microenvironment of colon cancers and 5-FU resistance. Frontiers in Bioscience-Landmark. 2023;28(4): 80.
Gmeiner WH, Okechukwu CC. Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects. Cancer Drug Resist. 2023;6(2):257.
Kciuk M, Marciniak B, Kontek R. Irinotecan—still an important player in cancer chemotherapy: a comprehensive overview. Int J Mol Sci. 2020;21(14): 4919.
Capello M, Lee M, Wang H, Babel I, Katz MH, Fleming JB, et al. Carboxylesterase 2 as a determinant of response to irinotecan and neoadjuvant FOLFIRINOX therapy in pancreatic ductal adenocarcinoma. J Natl Cancer Inst. 2015;107(8): djv132.
Xie F-W, Peng Y-H, Chen X, Chen X, Li J, Yu Z-Y, et al. Regulation and expression of aberrant methylation on Irinotecan metabolic genes CES2, UGT1A1 and GUSB in the in-vitro cultured colorectal cancer cells. Biomed Pharmacother. 2014;68(1):31–7.
Xiao D, Yang D, Guo L, Lu W, Charpentier M, Yan B. Regulation of carboxylesterase‐2 expression by p53 family proteins and enhanced anti‐cancer activities among 5‐fluorouracil, Irinotecan and Doxazolidine prodrug. Br J Pharmacol. 2013;168(8):1989–99.
Shaojun C, Li H, Haixin H, Guisheng L. Expression of topoisomerase 1 and carboxylesterase 2 correlates with Irinotecan treatment response in metastatic colorectal cancer. Cancer Biol Ther. 2018;19(3):153–9.
de Man FM, Goey AK, van Schaik RH, Mathijssen RH, Bins S. Individualization of Irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet. 2018;57:1229–54.
Paulík A, Grim J, Filip S. Predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer. Acta Medica (Hradec Kralove). 2012;55(4):153–9.
Tagawa K, Maruo Y, Mimura Y, Ikushiro S. Effects of common genetic variants of human uridine diphosphate glucuronosyltransferase subfamilies on irinotecan glucuronidation. Toxicol Mech Methods. 2023;33(3):197–205.
Li W, Zhang H, Assaraf YG, Zhao K, Xu X, Xie J, et al. Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies. Drug Resist Updat. 2016;27:14–29.
Lin L, Yee SW, Kim RB, Giacomini KM. Slc transporters as therapeutic targets: emerging opportunities. Nat Rev Drug Discov. 2015;14(8):543–60.
International Transporter Consortium; Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215–36. https://doi.org/10.1038/nrd3028.
Ceballos MP, Rigalli JP, Ceré LI, Semeniuk M, Catania VA, Ruiz ML. ABC transporters: regulation and association with multidrug resistance in hepatocellular carcinoma and colorectal carcinoma. Curr Med Chem. 2019;26(7):1224–50.
Sun L, Ke J, He Z, Chen Z, Huang Q, Ai W, et al. HES1 promotes colorectal cancer cell resistance to 5-Fu by inducing of EMT and ABC transporter proteins. J Cancer. 2017;8(14):2802.
Gao Q, Li X-x, Xu Y-m, Zhang J-z, Qin Y-q, Fang J. IRE1α-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells. Cancer Lett. 2020;476:67–74.
Wang JQ, Wu ZX, Yang Y, Teng QX, Li YD, Lei ZN, et al. ATP-binding cassette (ABC) transporters in cancer: A review of recent updates. J Evidence‐Based Med. 2021;14(3):232–56.
Liu X. ABC family transporters. In: Liu X, Pan G, editors. Drug transporters in drug disposition, effects and toxicity. Advances in experimental medicine and biology, vol 1141. Springer, Singapore; 2019. https://doi.org/10.1007/978-981-13-7647-4_2.
Zhou H, Lin C, Zhang Y, Zhang X, Zhang C, Zhang P, et al. Mir-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR 1/P‐gp expression. Cell Prolif. 2017;50(3): e12341.
Du J, He Y, Li P, Wu W, Chen Y, Ruan H. IL-8 regulates the doxorubicin resistance of colorectal cancer cells via modulation of multidrug resistance 1 (MDR1). Cancer Chemother Pharmacol. 2018;81:1111–9.
Wang T, Chen Z, Zhu Y, Pan Q, Liu Y, Qi X, et al. Inhibition of transient receptor potential channel 5 reverses 5-fluorouracil resistance in human colorectal cancer cells. J Biol Chem. 2015;290(1):448–56.
Westover D, Li F. New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies. J Exp Clin Cancer Res. 2015;34:1–9.
Guo J, Wang Q, Zhang Y, Sun W, Zhang S, Li Y, et al. Functional daidzein enhances the anticancer effect of topotecan and reverses BCRP-mediated drug resistance in breast cancer. Pharmacol Res. 2019;147: 104387.
Ozawa S, Miura T, Terashima J, Habano W. Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review. Cancer Drug Resist. 2021;4(4):946.
Lu JF, Pokharel D, Bebawy M. MRP1 and its role in anticancer drug resistance. Drug Metab Rev. 2015;47(4):406–19.
Cole SP. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future. Annu Rev Pharmacol Toxicol. 2014;54:95–117.
Blythe AJ, Fox AH, Bond CS. The ins and outs of LncRNA structure: how, why and what comes next? Biochim Et Biophys Acta (BBA)-Gene Regul Mech. 2016;1859(1):46–58.
Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics Proteomics Bioinf. 2016;14(1):42–54.
Mattick JS, Amaral PP, Carninci P, Carpenter S, Chang HY, Chen L-L, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023;24(6):430–47.
Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009;458(7235):223–7.
Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, et al. The GENCODE v7 catalog of human long noncoding rnas: analysis of their gene structure, evolution, and expression. Genome Res. 2012;22(9):1775–89.
Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011;25(18):1915–27.
Alvarez-Dominguez JR, Lodish HF. Emerging mechanisms of long noncoding RNA function during normal and malignant hematopoiesis. Blood. 2017;130(18):1965–75.
Zampetaki A, Albrecht A, Steinhofel K. Long non-coding RNA structure and function: is there a link?? Front Physiol. 2018;9: 1201.
Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43(6):904–14.
Ahmad P, Bensaoud C, Mekki I, Rehman MU, Kotsyfakis M. Long non-coding RNAs and their potential roles in the vector-host-pathogen triad. Life (Basel). 2021;11(1):56. https://doi.org/10.3390/life11010056.
Hu ZY, Wang XY, Guo WB, Xie LY, Huang YQ, Liu YP, et al. Long non-coding RNA MALAT1 increases AKAP-9 expression by promoting SRPK1-catalyzed SRSF1 phosphorylation in colorectal cancer cells. Oncotarget. 2016;7(10):11733–43.
He Y, Luo Y, Liang B, Ye L, Lu G, He W. Potential applications of MEG3 in cancer diagnosis and prognosis. Oncotarget. 2017;8(42):73282–95.
Cao Y, Shi H, Ren F, Jia Y, Zhang R. Long non-coding RNA CCAT1 promotes metastasis and poor prognosis in epithelial ovarian cancer. Exp Cell Res. 2017;359(1):185–94.
Dong X, Yang Z, Yang H, Li D, Qiu X. Long non-coding RNA MIR4435-2HG promotes colorectal cancer proliferation and metastasis through miR-206/YAP1 axis. Front Oncol. 2020;10: 160.
Yan S, Yue Y, Wang J, Li W, Sun M, Gu C, et al. LINC00668 promotes tumorigenesis and progression through sponging miR-188-5p and regulating USP47 in colorectal cancer. Eur J Pharmacol. 2019;858: 172464.
Ahadi A. Functional roles of LncRNAs in the pathogenesis and progression of cancer. Genes Dis. 2021;8(4):424–37.
Moayedi K, Orandi S, Ebrahimi R, Tanhapour M, Moradi M, Abbastabar M, et al. A novel approach to type 3 diabetes mechanism: the interplay between noncoding RNAs and insulin signaling pathway in Alzheimer’s disease. J Cell Physiol. 2022;237(7):2838–61.
Jin H, Du W, Huang W, Yan J, Tang Q, Chen Y, et al. LncRNA and breast cancer: progress from identifying mechanisms to challenges and opportunities of clinical treatment. Mol Ther. 2021;25:613–37.
Chen R, Li W-X, Sun Y, Duan Y, Li Q, Zhang A-X, et al. Comprehensive analysis of LncRNA and mRNA expression profiles in lung cancer. Clin Lab. 2017;63(2):313–20.
Jiang MC, Ni JJ, Cui WY, Wang BY, Zhuo W. Emerging roles of LncRNA in cancer and therapeutic opportunities. Am J Cancer Res. 2019;9(7):1354–66.
Sarfi M, Abbastabar M, Khalili E. Increased expression of urinary exosomal LnCRNA TUG-1 in early bladder cancer. Gene Rep. 2021;22: 101010.
Pardini B, Sabo AA, Birolo G, Calin GA. Noncoding RNAs in extracellular fluids as cancer biomarkers: the new frontier of liquid biopsies. Cancers. 2019;11(8):1170.
Wang WT, Sun YM, Huang W, He B, Zhao YN, Chen YQ. Genome-wide long non-coding RNA analysis identified circulating LncRNAs as novel non-invasive diagnostic biomarkers for gynecological disease. Sci Rep. 2016;6:23343.
Xu K, Jiang X, Ariston Gabriel AN, Li X, Wang Y, Xu S. Evolving landscape of long non-coding RNAs in cerebrospinal fluid: a key role from diagnosis to therapy in brain tumors. Front Cell Dev Biol. 2021;9:737670.
Luo Y, Chen JJ, Lv Q, Qin J, Huang YZ, Yu MH, et al. Long non-coding RNA NEAT1 promotes colorectal cancer progression by competitively binding miR-34a with SIRT1 and enhancing the Wnt/β-catenin signaling pathway. Cancer Lett. 2019;440–441:11–22.
Ye M, Zhao L, Zhang L, Wu S, Li Z, Qin Y, et al. LncRNA NALT1 promotes colorectal cancer progression via targeting PEG10 by sponging microRNA-574-5p. Cell Death Dis. 2022;13(11):960.
Zhu X, Bu F, Tan T, Luo Q, Zhu J, Lin K, et al. Long noncoding RNA RP11-757G1.5 sponges miR-139-5p and upregulates YAP1 thereby promoting the proliferation and liver, spleen metastasis of colorectal cancer. J Exp Clin Cancer Res. 2020;39(1):207.
Xu Y, Zhang X, Hu X, Zhou W, Zhang P, Zhang J, et al. The effects of LncRNA MALAT1 on proliferation, invasion and migration in colorectal cancer through regulating SOX9. Mol Med. 2018;24:1–15.
Zhang M, Li Y, Wang H, Yu W, Lin S, Guo J. LncRNA SNHG5 affects cell proliferation, metastasis and migration of colorectal cancer through regulating miR-132-3p/CREB5. Cancer Biol Ther. 2019;20(4):524–36.
Wang A-H, Fan W-J, Fu L, Wang X-T. LncRNA PCAT-1 regulated cell proliferation, invasion, migration and apoptosis in colorectal cancer through targeting miR-149-5p. Eur Rev Med Pharmacol Sci. 2019;23:19.
Zheng XY, Cao MZ, Ba Y, Li YF, Ye JL. Lncrna testis-specific transcript, Y-linked 15 (TTTY15) promotes proliferation, migration and invasion of colorectal cancer cells via regulating miR-29a-3p/DVL3 axis. Cancer Biomark. 2021;31(1):1–11.
Chen D, Sun Q, Zhang L, Zhou X, Cheng X, Zhou D, et al. The lncRNA HOXA11-AS functions as a competing endogenous RNA to regulate PADI2 expression by sponging miR-125a-5p in liver metastasis of colorectal cancer. Oncotarget. 2017;8(41):70642.
Xu J, Meng Q, Li X, Yang H, Xu J, Gao N, et al. Long noncoding RNA MIR17HG promotes colorectal cancer progression via miR-17-5p. Cancer Res. 2019;79(19):4882–95.
Chen D-l, Lu Y-x, Zhang J-x, Wei X-l, Wang F, Zeng Z-l, et al. Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a CeRNA for microRNA-215 to regulate ZEB2 expression. Theranostics. 2017;7(19):4836.
Zhang Y, Huang W, Yuan Y, Li J, Wu J, Yu J, et al. Long non-coding RNA H19 promotes colorectal cancer metastasis via binding to hnRNPA2B1. J Exp Clin Cancer Res. 2020;39(1):1–15.
Fang X, Xu Y, Li K, Liu P, Zhang H, Jiang Y et al. Exosomal lncRNA PCAT1 promotes tumor circulating cell-mediated colorectal cancer liver metastasis by regulating the activity of the miR-329-3p/Netrin-1-CD146 complex. Journal of Immunology Research. 2022;2022.
Zhan T, Cheng X, Zhu Q, Han Z, Zhu K, Tan J, et al. LncRNA LOC105369504 inhibits tumor proliferation and metastasis in colorectal cancer by regulating PSPC1. Cell Death Discov. 2023;9(1):89.
Yin DD, Liu ZJ, Zhang E, Kong R, Zhang ZH, Guo RH. Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. Tumour Biol. 2015;36(6):4851–9.
Amirmahani F, Asadi MH, Jannat Alipoor F. LncRNA MIAT promotes the proliferation and invasion of colorectal cancer via suppressing apoptosis and senescence. Middle East J Cancer. 2023;14(2):219–29.
Xu M, Xu X, Pan B, Chen X, Lin K, Zeng K, et al. LncRNA SATB2-AS1 inhibits tumor metastasis and affects the tumor immune cell microenvironment in colorectal cancer by regulating SATB2. Mol Cancer. 2019;18(1):135.
Zhang C, Wang L, Jin C, Zhou J, Peng C, Wang Y, et al. Long non-coding RNA Lnc-LALC facilitates colorectal cancer liver metastasis via epigenetically silencing LZTS1. Cell Death Dis. 2021;12(2):224.
Li J, Ji Y, Chen N, Wang H, Fang C, Yin X, et al. A specific upregulated long noncoding RNA in colorectal cancer promotes cancer progression. JCI Insight. 2022;7(15):e158855. https://doi.org/10.1172/jci.insight.158855.
Wang B, Chen W, Zhao Z, Sun Y, Huang Y. Lncrna-DANCR promotes growth and metastasis of colorectal cancer via activating epithelial-mesenchymal transition process. Transl Cancer Res. 2019;8(7):2517.
Xie J, Wang J-J, Li Y-J, Wu J, Gu X-J, Yang X-R. LncRNA GAS5 suppresses colorectal cancer progress by target miR-21/LIFR axis. Evidence‐Based Complement Altern Med. 2022;2022(1):3298939.
Corrà F, Agnoletto C, Minotti L, Baldassari F, Volinia S. The network of non-coding RNAs in cancer drug resistance. Front Oncol. 2018;8: 327.
Amiri R, Nabi PN, Fazilat A, Roshani F, Kararoudi AN, Hemmati-Dinarvand M, et al. Crosstalk between miRNAs and signaling pathways in the development of drug resistance in breast cancer. Horm Mol Biol Clin Investig. 2024. https://doi.org/10.1515/hmbci-2024-0066.
Bian Z, Jin L, Zhang J, Yin Y, Quan C, Hu Y, et al. Lncrna—UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p. Sci Rep. 2016;6(1):23892.
Jiang X, Li Q, Zhang S, Song C, Zheng P. Long noncoding RNA GIHCG induces cancer progression and chemoresistance and indicates poor prognosis in colorectal cancer. Onco Targets Ther. 2019;12:1059.
Qiao L, Liu X, Tang Y, Zhao Z, Zhang J, Liu H. Knockdown of long non-coding RNA prostate cancer-associated NcRNA transcript 1 inhibits multidrug resistance and c-Myc-dependent aggressiveness in colorectal cancer Caco-2 and HT-29 cells. Mol Cell Biochem. 2018;441:99–108.
Fan H, Zhu JH, Yao XQ. Knockdown of long non–coding RNA PVT1 reverses multidrug resistance in colorectal cancer cells. Mol Med Rep. 2018;17(6):8309–15.
Tang D, Yang Z, Long F, Luo L, Yang B, Zhu R, et al. Inhibition of MALAT1 reduces tumor growth and metastasis and promotes drug sensitivity in colorectal cancer. Cell Signal. 2019;57:21–8.
Li Y, Huang S, Li Y, Zhang W, He K, Zhao M, et al. Decreased expression of lncRNA SLC25A25-AS1 promotes proliferation, chemoresistance, and EMT in colorectal cancer cells. Tumor Biol. 2016;37:14205–15.
Lee H, Kim C, Ku J-L, Kim W, Yoon SK, Kuh H-J, et al. A long non-coding RNA SnaR contributes to 5-fluorouracil resistance in human colon cancer cells. Mol Cells. 2014;37(7):540.
Li J, Li X, Cen C, Ai X, Lin C, Hu G. The long non-coding RNA ENST00000547547 reduces 5-fluorouracil resistance of colorectal cancer cells via competitive binding to microRNA-31. Oncol Rep. 2018;39(1):217–26.
Bian Z, Zhang J, Li M, Feng Y, Yao S, Song M, et al. Long non-coding RNA LINC00152 promotes cell proliferation, metastasis, and confers 5-FU resistance in colorectal cancer by inhibiting miR-139-5p. Oncogenesis. 2017;6(11): 395.
Yue B, Cai D, Liu C, Fang C, Yan D. Linc00152 functions as a competing endogenous RNA to confer oxaliplatin resistance and holds prognostic values in colon cancer. Mol Ther. 2016;24(12):2064–77.
Li P, Zhang X, Wang H, Wang L, Liu T, Du L, et al. MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2. Mol Cancer Ther. 2017;16(4):739–51.
Ren J, Ding L, Zhang D, Shi G, Xu Q, Shen S, et al. Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal LncRNA H19. Theranostics. 2018;8(14):3932.
Wang H, Li H, Zhang L, Yang D. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis. Biomed Pharmacother. 2018;106:1607–15.
Li L, Shang J, Zhang Y, Liu S, Peng Y, Zhou Z, et al. MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis. Oncol Rep. 2017;38(3):1383–92.
Ping G, Xiong W, Zhang L, Li Y, Zhang Y, Zhao Y. Silencing long noncoding RNA PVT1 inhibits tumorigenesis and cisplatin resistance of colorectal cancer. Am J Transl Res. 2018;10(1):138.
Xiao Z, Qu Z, Chen Z, Fang Z, Zhou K, Huang Z, et al. LncRNA HOTAIR is a prognostic biomarker for the proliferation and chemoresistance of colorectal cancer via MiR-203a-3p-mediated Wnt/ss-catenin signaling pathway. Cell Physiol Biochem. 2018;46(3):1275–85.
Wu K-f, Liang W-C, Feng L, Pang J-x, Waye MM-Y, Zhang J-F, et al. H19 mediates methotrexate resistance in colorectal cancer through activating Wnt/β-catenin pathway. Exp Cell Res. 2017;350(2):312–7.
Li C, Gao Y, Li Y, Ding D. TUG1 mediates methotrexate resistance in colorectal cancer via miR-186/CPEB2 axis. Biochem Biophys Res Commun. 2017;491(2):552–7.
Zhu J, Zhang R, Yang D, Li J, Yan X, Jin K, et al. Knockdown of long non-coding RNA XIST inhibited doxorubicin resistance in colorectal cancer by upregulation of miR-124 and downregulation of SGK1. Cell Physiol Biochem. 2018;51(1):113–28.
Lu Y, Zhao X, Liu Q, Li C, Graves-Deal R, Cao Z, et al. LncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling. Nat Med. 2017;23(11):1331–41.
Doxtater KD, Tripathi MK. LncRNA UCA1 as a potential therapeutic target for drug resistance in colorectal cancer. Cancer Res. 2023;83(7Supplement):2854.
Yang Y-n, Zhang R, Du J-w, Yuan H-h, Li Y-j, Wei X-l, et al. Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer. Cancer Cell Int. 2018;18:1–11.
Ramli S, Sim MS, Guad RM, Gopinath SCB, Subramaniyan V, Fuloria S, et al. Long noncoding RNA UCA1 in Gastrointestinal cancers: molecular regulatory roles and patterns, mechanisms, and interactions. J Oncol. 2021;2021:1–15.
Amirinejad R, Rezaei M, Shirvani-Farsani Z. An update on long intergenic noncoding RNA p21: a regulatory molecule with various significant functions in cancer. Cell Biosci. 2020;10(1):82.
Silva-Fisher JM, Dang HX, White NM, Strand MS, Krasnick BA, Rozycki EB, et al. Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression. Nat Commun. 2020;11(1):2156.
Cabanski CR, White NM, Dang HX, Silva-Fisher JM, Rauck CE, Cicka D, et al. Pan-cancer transcriptome analysis reveals long noncoding RNAs with conserved function. RNA Biol. 2015;12(6):628–42.
White NM, Cabanski CR, Silva-Fisher JM, Dang HX, Govindan R, Maher CA. Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer. Genome Biol. 2014;15:1–16.
Zhang PF, Wu J, Wu Y, Huang W, Liu M, Dong ZR, et al. The lncRNA SCARNA2 mediates colorectal cancer chemoresistance through a conserved microRNA-342‐3p target sequence. J Cell Physiol. 2019;234(7):10157–65.
Weng W, Okugawa Y, Toden S, Toiyama Y, Kusunoki M, Goel A. FOXM1 and FOXQ1 are promising prognostic biomarkers and novel targets of tumor-suppressive miR-342 in human colorectal cancer. Clin Cancer Res. 2016;22(19):4947–57.
Lai X, Gupta SK, Schmitz U, Marquardt S, Knoll S, Spitschak A, et al. MiR-205-5p and miR-342-3p cooperate in the repression of the E2F1 transcription factor in the context of anticancer chemotherapy resistance. Theranostics. 2018;8(4):1106.
Ge X, Chen Y, Liao X, Liu D, Li F, Ruan H, et al. Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer. Med Oncol. 2013;30:1–6.
Qiao L, Liu X, Tang Y, Zhao Z, Zhang J, Feng Y. Down regulation of the long non-coding RNA PCAT-1 induced growth arrest and apoptosis of colorectal cancer cells. Life Sci. 2017;188:37–44.
Zhou Q, Hou Z, Zuo S, Zhou X, Feng Y, Sun Y, et al. LUCAT1 promotes colorectal cancer tumorigenesis by targeting the ribosomal protein L40-MDM 2‐p53 pathway through binding with UBA 52. Cancer Sci. 2019;110(4):1194–207.
Thorenoor N, Faltejskova-Vychytilova P, Hombach S, Mlcochova J, Kretz M, Svoboda M, et al. Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer. Oncotarget. 2016;7(1):622.
Shan TD, Tian ZB, Li Q, Jiang YP, Liu FG, Sun XG, et al. Long intergenic noncoding RNA 00908 promotes proliferation and inhibits apoptosis of colorectal cancer cells by regulating KLF5 expression. J Cell Physiol. 2021;236(2):889–99.
Zhang XT, Pan SX, Wang AH, Kong QY, Jiang KT, Yu ZB. Long non-coding RNA (lncRNA) X-inactive specific transcript (XIST) plays a critical role in predicting clinical prognosis and progression of colorectal cancer. Med Sci Monit. 2019;25:6429–35.
Xiao M, Liang Z, Yin Z. Long non–coding RNA ZFPM2–AS1 promotes colorectal cancer progression by sponging miR–137 to regulate TRIM24. Mol Med Rep. 2021;23(2):1.
Wang J, Zhu J, Dong M, Yu H, Dai X, Li K. Knockdown of tripartite motif containing 24 by lentivirus suppresses cell growth and induces apoptosis in human colorectal cancer cells. Oncol Res. 2014;22(1):39.
Xie W, Zhang Y, Wang B, Hu Y, Zhan B, Wei F, et al. Tripartite motif containing 24 regulates cell proliferation in colorectal cancer through YAP signaling. Cancer Med. 2020;9(17):6367–76.
Du T, Gao Q, Zhao Y, Gao J, Li J, Wang L, et al. Long non-coding RNA LINC02474 affects metastasis and apoptosis of colorectal cancer by inhibiting the expression of GZMB. Front Oncol. 2021;11: 651796.
Chiusolo V, Jacquemin G, Yonca Bassoy E, Vinet L, Liguori L, Walch M, et al. Granzyme B enters the mitochondria in a Sam50-, Tim22-and mtHsp70-dependent manner to induce apoptosis. Cell Death Differ. 2017;24(4):747–58.
Carrieri C, Cimatti L, Biagioli M, Beugnet A, Zucchelli S, Fedele S, et al. Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat. Nature. 2012;491(7424):454–7.
Hu J, Shan Y, Ma J, Pan Y, Zhou H, Jiang L, et al. LncRNA ST3Gal6-AS1/ST3Gal6 axis mediates colorectal cancer progression by regulating α‐2, 3 sialylation via PI3K/Akt signaling. Int J Cancer. 2019;145(2):450–60.
Zhang X, Tang N, Hadden TJ, Rishi AK, Akt. FoxO and regulation of apoptosis. Biochim Et Biophys Acta (BBA)-Molecular Cell Res. 2011;1813(11):1978–86.
Cheng K, Zhao Z, Wang G, Wang J, Zhu W. LncRNA GAS5 inhibits colorectal cancer cell proliferation via the miR–182–5p/FOXO3a axis. Oncol Rep. 2018;40(4):2371–80.
Cao M-Q, You A-B, Zhu X-D, Zhang W, Zhang Y-Y, Zhang S-Z, et al. miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a. J Hematol Oncol. 2018;11(1):1–12.
Zhang Y-H, Fu J, Zhang Z-J, Ge C-C, Yi Y. LncRNA-LINC00152 down-regulated by miR-376c-3p restricts viability and promotes apoptosis of colorectal cancer cells. Am J Transl Res. 2016;8(12):5286.
Chen Z, Cai X, Chang L, Xia Y, Wang L, Hou Y, et al. LINC00152 is a potential biomarker involved in the modulation of biological characteristics of residual colorectal cancer cells following chemoradiotherapy. Oncol Lett. 2018;15(4):4177–84.
Lian Y, Yan C, Xu H, Yang J, Yu Y, Zhou J, et al. A novel lncrna, LINC00460, affects cell proliferation and apoptosis by regulating KLF2 and CUL4A expression in colorectal cancer. Mol Ther Nucleic Acids. 2018;12:684–97.
Lepage C, Léger D, Bertrand J, Martin F, Beneytout J, Liagre B. Diosgenin induces death receptor-5 through activation of p38 pathway and promotes TRAIL-induced apoptosis in colon cancer cells. Cancer Lett. 2011;301(2):193–202.
Wang J, Huang F, Bai Z, Chi B, Wu J, Chen X. Curcumol inhibits growth and induces apoptosis of colorectal cancer LoVo cell line via IGF-1R and p38 MAPK pathway. Int J Mol Sci. 2015;16(8):19851–67.
Chiacchiera F, Grossi V, Cappellari M, Peserico A, Simonatto M, Germani A, et al. Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models. Cancer Lett. 2012;324(1):98–108.
Liang H, Zhao Q, Zhu Z, Zhang C, Zhang H. Long noncoding RNA LINC00958 suppresses apoptosis and radiosensitivity of colorectal cancer through targeting miR-422a. Cancer Cell Int. 2021;21:1–15.
Wei W-T, Nian X-X, Wang S-Y, Jiao H-L, Wang Y-X, Xiao Z-Y, et al. miR-422a inhibits cell proliferation in colorectal cancer by targeting AKT1 and MAPK1. Cancer Cell Int. 2017;17:1–12.
Zhu S, Mao J, Zhang X, Wang P, Zhou Y, Tong J, et al. CAF-derived exosomal lncRNA FAL1 promotes chemoresistance to oxaliplatin by regulating autophagy in colorectal cancer. Dig Liver Dis. 2024;56(2):330–42.
Mirza-Aghazadeh-Attari M, Ostadian C, Saei AA, Mihanfar A, Darband SG, Sadighparvar S, et al. DNA damage response and repair in ovarian cancer: potential targets for therapeutic strategies. DNA Repair. 2019;80:59–84.
Mihanfar A, Darband SG, Sadighparvar S, Kaviani M, Mirza-Aghazadeh-Attari M, Yousefi B, et al. In vitro and in vivo anticancer effects of syringic acid on colorectal cancer: possible mechanistic view. Chemico-Biological Interactions. 2021;337: 109337.
Sharma V, Khurana S, Kubben N, Abdelmohsen K, Oberdoerffer P, Gorospe M, et al. A BRCA 1-interacting lnc RNA regulates homologous recombination. EMBO Rep. 2015;16(11):1520–34.
Kaller M, Götz U, Hermeking H. Loss of p53-inducible long non-coding RNA LINC01021 increases chemosensitivity. Oncotarget. 2017;8(61):102783.
Ma S, Yang D, Liu Y, Wang Y, Lin T, Li Y, et al. LncRNA BANCR promotes tumorigenesis and enhances adriamycin resistance in colorectal cancer. Aging. 2018;10(8):2062.
Li Y, Yuan S, Liu J, Wang Y, Zhang Y, Chen X, et al. CSE1L silence inhibits the growth and metastasis in gastric cancer by repressing GPNMB via positively regulating transcription factor MITF. J Cell Physiol. 2020;235(3):2071–9.
Gao H, Song X, Kang T, Yan B, Feng L, Gao L, et al. Long noncoding RNA CRNDE functions as a competing endogenous RNA to promote metastasis and oxaliplatin resistance by sponging miR-136 in colorectal cancer. Onco Targets Ther. 2017;10:205–16. https://doi.org/10.2147/OTT.S116178.
Chaudhary R, Gryder B, Woods WS, Subramanian M, Jones MF, Li XL, et al. Prosurvival long noncoding RNA PINCR regulates a subset of p53 targets in human colorectal cancer cells by binding to matrin 3. Elife. 2017;6:e23244.
Shi L, Sun J, Kinomura A, Fukuto A, Horikoshi Y, Tashiro S. Matrin3 promotes homologous recombinational repair by regulation of RAD51. J Biochem. 2019;166(4):343–51.
Liu R, Zhang Q, Shen L, Chen S, He J, Wang D, et al. Long noncoding RNA lnc-RI regulates DNA damage repair and radiation sensitivity of CRC cells through NHEJ pathway. Cell Biol Toxicol. 2020;36:493–507.
Yao P, Wu Y, Zhao K, Li Y, Cao J, Xing C. The feedback loop of ANKHD1/lncRNA MALAT1/YAP1 strengthens the radioresistance of CRC by activating YAP1/AKT signaling. Cell Death Dis. 2022; 13: 103. Leukemia. 2018;32:2250-62.
Stanley L. Drug metabolism. Pharmacognosy: Elsevier; 2024. pp. 597–624.
Wang Y, Fang Z, Hong M, Yang D, Xie W. Long-noncoding RNAs (lncRNAs) in drug metabolism and disposition, implications in cancer chemo-resistance. Acta Pharm Sin B. 2020;10(1):105–12.
Liu LC, Wang YL, Lin PL, Zhang X, Cheng WC, Liu SH, et al. Long noncoding RNA HOTAIR promotes invasion of breast cancer cells through chondroitin sulfotransferase CHST15. Int J Cancer. 2019;145(9):2478–87.
Takahashi K, Yan IK, Wood J, Haga H, Patel T. Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Mol Cancer Res. 2014;12(10):1377–87.
Zhang XW, Bu P, Liu L, Zhang XZ, Li J. Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Biochem Biophys Res Commun. 2015;462(3):227–32.
Fang Z, Chen W, Yuan Z, Liu X, Jiang H. Lncrna-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation. Biomed Pharmacother. 2018;101:536–42.
Lan WG, Xu DH, Xu C, Ding CL, Ning FL, Zhou YL, et al. Silencing of long non-coding RNA ANRIL inhibits the development of multidrug resistance in gastric cancer cells. Oncol Rep. 2016;36(1):263–70.
Wang Y, Zhang D, Wu K, Zhao Q, Nie Y, Fan D. Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines. Mol Cell Biol. 2014;34(17):3182–93.
Hu H, Yang L, Li L, Zeng C. Long non-coding RNA KCNQ1OT1 modulates oxaliplatin resistance in hepatocellular carcinoma through miR-7-5p/ABCC1 axis. Biochem Biophys Res Commun. 2018;503(4):2400–6.
Chang L, Hu Z, Zhou Z, Zhang H. Linc00518 contributes to multidrug resistance through regulating the MiR-199a/MRP1 axis in breast cancer. Cell Physiol Biochem. 2018;48(1):16–28.
Wu X, Zheng Y, Han B, Dong X. Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361. Biomed Pharmacother. 2018;99:832–8.
Wang L, Bu P, Ai Y, Srinivasan T, Chen HJ, Xiang K, et al. A long non-coding RNA targets MicroRNA miR-34a to regulate colon cancer stem cell asymmetric division. Elife. 2016;5:e14620.
Sun J, Zhou H, Bao X, Wu Y, Jia H, Zhao H et al. lncRNA TUG1 facilitates colorectal cancer stem cell characteristics and chemoresistance by enhancing GATA6 protein stability. Stem cells international. 2021;2021.
Fu C, Li X, Han L, Xie M, Ouyang S. LncRNA PTPRG-AS1 maintains stem-cell-like features and promotes oxaliplatin resistance in colorectal cancer via regulating the miR-665 and STAT3 axis. Mol Cell Toxicol. 2024;20:35–45. https://doi.org/10.1007/s13273-022-00314-1.
Di Cecilia S, Zhang F, Sancho A, Li S, Aguiló F, Sun Y, et al. RBM5-AS1 is critical for self-renewal of colon cancer stem-like cells. Cancer Res. 2016;76(19):5615–27.
Yu Y, Nangia-Makker P, Farhana L, Majumdar AP. A novel mechanism of LncRNA and MiRNA interaction: CCAT2 regulates miR-145 expression by suppressing its maturation process in colon cancer cells. Mol Cancer. 2017;16(1):1–11.
Yu X, Mi L, Dong J, Zou J. Long intergenic non-protein-coding RNA 1567 (LINC01567) acts as a sponge against microRNA-93 in regulating the proliferation and tumorigenesis of human colon cancer stem cells. BMC Cancer. 2017;17(1):1–15.
Guo K, Gong W, Wang Q, Gu G, Zheng T, Li Y, et al. LINC01106 drives colorectal cancer growth and stemness through a positive feedback loop to regulate the Gli family factors. Cell Death Dis. 2020;11(10):869.
Zhou H, Xiong Y, Peng L, Wang R, Zhang H, Fu Z. LncRNA-cCSC1 modulates cancer stem cell properties in colorectal cancer via activation of the Hedgehog signaling pathway. J Cell Biochem. 2020;121(3):2510–24.
De Las Rivas J, Brozovic A, Izraely S, Casas-Pais A, Witz IP, Figueroa A. Cancer drug resistance induced by EMT: novel therapeutic strategies. Arch Toxicol. 2021;95(7):2279–97.
Cao H, Xu E, Liu H, Wan L, Lai M. Epithelial–mesenchymal transition in colorectal cancer metastasis: a system review. Pathol – Res Pract. 2015;211(8):557–69.
Liaghat M, Ferdousmakan S, Mortazavi SH, Yahyazadeh S, Irani A, Banihashemi S, et al. The impact of epithelial-mesenchymal transition (EMT) induced by metabolic processes and intracellular signaling pathways on chemo-resistance, metastasis, and recurrence in solid tumors. Cell Commun Signal. 2024;22(1):575.
Weng X, Ma T, Chen Q, Chen BW, Shan J, Chen W, et al. Decreased expression of H19/miR-675 ameliorates hypoxia-induced oxaliplatin resistance in colorectal cancer. Heliyon. 2024;10(5):e27027.
Li C-f, Li Y-c, Wang Y, Sun L-b. The effect of LncRNA H19/miR-194-5p axis on the epithelial-mesenchymal transition of colorectal adenocarcinoma. Cell Physiol Biochem. 2018;50(1):196–213.
Wang M, Han D, Yuan Z, Hu H, Zhao Z, Yang R, et al. Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy. Cell Death Dis. 2018;9(12):1149.
Park MS, Jeong SD, Shin CH, Cha S, Yu A, Kim EJ, et al. LINC02257 regulates malignant phenotypes of colorectal cancer via interacting with miR-1273 g-3p and YB1. Cell Death Dis. 2024;15(12):895.
Ding M, Wang W, Huo K, Song Y, Chen X, Xiang Z, et al. The role of LncRNA FEZF1-AS1 in colorectal cancer progression via the P53 signaling pathway. DNA Cell Biol. 2025;44(1):32–45.
Wu W, Li A, He H, Ye S, Zhou Z, Quan JH, et al. Long noncoding RNA LINC01550 inhibits colorectal cancer malignancy by suppressing the Wnt/β-catenin signaling pathway. J Biochem Mol Toxicol. 2024;38(8): e23774.
Shi CJ, Xue ZH, Zeng WQ, Deng LQ, Pang FX, Zhang FW, et al. LncRNA-NEF suppressed oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer through epigenetically inactivating MEK/ERK signaling. Cancer Gene Ther. 2023;30(6):855–65.
Zhang L, Wu H, Zhang Y, Xiao X, Chu F, Zhang L. Induction of lncRNA NORAD accounts for hypoxia-induced chemoresistance and vasculogenic mimicry in colorectal cancer by sponging the miR-495-3p/ hypoxia-inducible factor-1α (HIF-1α). Bioengineered. 2022;13(1):950–62.
Wang W, Zhou Z, Dai X, Wang H, Jin J, Min K, et al. LncRNA-ENST00000543604 exerts a tumor-promoting effect via miRNA 564/AEG-1 or ZNF326/EMT and predicts the prognosis of and chemotherapeutic effect in colorectal cancer. Front Oncol. 2022;12: 960481.
Wu Z-H, Wang X-L, Tang H-M, Jiang T, Chen J, Lu S, et al. Long non-coding RNA HOTAIR is a powerful predictor of metastasis and poor prognosis and is associated with epithelial-mesenchymal transition in colon cancer. Oncol Rep. 2014;32(1):395–402.
Liu Y, Sun M, Xia R, Zhang E, Liu X, Zhang Z, et al. LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer. Cell Death Dis. 2015;6(7):e1802–e.
Jiang Y, Liu G, Ye W, Xie J, Shao C, Wang X, et al. ZEB2-AS1 accelerates epithelial/mesenchymal transition through miR-1205/CRKL pathway in colorectal cancer. Cancer Biother Radiopharm. 2020;35(2):153–62.
Long F, Li X, Pan J, Ye H, Di C, Huang Y, et al. The role of LncRNA NEAT1 in human cancer chemoresistance. Cancer Cell Int. 2024;24(1):236.
Jiang P, Xu H, Xu C, Chen A, Chen L, Zhou M, et al. NEAT1 contributes to the CSC-like traits of A549/CDDP cells via activating Wnt signaling pathway. Chemico-Biological Interactions. 2018;296:154–61.
Azizidoost S, Ghaedrahmati F, Anbiyaee O, Ahmad Ali R, Cheraghzadeh M, Farzaneh M. Emerging roles for lncRNA-NEAT1 in colorectal cancer. Cancer Cell Int. 2022;22(1):209.
Ye Z, Zhou M, Tian B, Wu B, Li J. Expression of lncRNA-CCAT1, E-cadherin and N-cadherin in colorectal cancer and its clinical significance. Int J Clin Exp Med. 2015;8(3):3707.
Yang C, Pan Y, Deng SP. Downregulation of LncRNA CCAT1 enhances 5-fluorouracil sensitivity in human colon cancer cells. BMC Mol Cell Biol. 2019;20:1–11.
Sun F, Liang W, Qian J. The identification of CRNDE, H19, UCA1 and HOTAIR as the key LncRNAs involved in oxaliplatin or Irinotecan resistance in the chemotherapy of colorectal cancer based on integrative bioinformatics analysis. Mol Med Rep. 2019;20(4):3583–96.
Selem NA, Youness RA, Gad MZ. What is beyond LncRNAs in breast cancer: a special focus on colon cancer-associated transcript-1 (CCAT-1). Non-coding RNA Research. 2021;6(4):174–86.
Ghafouri-Fard S, Abak A, Anamag FT, Shoorei H, Majidpoor J, Taheri M. The emerging role of non-coding RNAs in the regulation of PI3K/AKT pathway in the carcinogenesis process. Biomed Pharmacother. 2021;137: 111279.
Tsang S, Patel T, Yustein JT. Long non-coding RNAs regulation of therapeutic resistance. Cancer Drug Resist. 2019;2(3):550.
Poursheikhani A, Abbaszadegan MR, Kerachian MA. Mechanisms of long non-coding RNA function in colorectal cancer tumorigenesis. Asia-Pac J Clin Oncol. 2021;17(1):7–23.
: First, conduct a thorough analysis of the source text to identify its core subject matter.
Determine Keywords:
Primary Keyword: Identify and define the single most important 2-4 word search phrase that represents the main topic.
Related Keywords: Identify and define 3-5 additional terms (people, places, concepts) that provide essential context.
Strategic Integration: You will seamlessly weave these identified keywords into the article’s headlines, subheadings, and body text to maximize search visibility.
2. Content Blueprint & Narrative
H1 Headline: Write a compelling, keyword-rich headline that captures the essence of the story. It must be powerful and intriguing.
Meta Description: Immediately following the H1, write an expert meta description (≤155 characters) that summarizes the article’s value and includes the primary keyword.
Lead Paragraph: Write a 2-3 sentence opening that hooks the reader immediately with the most critical information. Do not label it.
Narrative Flow: Structure the body with a clear narrative arc. Introduce the core events, develop the story with context and data, and build toward a powerful final insight.
Body & Subheadings: Use H2 and H3 subheadings to organize the story into logical, easy-to-digest sections. Keep paragraphs short (2-4 sentences) to maintain reader momentum.
3. Execution Standards & Style
Authoritative Voice: Write with a warm, confident, and authoritative tone befitting a seasoned US news editor. The language must be polished, clear, and accessible.
Original Analysis: Do not merely summarize. Paraphrase all information completely and add your own expert commentary. Focus on the implications and the “so what?” factor behind the facts to provide unique value.
Engagement: Use vivid storytelling and dynamic phrasing. Bold key terms on their first appearance. Employ bullet points or lists for clarity where appropriate.
AP Style: Adhere strictly to AP Style for all numbers, capitalization, punctuation, and formatting.
What to Avoid: All clichés, robotic phrasing, and rhetorical questions.
4. Journalistic Integrity & Nuance
Trust & Accuracy (E-E-A-T): Your output must be factually impeccable, based only on
Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233–54.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
Van der Jeught K, Xu H-C, Li Y-J, Lu X-B, Ji G. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol. 2018;24(34):3834.
Shinji S, Yamada T, Matsuda A, Sonoda H, Ohta R, Iwai T, et al. Recent advances in the treatment of colorectal cancer: a review. J Nippon Med Sch. 2022;89(3):246–54.
Haider T, Pandey V, Banjare N, Gupta PN, Soni V. Drug resistance in cancer: mechanisms and tackling strategies. Pharmacol Rep. 2020;72(5):1125–51.
Sheikhnia F, Maghsoudi H, Majidinia M. The critical function of MicroRNAs in developing resistance against 5- fluorouracil in cancer cells. Mini Rev Med Chem. 2024;24(6):601–17.
Zhou J, Ji Q, Li Q. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. J Exp Clin Cancer Res. 2021;40:1–17.
Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016;8(1):57–84.
Sharifi-Azad M, Fathi M, Cho WC, Barzegari A, Dadashi H, Dadashpour M, et al. Recent advances in targeted drug delivery systems for resistant colorectal cancer. Cancer Cell Int. 2022;22(1):196.
Khosravi M, Poursaleh A, Ghasempour G, Farhad S, Najafi M. The effects of oxidative stress on the development of atherosclerosis. Biol Chem. 2019;400(6):711–32.
Basak D, Uddin MN, Hancock J. The role of oxidative stress and its counteractive utility in colorectal cancer (CRC). Cancers. 2020;12(11):3336.
Yang L, Fang C, Zhang R, Zhou S. Prognostic value of oxidative stress-related genes in colorectal cancer and its correlation with tumor immunity. BMC Genomics. 2024;25(1):8.
Briffa R, Langdon SP, Grech G, Harrison DJ. Acquired and intrinsic resistance to colorectal cancer treatment. Colorectal Cancer-Diagnosis. Screening and Management: Intech Open London; 2018. pp. 57–81.
To KK, Wu M, Tong CW, Yan W. Drug transporters in the development of multidrug resistance in colorectal cancer. Drug resistance in colorectal cancer: molecular mechanisms and therapeutic strategies. Elsevier; 2020. pp. 35–55.
Maali A, Sarfi M, Mirzakhani M, Goodarzi G, Maghsoudi H, Maniati M, et al. Peaceful existence of tumor cells with their non-malignant neighbors: the trade of tumor cells with tumor microenvironment. Curr Chem Biol. 2020;14(4):228–39.
Zafari N, Khosravi F, Rezaee Z, Esfandyari S, Bahiraei M, Bahramy A, et al. The role of the tumor microenvironment in colorectal cancer and the potential therapeutic approaches. J Clin Lab Anal. 2022;36(8): e24585.
Chen Y, Zheng X, Wu C. The role of the tumor microenvironment and treatment strategies in colorectal cancer. Front Immunol. 2021;12:792691.
Liu K, Gao L, Ma X, Huang J-J, Chen J, Zeng L, et al. Long non-coding RNAs regulate drug resistance in cancer. Mol Cancer. 2020;19(1):1–13.
Sheikhnia F, Fazilat A, Rashidi V, Azizzadeh B, Mohammadi M, Maghsoudi H, et al. Exploring the therapeutic potential of Quercetin in cancer treatment: targeting long non-coding RNAs. Pathology. 2024;260: 155374.
Mohammadi F, Nejatollahi M, Sheikhnia F, Ebrahimi Y, Mohammadi M, Rashidi V, et al. MiRNAs: main players of cancer drug resistance target ABC transporters. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2025. https://doi.org/10.1007/s00210-024-03719-y.
Alizadeh-Fanalou S, Khosravi M, Alian F, Rokhsartalb-Azar S, Nazarizadeh A, Karimi-Dehkordi M, et al. Dual role of microRNA-1297 in the suppression and progression of human malignancies. Biomed Pharmacother. 2021;141: 111863.
Tajik F, Alian F, Yousefi M, Azadfallah A, Hoseini A, Mohammadi F, et al. MicroRNA-372 acts as a double-edged sword in human cancers. Heliyon. 2023;9(5):e15991. https://doi.org/10.1016/j.heliyon.2023.e15991.
Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669–85.
Yau TO. Precision treatment in colorectal cancer: now and the future. JGH Open. 2019;3(5):361–9.
McNair AG, Whistance RN, Forsythe RO, Macefield R, Rees J, Pullyblank AM, et al. Core outcomes for colorectal cancer surgery: a consensus study. PLoS Med. 2016;13(8): e1002071.
Vennix S, Bakker OJ, Prins HA, Lips DJ. Re-interventions following laparoscopic surgery for colorectal cancer: data from 818 individuals from the Dutch surgical colorectal audit. Journal of Laparoendoscopic & Advanced Surgical Techniques. 2014;24(11):751–5.
Ammerata G, Filippo R, Laface C, Memeo R, Solaini L, Cavaliere D, et al. Hyperthermic intraperitoneal chemotherapy and colorectal cancer: from physiology to surgery. World J Clin Cases. 2022;10(30):10852.
McQuade M, Stojanovska R, Bornstein VC, Nurgali J. Colorectal cancer chemotherapy: the evolution of treatment and new approaches. Curr Med Chem. 2017;24(15):1537–57.
Xie Y-H, Chen Y-X, Fang J-Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5(1): 22.
Sakata S, Larson DW. Targeted therapy for colorectal cancer. Surg Oncol Clin N Am. 2022;31(2):255–64.
Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–75.
Golshani G, Zhang Y. Advances in immunotherapy for colorectal cancer: a review. Therapeutic Adv Gastroenterol. 2020;13:1756284820917527.
Boushey R, Williams LJ, Weiser M, Chen W. Management of anastomotic complications of colorectal surgery. 2017.
Köhne C. Current stages of adjuvant treatment of colon cancer. Ann Oncol. 2012;23:x71–6.
Sheikhnia F, Rashidi V, Maghsoudi H, Majidinia M. Potential anticancer properties and mechanisms of thymoquinone in colorectal cancer. Cancer Cell Int. 2023;23(1): 320.
Hossain MS, Karuniawati H, Jairoun AA, Urbi Z, Ooi DJ, John A, et al. Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers. 2022;14(7):1732.
Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2(2):141.
Fu J, Xu Y, Yang Y, Liu Y, Ma L, Zhang Y. Aspirin suppresses chemoresistance and enhances antitumor activity of 5-Fu in 5-Fu-resistant colorectal cancer by abolishing 5-Fu-induced NF-κB activation. Sci Rep. 2019;9(1):16937.
Wawro ME, Sobierajska K, Ciszewski WM, Niewiarowska J. Nonsteroidal anti-inflammatory drugs prevent vincristine-dependent cancer-associated fibroblasts formation. Int J Mol Sci. 2019;20(8): 1941.
Esra’a IK, Ismail WW, Mhaidat NM, Alqudah MA. Effect of metformin on irinotecan-induced cell cycle arrest in colorectal cancer cell lines HCT116 and SW480. Int J Health Sci. 2021;15(5):34.
Zhang P, Zhao S, Lu X, Shi Z, Liu H, Zhu B. Metformin enhances the sensitivity of colorectal cancer cells to cisplatin through ROS-mediated PI3K/Akt signaling pathway. Gene. 2020;745:144623.
Maghsoudi H, Sheikhnia F, Sitarek P, Hajmalek N, Hassani S, Rashidi V, et al. The potential preventive and therapeutic roles of NSAIDs in prostate cancer. Cancers. 2023;15(22):5435.
Hassani S, Maghsoudi H, Fattahi F, Malekinejad F, Hajmalek N, Sheikhnia F, et al. Flavonoids nanostructures promising therapeutic efficiencies in colorectal cancer. Int J Biol Macromol. 2023;241: 124508.
Wu S, Wen F, Li Y, Gao X, He S, Liu M, et al. PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma. Tumor Biol. 2016;37:8799–809.
Xia Z, Zhang L, Chen Q, Royal C, Yu Z, Liu Z, et al. Stable reversal of multidrug resistance in colon cancer cells by RNA interference targeting the MDR1 gene. Mol Med Rep. 2009;2(4):579–84.
Ma SC, Zhang JQ, Yan TH, Miao MX, Cao YM, Cao YB, et al. Novel strategies to reverse chemoresistance in colorectal cancer. Cancer Med. 2023;12(10):11073–96.
Singh D, Khan MA, Siddique HR. Emerging role of long non-coding RNAs in cancer chemoresistance: unravelling the multifaceted role and prospective therapeutic targeting. Mol Biol Rep. 2020;47(7):5569–85.
Mahato RK, Bhattacharya S, Khullar N, Sidhu IS, Reddy PH, Bhatti GK, et al. Targeting long non-coding RNAs in cancer therapy using CRISPR-Cas9 technology: a novel paradigm for precision oncology. J Biotechnol. 2024;379:98–119. https://doi.org/10.1016/j.jbiotec.2023.12.003.
Wang X, Zhao X, Zhong Y, Shen J, An W. Biomimetic exosomes: a new generation of drug delivery system. Front Bioeng Biotechnol. 2022;10:865682.
Chabria Y, Duffy GP, Lowery AJ, Dwyer RM. Hydrogels: 3d drug delivery systems for nanoparticles and extracellular vesicles. Biomedicines. 2021;9(11): 1694.
Sui H, Zhou S, Wang Y, Liu X, Zhou L, Yin P, et al. COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer. Carcinogenesis. 2011;32(5):667–75.
Kim S-H, Kim S-C, Ku J-L. Metformin increases chemo-sensitivity via gene downregulation encoding DNA replication proteins in 5-Fu resistant colorectal cancer cells. Oncotarget. 2017;8(34):56546.
Zhang C, Wang Y. Metformin attenuates cells stemness and epithelial–mesenchymal transition in colorectal cancer cells by inhibiting the Wnt3a/β–catenin pathway. Mol Med Rep. 2019;19(2):1203–9.
Liang Y, Hou L, Li L, Li L, Zhu L, Wang Y, et al. Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway. Oncogene. 2020;39(2):469–85.
Liang Y, Zhu D, Hou L, Wang Y, Huang X, Zhou C, et al. MiR-107 confers chemoresistance to colorectal cancer by targeting calcium-binding protein 39. Br J Cancer. 2020;122(5):705–14.
Yang Y, Ma L, Xu Y, Liu Y, Li W, Cai J, et al. Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins. Cell Death Dis. 2020;11(6):477.
Jiang L, Wang P, Sun Y-J, Wu Y-J. Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway. J Exp Clin Cancer Res. 2019;38(1):1–18.
Li S, Tian J, Zhang H, Zhou S, Wang X, Zhang L, et al. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer. Apoptosis. 2018;23:356–74.
Sakatani A, Sonohara F, Goel A. Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells. Carcinogenesis. 2019;40(3):422–31.
Mosca L, Pagano M, Borzacchiello L, Mele L, Russo A, Russo G, et al. S-adenosylmethionine increases the sensitivity of human colorectal cancer cells to 5-fluorouracil by inhibiting P-glycoprotein expression and NF-κB activation. Int J Mol Sci. 2021;22(17): 9286.
Pires AS, Marques CR, Encarnação JC, Abrantes AM, Marques IA, Laranjo M, et al. Ascorbic acid chemosensitizes colorectal cancer cells and synergistically inhibits tumor growth. Front Physiol. 2018;9:911.
Liu G, Hu X, Chakrabarty S. Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor‐dependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5‐FU. Int J Cancer. 2010;126(3):631–9.
Taghizadeh F, Tang MJ, Tai IT. Synergism between vitamin D and secreted protein acidic and rich in cysteine–induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy. Mol Cancer Ther. 2007;6(1):309–17.
Wang Z, Sun X, Feng Y, Wang Y, Zhang L, Wang Y, et al. Dihydromyricetin reverses MRP2-induced multidrug resistance by preventing NF-κB-Nrf2 signaling in colorectal cancer cell. Phytomedicine. 2021;82:153414.
Fan Y, Abulimiti P, Zhang H, Zhou Y, Zhu L. Mechanism of reversal of multidrug resistance by curcumin in human colorectal cancer cell line HCT-8/5-FU. Genet Mol Res. 2017;16(2): 16029414.
Lu Y, Zhang R, Zhang X, Zhang B, Yao Q. Curcumin may reverse 5-fluorouracil resistance on colonic cancer cells by regulating TET1-NKD-Wnt signal pathway to inhibit the EMT progress. Biomed Pharmacother. 2020;129: 110381.
Buhrmann C, Shayan P, Kraehe P, Popper B, Goel A, Shakibaei M. Resveratrol induces chemosensitization to 5-fluorouracil through up-regulation of intercellular junctions, epithelial-to-mesenchymal transition and apoptosis in colorectal cancer. Biochem Pharmacol. 2015;98(1):51–68.
Zhang R, Pan T, Xiang Y, Zhang M, Feng J, Liu S, et al. Β-elemene reverses the resistance of p53-deficient colorectal cancer cells to 5-fluorouracil by inducing pro-death autophagy and cyclin D3-dependent cycle arrest. Front Bioeng Biotechnol. 2020;8:378.
Li T, Si W, Zhu J, Yin L, Zhong C. Emodin reverses 5-Fu resistance in human colorectal cancer via downregulation of PI3K/Akt signaling pathway. Am J Transl Res. 2020;12(5):1851.
Hu T, Wang L, Zhang L, Lu L, Shen J, Chan RL, et al. Sensitivity of apoptosis-resistant colon cancer cells to Tanshinones is mediated by autophagic cell death and p53-independent cytotoxicity. Phytomedicine. 2015;22(5):536–44.
Zhang Y, Ge T, Xiang P, Zhou J, Tang S, Mao H, et al. Tanshinone IIA reverses oxaliplatin resistance in human colorectal cancer via Inhibition of erk/akt signaling pathway. OncoTargets Therapy. 2019;12:9725.
Lin S, Lei K, Du W, Yang L, Shi H, Gao Y, et al. Enhancement of oxaliplatin sensitivity in human colorectal cancer by hypericin mediated photodynamic therapy via ROS-related mechanism. Int J Biochem Cell Biol. 2016;71:24–34.
Sui H, Zhou LH, Zhang YL, Huang JP, Liu X, Ji Q, et al. Evodiamine suppresses ABCG2 mediated drug resistance by inhibiting p50/p65 NF-κB pathway in colorectal cancer. J Cell Biochem. 2016;117(6):1471–81.
Liu GW, Liu YH, Jiang GS, Ren WD. The reversal effect of ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism. Hum Cell. 2018;31(3):189–98.
Wang Z, Zhan Y, Xu J, Wang Y, Sun M, Chen J, et al. β-Sitosterol reverses multidrug resistance via BCRP suppression by inhibiting the p53-MDM2 interaction in colorectal cancer. J Agric Food Chem. 2020;68(12):3850–8.
Guo P, Wang S, Liang W, Wang W, Wang H, Zhao M, et al. Salvianolic acid B reverses multidrug resistance in HCT–8/VCR human colorectal cancer cells by increasing ROS levels. Mol Med Rep. 2017;15(2):724–30.
Al Bitar S, El-Sabban M, Doughan S, Abou-Kheir W. Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: updates and beyond. World J Gastroenterol. 2023;29(9):1395.
Ahmadi D, Zarei M, Rahimi M, Khazaie M, Asemi Z, Mir SM, et al. Preparation and in-vitro evaluation of pH-responsive cationic cyclodextrin coated magnetic nanoparticles for delivery of methotrexate to the Saos-2 bone cancer cells. J Drug Deliv Sci Technol. 2020;57:101584.
Kist M, Vucic D. Cell death pathways: intricate connections and disease implications. EMBO J. 2021;40(5): e106700.
Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011;30:1–14.
Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B, et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 2012;45(6):487–98.
Wang H, Liu H, Zheng Z-M, Zhang K-B, Wang T-P, Sribastav S-S, et al. Role of death receptor, mitochondrial and endoplasmic reticulum pathways in different stages of degenerative human lumbar disc. Apoptosis. 2011;16:990–1003.
Cavalcante GC, Schaan AP, Cabral GF, Santana-da-Silva MN, Pinto P, Vidal AF, et al. A cell’s fate: an overview of the molecular biology and genetics of apoptosis. Int J Mol Sci. 2019;20(17):4133.
Neophytou CM, Trougakos IP, Erin N, Papageorgis P. Apoptosis deregulation and the development of cancer multi-drug resistance. Cancers (Basel). 2021;13(17):4363.
Berindan-Neagoe I, Braicu C, Pileczki V, Petric RC, Miron N, Balacescu O, et al. 5-Fluorouracil potentiates the anti-cancer effect of oxaliplatin on Colo320 colorectal adenocarcinoma cells. J Gastrointestin Liver Dis. 2013;22(1):37–43.
Silke J, Vince J. IAPs and cell death. In: Nagata S, Nakano H, editor. Apoptotic and non-apoptotic cell death. Current topics in microbiology and immunology, vol. 403. Springer, Cham; 2016. https://doi.org/10.1007/82_2016_507.
Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov. 2012;11(2):109–24.
Meyer M. Pre-Clinical application of inhibitor of apoptosis protein (IAP) antagonists in colorectal cancer (CRC). Royal College of Surgeons in Ireland; 2022.
Knoll G, Ehrenschwender M. The non-peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis. FEBS Open Bio. 2021;11(3):714–23.
Enoch T, Norbury C. Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. Trends Biochem Sci. 1995;20(10):426–30.
Yao J, Huang A, Zheng X, Liu T, Lin Z, Zhang S, et al. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM–CHK2–P53 pathway. J Cancer Res Clin Oncol. 2017;143:419–31.
Xie Q, Wu M-Y, Zhang D-X, Yang Y-M, Wang B-S, Zhang J, et al. Synergistic anticancer effect of exogenous wild-type p53 gene combined with 5-FU in human colon cancer resistant to 5-FU in vivo. World J Gastroenterol. 2016;22(32): 7342.
Dominijanni A, Gmeiner WH. Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations. Cancer Drug Resist. 2018;1:48.
Kandioler D, Mittlböck M, Kappel S, Puhalla H, Herbst F, Langner C, et al. TP53 mutational status and prediction of benefit from adjuvant 5-fluorouracil in stage III colon cancer patients. EBioMedicine. 2015;2(8):825–30.
Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev. 2010;24(8):837–52.
Chan Wah Hak CM, Rullan A, Patin EC, Pedersen M, Melcher AA, Harrington KJ. Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy. Front Oncol. 2022;12: 971959.
Koirala M, DiPaola M. Overcoming cancer resistance: strategies and modalities for effective treatment. Biomedicines. 2024;12(8):1801.
Gurjao C, Liu D, Hofree M, AlDubayan SH, Wakiro I, Su M-J, et al. Intrinsic resistance to immune checkpoint blockade in a mismatch repair–deficient colorectal cancer. Cancer Immunol Res. 2019;7(8):1230–6.
Neboori HJ, Haffty BG, Wu H, Yang Q, Aly A, Goyal S, et al. Low p53 binding protein 1 (53BP1) expression is associated with increased local recurrence in breast cancer patients treated with breast-conserving surgery and radiotherapy. Int J Radiation Oncology* Biology* Phys. 2012;83(5):e677–83.
Ma J, Benitez JA, Li J, Miki S, de Albuquerque CP, Galatro T, et al. Inhibition of nuclear PTEN tyrosine phosphorylation enhances glioma radiation sensitivity through attenuated DNA repair. Cancer Cell. 2019;35(3):504–18. e7.
Najafi M, Farhood B, Mortezaee K. Cancer stem cells (CSCs) in cancer progression and therapy. J Cell Physiol. 2019;234(6):8381–95.
Fakhrioliaei A, Tanhaei S, Pakmehr S, Noori Shakir M, Qasim MT, Hariri M, et al. Potential role of Nrf2, HER2, and ALDH in cancer stem cells: a narrative review. J Membr Biol. 2024;257(1):3–16.
Ebrahimi N, Afshinpour M, Fakhr SS, Kalkhoran PG, Shadman-Manesh V, Adelian S, et al. Cancer stem cells in colorectal cancer: signaling pathways involved in stemness and therapy resistance. Crit Rev Oncol-Hematol. 2023;182: 103920.
Das PK, Islam F, Lam AK. The roles of cancer stem cells and therapy resistance in colorectal carcinoma. Cells. 2020;9(6):1392.
Phi LTH, Sari IN, Yang Y-G, Lee S-H, Jun N, Kim KS et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem cells international. 2018;2018.
Smith AG, Macleod KF. Autophagy, cancer stem cells and drug resistance. J Pathol. 2019;247(5):708–18.
Guo Q, Zhou Y, Xie T, Yuan Y, Li H, Shi W, et al. Tumor microenvironment of cancer stem cells: perspectives on cancer stem cell targeting. Genes Dis. 2024;11(3): 101043.
Desai N, Hasan U, Jeyashree K, Mani R, Chauhan M, Basu SM, et al. Biomaterial-based platforms for modulating immune components against cancer and cancer stem cells. Acta Biomater. 2023;161:1–36.
Vermeulen L, De Sousa E, Melo F, Van Der Heijden M, Cameron K, De Jong JH, Borovski T, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010;12(5):468–76.
Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 2014;14(3):342–56.
Lu H, Clauser KR, Tam WL, Fröse J, Ye X, Eaton EN, et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol. 2014;16(11):1105–17.
Zhou W, Ke SQ, Huang Z, Flavahan W, Fang X, Paul J, et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol. 2015;17(2):170–82.
Sansone P, Berishaj M, Rajasekhar VK, Ceccarelli C, Chang Q, Strillacci A, et al. Evolution of cancer stem-like cells in endocrine-resistant metastatic breast cancers is mediated by stromal microvesicles. Cancer Res. 2017;77(8):1927–41.
Shi X, Valizadeh A, Mir SM, Asemi Z, Karimian A, Majidina M, et al. MiRNA-29a reverses P-glycoprotein-mediated drug resistance and inhibits proliferation via up-regulation of PTEN in colon cancer cells. Eur J Pharmacol. 2020;880: 173138.
Nieto MA, Huang RY-J, Jackson RA, Thiery JP. EMT: 2016 Cell. 2016;166(1):21–45.
Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212–26.
Shibue T, Weinberg RA. EMT, CSCS, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611–29.
Roy S, Sunkara RR, Parmar MY, Shaikh S, Waghmare SK. EMT imparts cancer stemness and plasticity: new perspectives and therapeutic potential. Front Bioscience-Landmark. 2020;26(2):238–65.
Nobili S, Lapucci A, Landini I, Coronnello M, Roviello G, Mini E, editors. Role of ATP-binding cassette transporters in cancer initiation and progression. Seminars in cancer biology. Elsevier; 2020.
Silvestrini A, Meucci E, Martorana GE, Giardina B, Mordente A. Cancer stem cell and ATP-Binding cassette: which role in chemoresistance?? Advances in cancer stem cell biology. 2012:267–88.
Jiang Z-S, Sun Y-Z, Wang S-M, Ruan J-S. Epithelial-mesenchymal transition: potential regulator of ABC transporters in tumor progression. J Cancer. 2017;8(12):2319.
Saxena M, Stephens MA, Pathak H, Rangarajan A. Transcription factors that mediate epithelial–mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2011;2(7):e179–e.
Lindner D, editor. Editor animal models and the tumor microenvironment: studies of tumor–Host symbiosis. Seminars in oncology. Elsevier; 2014.
Li J, Liu H, Yu J, Yu H. Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells. Mol Med Rep. 2015;12(1):192–8.
Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D, et al. Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res. 2012;10(12):1597–606.
Cai J, Tian A-X, Wang Q-S, Kong P-Z, Du X, Li X-Q, et al. FOXF2 suppresses the FOXC2-mediated epithelial–mesenchymal transition and multidrug resistance of basal-like breast cancer. Cancer Lett. 2015;367(2):129–37.
Kaşıkcı E, Aydemir E, Bayrak ÖF, Şahin F. Inhibition of migration, invasion and drug resistance of pancreatic adenocarcinoma cells – role of snail, slug and twist and small molecule inhibitors. Onco Targets Ther. 2020;13:5763–77.
Lazarova D, Bordonaro M. ZEB1 mediates drug resistance and EMT in p300-deficient CRC. J Cancer. 2017;8(8):1453–9.
Bremnes RM, Dønnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol. 2011;6(1):209–17.
Guan J, Zhang H, Wen Z, Gu Y, Cheng Y, Sun Y, et al. Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells. Cancer Lett. 2014;345(1):132–9.
Sui H, Zhu L, Deng W, Li Q. Epithelial-mesenchymal transition and drug resistance: role, molecular mechanisms, and therapeutic strategies. Oncol Res Treat. 2014;37(10):584–9.
Jiao M, Nan K-J. Activation of PI3 kinase/Akt/HIF-1α pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma. Int J Oncol. 2012;40(2):461–8.
Kosuri K, Wu X, Wang L, Villalona-Calero M, Otterson G. An epigenetic mechanism for capecitabine resistance in mesothelioma. Biochem Biophys Res Commun. 2010;391(3):1465–70.
Alzahrani SM, Al Doghaither HA, Al-Ghafari AB, Pushparaj PN. 5–fluorouracil and capecitabine therapies for the treatment of colorectal cancer. Oncol Rep. 2023;50(4):175.
Kumar A, Singh AK, Singh H, Thareja S, Kumar P. Regulation of thymidylate synthase: an approach to overcome 5-FU resistance in colorectal cancer. Med Oncol. 2022;40(1):3.
Blondy S, David V, Verdier M, Mathonnet M, Perraud A, Christou N. 5-fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes. Cancer Sci. 2020;111(9):3142–54.
Kurasaka C, Nishizawa N, Ogino Y, Sato A. Trapping of 5-fluorodeoxyuridine monophosphate by thymidylate synthase confers resistance to 5-fluorouracil. ACS Omega. 2022;7(7):6046–52.
Kurasaka C, Ogino Y, Sato A. Molecular mechanisms and tumor biological aspects of 5-fluorouracil resistance in HCT116 human colorectal cancer cells. Int J Mol Sci. 2021;22(6): 2916.
Che J, Pan L, Yang X, Liu Z, Huang L, Wen C, et al. Thymidine phosphorylase expression and prognosis in colorectal cancer treated with 5–fluorouracil–based chemotherapy: A meta–analysis. Mol Clin Oncol. 2017;7(6):943–52.
Furukawa T, Tabata S, Yamamoto M, Kawahara K, Shinsato Y, Minami K, et al. Thymidine phosphorylase in cancer aggressiveness and chemoresistance. Pharmacol Res. 2018;132:15–20.
Saif MW, Syrigos KN, Katirtzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs. 2009;18(3):335–48.
Sharma V, Gupta SK, Verma M. Dihydropyrimidine dehydrogenase in the metabolism of the anticancer drugs. Cancer Chemother Pharmacol. 2019;84(6):1157–66.
Verma H, Narendra G, Raju B, Singh PK, Silakari O. Dihydropyrimidine dehydrogenase-mediated resistance to 5-fluorouracil: mechanistic investigation and solution. ACS Pharmacol Transl Sci. 2022;5(11):1017–33.
Maslarinou A, Manolopoulos VG, Ragia G. Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm? Front Pharmacol. 2023;14:1184523.
Cui Z, He S, Wen F, Lu L, Xu L, Wu H, et al. Dihydropyrimidine dehydrogenase (DPD) as a bridge between the immune microenvironment of colon cancers and 5-FU resistance. Frontiers in Bioscience-Landmark. 2023;28(4): 80.
Gmeiner WH, Okechukwu CC. Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects. Cancer Drug Resist. 2023;6(2):257.
Kciuk M, Marciniak B, Kontek R. Irinotecan—still an important player in cancer chemotherapy: a comprehensive overview. Int J Mol Sci. 2020;21(14): 4919.
Capello M, Lee M, Wang H, Babel I, Katz MH, Fleming JB, et al. Carboxylesterase 2 as a determinant of response to irinotecan and neoadjuvant FOLFIRINOX therapy in pancreatic ductal adenocarcinoma. J Natl Cancer Inst. 2015;107(8): djv132.
Xie F-W, Peng Y-H, Chen X, Chen X, Li J, Yu Z-Y, et al. Regulation and expression of aberrant methylation on Irinotecan metabolic genes CES2, UGT1A1 and GUSB in the in-vitro cultured colorectal cancer cells. Biomed Pharmacother. 2014;68(1):31–7.
Xiao D, Yang D, Guo L, Lu W, Charpentier M, Yan B. Regulation of carboxylesterase‐2 expression by p53 family proteins and enhanced anti‐cancer activities among 5‐fluorouracil, Irinotecan and Doxazolidine prodrug. Br J Pharmacol. 2013;168(8):1989–99.
Shaojun C, Li H, Haixin H, Guisheng L. Expression of topoisomerase 1 and carboxylesterase 2 correlates with Irinotecan treatment response in metastatic colorectal cancer. Cancer Biol Ther. 2018;19(3):153–9.
de Man FM, Goey AK, van Schaik RH, Mathijssen RH, Bins S. Individualization of Irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet. 2018;57:1229–54.
Paulík A, Grim J, Filip S. Predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer. Acta Medica (Hradec Kralove). 2012;55(4):153–9.
Tagawa K, Maruo Y, Mimura Y, Ikushiro S. Effects of common genetic variants of human uridine diphosphate glucuronosyltransferase subfamilies on irinotecan glucuronidation. Toxicol Mech Methods. 2023;33(3):197–205.
Li W, Zhang H, Assaraf YG, Zhao K, Xu X, Xie J, et al. Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies. Drug Resist Updat. 2016;27:14–29.
Lin L, Yee SW, Kim RB, Giacomini KM. Slc transporters as therapeutic targets: emerging opportunities. Nat Rev Drug Discov. 2015;14(8):543–60.
International Transporter Consortium; Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215–36. https://doi.org/10.1038/nrd3028.
Ceballos MP, Rigalli JP, Ceré LI, Semeniuk M, Catania VA, Ruiz ML. ABC transporters: regulation and association with multidrug resistance in hepatocellular carcinoma and colorectal carcinoma. Curr Med Chem. 2019;26(7):1224–50.
Sun L, Ke J, He Z, Chen Z, Huang Q, Ai W, et al. HES1 promotes colorectal cancer cell resistance to 5-Fu by inducing of EMT and ABC transporter proteins. J Cancer. 2017;8(14):2802.
Gao Q, Li X-x, Xu Y-m, Zhang J-z, Qin Y-q, Fang J. IRE1α-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells. Cancer Lett. 2020;476:67–74.
Wang JQ, Wu ZX, Yang Y, Teng QX, Li YD, Lei ZN, et al. ATP-binding cassette (ABC) transporters in cancer: A review of recent updates. J Evidence‐Based Med. 2021;14(3):232–56.
Liu X. ABC family transporters. In: Liu X, Pan G, editors. Drug transporters in drug disposition, effects and toxicity. Advances in experimental medicine and biology, vol 1141. Springer, Singapore; 2019. https://doi.org/10.1007/978-981-13-7647-4_2.
Zhou H, Lin C, Zhang Y, Zhang X, Zhang C, Zhang P, et al. Mir-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR 1/P‐gp expression. Cell Prolif. 2017;50(3): e12341.
Du J, He Y, Li P, Wu W, Chen Y, Ruan H. IL-8 regulates the doxorubicin resistance of colorectal cancer cells via modulation of multidrug resistance 1 (MDR1). Cancer Chemother Pharmacol. 2018;81:1111–9.
Wang T, Chen Z, Zhu Y, Pan Q, Liu Y, Qi X, et al. Inhibition of transient receptor potential channel 5 reverses 5-fluorouracil resistance in human colorectal cancer cells. J Biol Chem. 2015;290(1):448–56.
Westover D, Li F. New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies. J Exp Clin Cancer Res. 2015;34:1–9.
Guo J, Wang Q, Zhang Y, Sun W, Zhang S, Li Y, et al. Functional daidzein enhances the anticancer effect of topotecan and reverses BCRP-mediated drug resistance in breast cancer. Pharmacol Res. 2019;147: 104387.
Ozawa S, Miura T, Terashima J, Habano W. Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review. Cancer Drug Resist. 2021;4(4):946.
Lu JF, Pokharel D, Bebawy M. MRP1 and its role in anticancer drug resistance. Drug Metab Rev. 2015;47(4):406–19.
Cole SP. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future. Annu Rev Pharmacol Toxicol. 2014;54:95–117.
Blythe AJ, Fox AH, Bond CS. The ins and outs of LncRNA structure: how, why and what comes next? Biochim Et Biophys Acta (BBA)-Gene Regul Mech. 2016;1859(1):46–58.
Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics Proteomics Bioinf. 2016;14(1):42–54.
Mattick JS, Amaral PP, Carninci P, Carpenter S, Chang HY, Chen L-L, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023;24(6):430–47.
Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009;458(7235):223–7.
Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, et al. The GENCODE v7 catalog of human long noncoding rnas: analysis of their gene structure, evolution, and expression. Genome Res. 2012;22(9):1775–89.
Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011;25(18):1915–27.
Alvarez-Dominguez JR, Lodish HF. Emerging mechanisms of long noncoding RNA function during normal and malignant hematopoiesis. Blood. 2017;130(18):1965–75.
Zampetaki A, Albrecht A, Steinhofel K. Long non-coding RNA structure and function: is there a link?? Front Physiol. 2018;9: 1201.
Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43(6):904–14.
Ahmad P, Bensaoud C, Mekki I, Rehman MU, Kotsyfakis M. Long non-coding RNAs and their potential roles in the vector-host-pathogen triad. Life (Basel). 2021;11(1):56. https://doi.org/10.3390/life11010056.
Hu ZY, Wang XY, Guo WB, Xie LY, Huang YQ, Liu YP, et al. Long non-coding RNA MALAT1 increases AKAP-9 expression by promoting SRPK1-catalyzed SRSF1 phosphorylation in colorectal cancer cells. Oncotarget. 2016;7(10):11733–43.
He Y, Luo Y, Liang B, Ye L, Lu G, He W. Potential applications of MEG3 in cancer diagnosis and prognosis. Oncotarget. 2017;8(42):73282–95.
Cao Y, Shi H, Ren F, Jia Y, Zhang R. Long non-coding RNA CCAT1 promotes metastasis and poor prognosis in epithelial ovarian cancer. Exp Cell Res. 2017;359(1):185–94.
Dong X, Yang Z, Yang H, Li D, Qiu X. Long non-coding RNA MIR4435-2HG promotes colorectal cancer proliferation and metastasis through miR-206/YAP1 axis. Front Oncol. 2020;10: 160.
Yan S, Yue Y, Wang J, Li W, Sun M, Gu C, et al. LINC00668 promotes tumorigenesis and progression through sponging miR-188-5p and regulating USP47 in colorectal cancer. Eur J Pharmacol. 2019;858: 172464.
Ahadi A. Functional roles of LncRNAs in the pathogenesis and progression of cancer. Genes Dis. 2021;8(4):424–37.
Moayedi K, Orandi S, Ebrahimi R, Tanhapour M, Moradi M, Abbastabar M, et al. A novel approach to type 3 diabetes mechanism: the interplay between noncoding RNAs and insulin signaling pathway in Alzheimer’s disease. J Cell Physiol. 2022;237(7):2838–61.
Jin H, Du W, Huang W, Yan J, Tang Q, Chen Y, et al. LncRNA and breast cancer: progress from identifying mechanisms to challenges and opportunities of clinical treatment. Mol Ther. 2021;25:613–37.
Chen R, Li W-X, Sun Y, Duan Y, Li Q, Zhang A-X, et al. Comprehensive analysis of LncRNA and mRNA expression profiles in lung cancer. Clin Lab. 2017;63(2):313–20.
Jiang MC, Ni JJ, Cui WY, Wang BY, Zhuo W. Emerging roles of LncRNA in cancer and therapeutic opportunities. Am J Cancer Res. 2019;9(7):1354–66.
Sarfi M, Abbastabar M, Khalili E. Increased expression of urinary exosomal LnCRNA TUG-1 in early bladder cancer. Gene Rep. 2021;22: 101010.
Pardini B, Sabo AA, Birolo G, Calin GA. Noncoding RNAs in extracellular fluids as cancer biomarkers: the new frontier of liquid biopsies. Cancers. 2019;11(8):1170.
Wang WT, Sun YM, Huang W, He B, Zhao YN, Chen YQ. Genome-wide long non-coding RNA analysis identified circulating LncRNAs as novel non-invasive diagnostic biomarkers for gynecological disease. Sci Rep. 2016;6:23343.
Xu K, Jiang X, Ariston Gabriel AN, Li X, Wang Y, Xu S. Evolving landscape of long non-coding RNAs in cerebrospinal fluid: a key role from diagnosis to therapy in brain tumors. Front Cell Dev Biol. 2021;9:737670.
Luo Y, Chen JJ, Lv Q, Qin J, Huang YZ, Yu MH, et al. Long non-coding RNA NEAT1 promotes colorectal cancer progression by competitively binding miR-34a with SIRT1 and enhancing the Wnt/β-catenin signaling pathway. Cancer Lett. 2019;440–441:11–22.
Ye M, Zhao L, Zhang L, Wu S, Li Z, Qin Y, et al. LncRNA NALT1 promotes colorectal cancer progression via targeting PEG10 by sponging microRNA-574-5p. Cell Death Dis. 2022;13(11):960.
Zhu X, Bu F, Tan T, Luo Q, Zhu J, Lin K, et al. Long noncoding RNA RP11-757G1.5 sponges miR-139-5p and upregulates YAP1 thereby promoting the proliferation and liver, spleen metastasis of colorectal cancer. J Exp Clin Cancer Res. 2020;39(1):207.
Xu Y, Zhang X, Hu X, Zhou W, Zhang P, Zhang J, et al. The effects of LncRNA MALAT1 on proliferation, invasion and migration in colorectal cancer through regulating SOX9. Mol Med. 2018;24:1–15.
Zhang M, Li Y, Wang H, Yu W, Lin S, Guo J. LncRNA SNHG5 affects cell proliferation, metastasis and migration of colorectal cancer through regulating miR-132-3p/CREB5. Cancer Biol Ther. 2019;20(4):524–36.
Wang A-H, Fan W-J, Fu L, Wang X-T. LncRNA PCAT-1 regulated cell proliferation, invasion, migration and apoptosis in colorectal cancer through targeting miR-149-5p. Eur Rev Med Pharmacol Sci. 2019;23:19.
Zheng XY, Cao MZ, Ba Y, Li YF, Ye JL. Lncrna testis-specific transcript, Y-linked 15 (TTTY15) promotes proliferation, migration and invasion of colorectal cancer cells via regulating miR-29a-3p/DVL3 axis. Cancer Biomark. 2021;31(1):1–11.
Chen D, Sun Q, Zhang L, Zhou X, Cheng X, Zhou D, et al. The lncRNA HOXA11-AS functions as a competing endogenous RNA to regulate PADI2 expression by sponging miR-125a-5p in liver metastasis of colorectal cancer. Oncotarget. 2017;8(41):70642.
Xu J, Meng Q, Li X, Yang H, Xu J, Gao N, et al. Long noncoding RNA MIR17HG promotes colorectal cancer progression via miR-17-5p. Cancer Res. 2019;79(19):4882–95.
Chen D-l, Lu Y-x, Zhang J-x, Wei X-l, Wang F, Zeng Z-l, et al. Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a CeRNA for microRNA-215 to regulate ZEB2 expression. Theranostics. 2017;7(19):4836.
Zhang Y, Huang W, Yuan Y, Li J, Wu J, Yu J, et al. Long non-coding RNA H19 promotes colorectal cancer metastasis via binding to hnRNPA2B1. J Exp Clin Cancer Res. 2020;39(1):1–15.
Fang X, Xu Y, Li K, Liu P, Zhang H, Jiang Y et al. Exosomal lncRNA PCAT1 promotes tumor circulating cell-mediated colorectal cancer liver metastasis by regulating the activity of the miR-329-3p/Netrin-1-CD146 complex. Journal of Immunology Research. 2022;2022.
Zhan T, Cheng X, Zhu Q, Han Z, Zhu K, Tan J, et al. LncRNA LOC105369504 inhibits tumor proliferation and metastasis in colorectal cancer by regulating PSPC1. Cell Death Discov. 2023;9(1):89.
Yin DD, Liu ZJ, Zhang E, Kong R, Zhang ZH, Guo RH. Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. Tumour Biol. 2015;36(6):4851–9.
Amirmahani F, Asadi MH, Jannat Alipoor F. LncRNA MIAT promotes the proliferation and invasion of colorectal cancer via suppressing apoptosis and senescence. Middle East J Cancer. 2023;14(2):219–29.
Xu M, Xu X, Pan B, Chen X, Lin K, Zeng K, et al. LncRNA SATB2-AS1 inhibits tumor metastasis and affects the tumor immune cell microenvironment in colorectal cancer by regulating SATB2. Mol Cancer. 2019;18(1):135.
Zhang C, Wang L, Jin C, Zhou J, Peng C, Wang Y, et al. Long non-coding RNA Lnc-LALC facilitates colorectal cancer liver metastasis via epigenetically silencing LZTS1. Cell Death Dis. 2021;12(2):224.
Li J, Ji Y, Chen N, Wang H, Fang C, Yin X, et al. A specific upregulated long noncoding RNA in colorectal cancer promotes cancer progression. JCI Insight. 2022;7(15):e158855. https://doi.org/10.1172/jci.insight.158855.
Wang B, Chen W, Zhao Z, Sun Y, Huang Y. Lncrna-DANCR promotes growth and metastasis of colorectal cancer via activating epithelial-mesenchymal transition process. Transl Cancer Res. 2019;8(7):2517.
Xie J, Wang J-J, Li Y-J, Wu J, Gu X-J, Yang X-R. LncRNA GAS5 suppresses colorectal cancer progress by target miR-21/LIFR axis. Evidence‐Based Complement Altern Med. 2022;2022(1):3298939.
Corrà F, Agnoletto C, Minotti L, Baldassari F, Volinia S. The network of non-coding RNAs in cancer drug resistance. Front Oncol. 2018;8: 327.
Amiri R, Nabi PN, Fazilat A, Roshani F, Kararoudi AN, Hemmati-Dinarvand M, et al. Crosstalk between miRNAs and signaling pathways in the development of drug resistance in breast cancer. Horm Mol Biol Clin Investig. 2024. https://doi.org/10.1515/hmbci-2024-0066.
Bian Z, Jin L, Zhang J, Yin Y, Quan C, Hu Y, et al. Lncrna—UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p. Sci Rep. 2016;6(1):23892.
Jiang X, Li Q, Zhang S, Song C, Zheng P. Long noncoding RNA GIHCG induces cancer progression and chemoresistance and indicates poor prognosis in colorectal cancer. Onco Targets Ther. 2019;12:1059.
Qiao L, Liu X, Tang Y, Zhao Z, Zhang J, Liu H. Knockdown of long non-coding RNA prostate cancer-associated NcRNA transcript 1 inhibits multidrug resistance and c-Myc-dependent aggressiveness in colorectal cancer Caco-2 and HT-29 cells. Mol Cell Biochem. 2018;441:99–108.
Fan H, Zhu JH, Yao XQ. Knockdown of long non–coding RNA PVT1 reverses multidrug resistance in colorectal cancer cells. Mol Med Rep. 2018;17(6):8309–15.
Tang D, Yang Z, Long F, Luo L, Yang B, Zhu R, et al. Inhibition of MALAT1 reduces tumor growth and metastasis and promotes drug sensitivity in colorectal cancer. Cell Signal. 2019;57:21–8.
Li Y, Huang S, Li Y, Zhang W, He K, Zhao M, et al. Decreased expression of lncRNA SLC25A25-AS1 promotes proliferation, chemoresistance, and EMT in colorectal cancer cells. Tumor Biol. 2016;37:14205–15.
Lee H, Kim C, Ku J-L, Kim W, Yoon SK, Kuh H-J, et al. A long non-coding RNA SnaR contributes to 5-fluorouracil resistance in human colon cancer cells. Mol Cells. 2014;37(7):540.
Li J, Li X, Cen C, Ai X, Lin C, Hu G. The long non-coding RNA ENST00000547547 reduces 5-fluorouracil resistance of colorectal cancer cells via competitive binding to microRNA-31. Oncol Rep. 2018;39(1):217–26.
Bian Z, Zhang J, Li M, Feng Y, Yao S, Song M, et al. Long non-coding RNA LINC00152 promotes cell proliferation, metastasis, and confers 5-FU resistance in colorectal cancer by inhibiting miR-139-5p. Oncogenesis. 2017;6(11): 395.
Yue B, Cai D, Liu C, Fang C, Yan D. Linc00152 functions as a competing endogenous RNA to confer oxaliplatin resistance and holds prognostic values in colon cancer. Mol Ther. 2016;24(12):2064–77.
Li P, Zhang X, Wang H, Wang L, Liu T, Du L, et al. MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2. Mol Cancer Ther. 2017;16(4):739–51.
Ren J, Ding L, Zhang D, Shi G, Xu Q, Shen S, et al. Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal LncRNA H19. Theranostics. 2018;8(14):3932.
Wang H, Li H, Zhang L, Yang D. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis. Biomed Pharmacother. 2018;106:1607–15.
Li L, Shang J, Zhang Y, Liu S, Peng Y, Zhou Z, et al. MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis. Oncol Rep. 2017;38(3):1383–92.
Ping G, Xiong W, Zhang L, Li Y, Zhang Y, Zhao Y. Silencing long noncoding RNA PVT1 inhibits tumorigenesis and cisplatin resistance of colorectal cancer. Am J Transl Res. 2018;10(1):138.
Xiao Z, Qu Z, Chen Z, Fang Z, Zhou K, Huang Z, et al. LncRNA HOTAIR is a prognostic biomarker for the proliferation and chemoresistance of colorectal cancer via MiR-203a-3p-mediated Wnt/ss-catenin signaling pathway. Cell Physiol Biochem. 2018;46(3):1275–85.
Wu K-f, Liang W-C, Feng L, Pang J-x, Waye MM-Y, Zhang J-F, et al. H19 mediates methotrexate resistance in colorectal cancer through activating Wnt/β-catenin pathway. Exp Cell Res. 2017;350(2):312–7.
Li C, Gao Y, Li Y, Ding D. TUG1 mediates methotrexate resistance in colorectal cancer via miR-186/CPEB2 axis. Biochem Biophys Res Commun. 2017;491(2):552–7.
Zhu J, Zhang R, Yang D, Li J, Yan X, Jin K, et al. Knockdown of long non-coding RNA XIST inhibited doxorubicin resistance in colorectal cancer by upregulation of miR-124 and downregulation of SGK1. Cell Physiol Biochem. 2018;51(1):113–28.
Lu Y, Zhao X, Liu Q, Li C, Graves-Deal R, Cao Z, et al. LncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling. Nat Med. 2017;23(11):1331–41.
Doxtater KD, Tripathi MK. LncRNA UCA1 as a potential therapeutic target for drug resistance in colorectal cancer. Cancer Res. 2023;83(7Supplement):2854.
Yang Y-n, Zhang R, Du J-w, Yuan H-h, Li Y-j, Wei X-l, et al. Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer. Cancer Cell Int. 2018;18:1–11.
Ramli S, Sim MS, Guad RM, Gopinath SCB, Subramaniyan V, Fuloria S, et al. Long noncoding RNA UCA1 in Gastrointestinal cancers: molecular regulatory roles and patterns, mechanisms, and interactions. J Oncol. 2021;2021:1–15.
Amirinejad R, Rezaei M, Shirvani-Farsani Z. An update on long intergenic noncoding RNA p21: a regulatory molecule with various significant functions in cancer. Cell Biosci. 2020;10(1):82.
Silva-Fisher JM, Dang HX, White NM, Strand MS, Krasnick BA, Rozycki EB, et al. Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression. Nat Commun. 2020;11(1):2156.
Cabanski CR, White NM, Dang HX, Silva-Fisher JM, Rauck CE, Cicka D, et al. Pan-cancer transcriptome analysis reveals long noncoding RNAs with conserved function. RNA Biol. 2015;12(6):628–42.
White NM, Cabanski CR, Silva-Fisher JM, Dang HX, Govindan R, Maher CA. Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer. Genome Biol. 2014;15:1–16.
Zhang PF, Wu J, Wu Y, Huang W, Liu M, Dong ZR, et al. The lncRNA SCARNA2 mediates colorectal cancer chemoresistance through a conserved microRNA-342‐3p target sequence. J Cell Physiol. 2019;234(7):10157–65.
Weng W, Okugawa Y, Toden S, Toiyama Y, Kusunoki M, Goel A. FOXM1 and FOXQ1 are promising prognostic biomarkers and novel targets of tumor-suppressive miR-342 in human colorectal cancer. Clin Cancer Res. 2016;22(19):4947–57.
Lai X, Gupta SK, Schmitz U, Marquardt S, Knoll S, Spitschak A, et al. MiR-205-5p and miR-342-3p cooperate in the repression of the E2F1 transcription factor in the context of anticancer chemotherapy resistance. Theranostics. 2018;8(4):1106.
Ge X, Chen Y, Liao X, Liu D, Li F, Ruan H, et al. Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer. Med Oncol. 2013;30:1–6.
Qiao L, Liu X, Tang Y, Zhao Z, Zhang J, Feng Y. Down regulation of the long non-coding RNA PCAT-1 induced growth arrest and apoptosis of colorectal cancer cells. Life Sci. 2017;188:37–44.
Zhou Q, Hou Z, Zuo S, Zhou X, Feng Y, Sun Y, et al. LUCAT1 promotes colorectal cancer tumorigenesis by targeting the ribosomal protein L40-MDM 2‐p53 pathway through binding with UBA 52. Cancer Sci. 2019;110(4):1194–207.
Thorenoor N, Faltejskova-Vychytilova P, Hombach S, Mlcochova J, Kretz M, Svoboda M, et al. Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer. Oncotarget. 2016;7(1):622.
Shan TD, Tian ZB, Li Q, Jiang YP, Liu FG, Sun XG, et al. Long intergenic noncoding RNA 00908 promotes proliferation and inhibits apoptosis of colorectal cancer cells by regulating KLF5 expression. J Cell Physiol. 2021;236(2):889–99.
Zhang XT, Pan SX, Wang AH, Kong QY, Jiang KT, Yu ZB. Long non-coding RNA (lncRNA) X-inactive specific transcript (XIST) plays a critical role in predicting clinical prognosis and progression of colorectal cancer. Med Sci Monit. 2019;25:6429–35.
Xiao M, Liang Z, Yin Z. Long non–coding RNA ZFPM2–AS1 promotes colorectal cancer progression by sponging miR–137 to regulate TRIM24. Mol Med Rep. 2021;23(2):1.
Wang J, Zhu J, Dong M, Yu H, Dai X, Li K. Knockdown of tripartite motif containing 24 by lentivirus suppresses cell growth and induces apoptosis in human colorectal cancer cells. Oncol Res. 2014;22(1):39.
Xie W, Zhang Y, Wang B, Hu Y, Zhan B, Wei F, et al. Tripartite motif containing 24 regulates cell proliferation in colorectal cancer through YAP signaling. Cancer Med. 2020;9(17):6367–76.
Du T, Gao Q, Zhao Y, Gao J, Li J, Wang L, et al. Long non-coding RNA LINC02474 affects metastasis and apoptosis of colorectal cancer by inhibiting the expression of GZMB. Front Oncol. 2021;11: 651796.
Chiusolo V, Jacquemin G, Yonca Bassoy E, Vinet L, Liguori L, Walch M, et al. Granzyme B enters the mitochondria in a Sam50-, Tim22-and mtHsp70-dependent manner to induce apoptosis. Cell Death Differ. 2017;24(4):747–58.
Carrieri C, Cimatti L, Biagioli M, Beugnet A, Zucchelli S, Fedele S, et al. Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat. Nature. 2012;491(7424):454–7.
Hu J, Shan Y, Ma J, Pan Y, Zhou H, Jiang L, et al. LncRNA ST3Gal6-AS1/ST3Gal6 axis mediates colorectal cancer progression by regulating α‐2, 3 sialylation via PI3K/Akt signaling. Int J Cancer. 2019;145(2):450–60.
Zhang X, Tang N, Hadden TJ, Rishi AK, Akt. FoxO and regulation of apoptosis. Biochim Et Biophys Acta (BBA)-Molecular Cell Res. 2011;1813(11):1978–86.
Cheng K, Zhao Z, Wang G, Wang J, Zhu W. LncRNA GAS5 inhibits colorectal cancer cell proliferation via the miR–182–5p/FOXO3a axis. Oncol Rep. 2018;40(4):2371–80.
Cao M-Q, You A-B, Zhu X-D, Zhang W, Zhang Y-Y, Zhang S-Z, et al. miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a. J Hematol Oncol. 2018;11(1):1–12.
Zhang Y-H, Fu J, Zhang Z-J, Ge C-C, Yi Y. LncRNA-LINC00152 down-regulated by miR-376c-3p restricts viability and promotes apoptosis of colorectal cancer cells. Am J Transl Res. 2016;8(12):5286.
Chen Z, Cai X, Chang L, Xia Y, Wang L, Hou Y, et al. LINC00152 is a potential biomarker involved in the modulation of biological characteristics of residual colorectal cancer cells following chemoradiotherapy. Oncol Lett. 2018;15(4):4177–84.
Lian Y, Yan C, Xu H, Yang J, Yu Y, Zhou J, et al. A novel lncrna, LINC00460, affects cell proliferation and apoptosis by regulating KLF2 and CUL4A expression in colorectal cancer. Mol Ther Nucleic Acids. 2018;12:684–97.
Lepage C, Léger D, Bertrand J, Martin F, Beneytout J, Liagre B. Diosgenin induces death receptor-5 through activation of p38 pathway and promotes TRAIL-induced apoptosis in colon cancer cells. Cancer Lett. 2011;301(2):193–202.
Wang J, Huang F, Bai Z, Chi B, Wu J, Chen X. Curcumol inhibits growth and induces apoptosis of colorectal cancer LoVo cell line via IGF-1R and p38 MAPK pathway. Int J Mol Sci. 2015;16(8):19851–67.
Chiacchiera F, Grossi V, Cappellari M, Peserico A, Simonatto M, Germani A, et al. Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models. Cancer Lett. 2012;324(1):98–108.
Liang H, Zhao Q, Zhu Z, Zhang C, Zhang H. Long noncoding RNA LINC00958 suppresses apoptosis and radiosensitivity of colorectal cancer through targeting miR-422a. Cancer Cell Int. 2021;21:1–15.
Wei W-T, Nian X-X, Wang S-Y, Jiao H-L, Wang Y-X, Xiao Z-Y, et al. miR-422a inhibits cell proliferation in colorectal cancer by targeting AKT1 and MAPK1. Cancer Cell Int. 2017;17:1–12.
Zhu S, Mao J, Zhang X, Wang P, Zhou Y, Tong J, et al. CAF-derived exosomal lncRNA FAL1 promotes chemoresistance to oxaliplatin by regulating autophagy in colorectal cancer. Dig Liver Dis. 2024;56(2):330–42.
Mirza-Aghazadeh-Attari M, Ostadian C, Saei AA, Mihanfar A, Darband SG, Sadighparvar S, et al. DNA damage response and repair in ovarian cancer: potential targets for therapeutic strategies. DNA Repair. 2019;80:59–84.
Mihanfar A, Darband SG, Sadighparvar S, Kaviani M, Mirza-Aghazadeh-Attari M, Yousefi B, et al. In vitro and in vivo anticancer effects of syringic acid on colorectal cancer: possible mechanistic view. Chemico-Biological Interactions. 2021;337: 109337.
Sharma V, Khurana S, Kubben N, Abdelmohsen K, Oberdoerffer P, Gorospe M, et al. A BRCA 1-interacting lnc RNA regulates homologous recombination. EMBO Rep. 2015;16(11):1520–34.
Kaller M, Götz U, Hermeking H. Loss of p53-inducible long non-coding RNA LINC01021 increases chemosensitivity. Oncotarget. 2017;8(61):102783.
Ma S, Yang D, Liu Y, Wang Y, Lin T, Li Y, et al. LncRNA BANCR promotes tumorigenesis and enhances adriamycin resistance in colorectal cancer. Aging. 2018;10(8):2062.
Li Y, Yuan S, Liu J, Wang Y, Zhang Y, Chen X, et al. CSE1L silence inhibits the growth and metastasis in gastric cancer by repressing GPNMB via positively regulating transcription factor MITF. J Cell Physiol. 2020;235(3):2071–9.
Gao H, Song X, Kang T, Yan B, Feng L, Gao L, et al. Long noncoding RNA CRNDE functions as a competing endogenous RNA to promote metastasis and oxaliplatin resistance by sponging miR-136 in colorectal cancer. Onco Targets Ther. 2017;10:205–16. https://doi.org/10.2147/OTT.S116178.
Chaudhary R, Gryder B, Woods WS, Subramanian M, Jones MF, Li XL, et al. Prosurvival long noncoding RNA PINCR regulates a subset of p53 targets in human colorectal cancer cells by binding to matrin 3. Elife. 2017;6:e23244.
Shi L, Sun J, Kinomura A, Fukuto A, Horikoshi Y, Tashiro S. Matrin3 promotes homologous recombinational repair by regulation of RAD51. J Biochem. 2019;166(4):343–51.
Liu R, Zhang Q, Shen L, Chen S, He J, Wang D, et al. Long noncoding RNA lnc-RI regulates DNA damage repair and radiation sensitivity of CRC cells through NHEJ pathway. Cell Biol Toxicol. 2020;36:493–507.
Yao P, Wu Y, Zhao K, Li Y, Cao J, Xing C. The feedback loop of ANKHD1/lncRNA MALAT1/YAP1 strengthens the radioresistance of CRC by activating YAP1/AKT signaling. Cell Death Dis. 2022; 13: 103. Leukemia. 2018;32:2250-62.
Stanley L. Drug metabolism. Pharmacognosy: Elsevier; 2024. pp. 597–624.
Wang Y, Fang Z, Hong M, Yang D, Xie W. Long-noncoding RNAs (lncRNAs) in drug metabolism and disposition, implications in cancer chemo-resistance. Acta Pharm Sin B. 2020;10(1):105–12.
Liu LC, Wang YL, Lin PL, Zhang X, Cheng WC, Liu SH, et al. Long noncoding RNA HOTAIR promotes invasion of breast cancer cells through chondroitin sulfotransferase CHST15. Int J Cancer. 2019;145(9):2478–87.
Takahashi K, Yan IK, Wood J, Haga H, Patel T. Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Mol Cancer Res. 2014;12(10):1377–87.
Zhang XW, Bu P, Liu L, Zhang XZ, Li J. Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Biochem Biophys Res Commun. 2015;462(3):227–32.
Fang Z, Chen W, Yuan Z, Liu X, Jiang H. Lncrna-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation. Biomed Pharmacother. 2018;101:536–42.
Lan WG, Xu DH, Xu C, Ding CL, Ning FL, Zhou YL, et al. Silencing of long non-coding RNA ANRIL inhibits the development of multidrug resistance in gastric cancer cells. Oncol Rep. 2016;36(1):263–70.
Wang Y, Zhang D, Wu K, Zhao Q, Nie Y, Fan D. Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines. Mol Cell Biol. 2014;34(17):3182–93.
Hu H, Yang L, Li L, Zeng C. Long non-coding RNA KCNQ1OT1 modulates oxaliplatin resistance in hepatocellular carcinoma through miR-7-5p/ABCC1 axis. Biochem Biophys Res Commun. 2018;503(4):2400–6.
Chang L, Hu Z, Zhou Z, Zhang H. Linc00518 contributes to multidrug resistance through regulating the MiR-199a/MRP1 axis in breast cancer. Cell Physiol Biochem. 2018;48(1):16–28.
Wu X, Zheng Y, Han B, Dong X. Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361. Biomed Pharmacother. 2018;99:832–8.
Wang L, Bu P, Ai Y, Srinivasan T, Chen HJ, Xiang K, et al. A long non-coding RNA targets MicroRNA miR-34a to regulate colon cancer stem cell asymmetric division. Elife. 2016;5:e14620.
Sun J, Zhou H, Bao X, Wu Y, Jia H, Zhao H et al. lncRNA TUG1 facilitates colorectal cancer stem cell characteristics and chemoresistance by enhancing GATA6 protein stability. Stem cells international. 2021;2021.
Fu C, Li X, Han L, Xie M, Ouyang S. LncRNA PTPRG-AS1 maintains stem-cell-like features and promotes oxaliplatin resistance in colorectal cancer via regulating the miR-665 and STAT3 axis. Mol Cell Toxicol. 2024;20:35–45. https://doi.org/10.1007/s13273-022-00314-1.
Di Cecilia S, Zhang F, Sancho A, Li S, Aguiló F, Sun Y, et al. RBM5-AS1 is critical for self-renewal of colon cancer stem-like cells. Cancer Res. 2016;76(19):5615–27.
Yu Y, Nangia-Makker P, Farhana L, Majumdar AP. A novel mechanism of LncRNA and MiRNA interaction: CCAT2 regulates miR-145 expression by suppressing its maturation process in colon cancer cells. Mol Cancer. 2017;16(1):1–11.
Yu X, Mi L, Dong J, Zou J. Long intergenic non-protein-coding RNA 1567 (LINC01567) acts as a sponge against microRNA-93 in regulating the proliferation and tumorigenesis of human colon cancer stem cells. BMC Cancer. 2017;17(1):1–15.
Guo K, Gong W, Wang Q, Gu G, Zheng T, Li Y, et al. LINC01106 drives colorectal cancer growth and stemness through a positive feedback loop to regulate the Gli family factors. Cell Death Dis. 2020;11(10):869.
Zhou H, Xiong Y, Peng L, Wang R, Zhang H, Fu Z. LncRNA-cCSC1 modulates cancer stem cell properties in colorectal cancer via activation of the Hedgehog signaling pathway. J Cell Biochem. 2020;121(3):2510–24.
De Las Rivas J, Brozovic A, Izraely S, Casas-Pais A, Witz IP, Figueroa A. Cancer drug resistance induced by EMT: novel therapeutic strategies. Arch Toxicol. 2021;95(7):2279–97.
Cao H, Xu E, Liu H, Wan L, Lai M. Epithelial–mesenchymal transition in colorectal cancer metastasis: a system review. Pathol – Res Pract. 2015;211(8):557–69.
Liaghat M, Ferdousmakan S, Mortazavi SH, Yahyazadeh S, Irani A, Banihashemi S, et al. The impact of epithelial-mesenchymal transition (EMT) induced by metabolic processes and intracellular signaling pathways on chemo-resistance, metastasis, and recurrence in solid tumors. Cell Commun Signal. 2024;22(1):575.
Weng X, Ma T, Chen Q, Chen BW, Shan J, Chen W, et al. Decreased expression of H19/miR-675 ameliorates hypoxia-induced oxaliplatin resistance in colorectal cancer. Heliyon. 2024;10(5):e27027.
Li C-f, Li Y-c, Wang Y, Sun L-b. The effect of LncRNA H19/miR-194-5p axis on the epithelial-mesenchymal transition of colorectal adenocarcinoma. Cell Physiol Biochem. 2018;50(1):196–213.
Wang M, Han D, Yuan Z, Hu H, Zhao Z, Yang R, et al. Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy. Cell Death Dis. 2018;9(12):1149.
Park MS, Jeong SD, Shin CH, Cha S, Yu A, Kim EJ, et al. LINC02257 regulates malignant phenotypes of colorectal cancer via interacting with miR-1273 g-3p and YB1. Cell Death Dis. 2024;15(12):895.
Ding M, Wang W, Huo K, Song Y, Chen X, Xiang Z, et al. The role of LncRNA FEZF1-AS1 in colorectal cancer progression via the P53 signaling pathway. DNA Cell Biol. 2025;44(1):32–45.
Wu W, Li A, He H, Ye S, Zhou Z, Quan JH, et al. Long noncoding RNA LINC01550 inhibits colorectal cancer malignancy by suppressing the Wnt/β-catenin signaling pathway. J Biochem Mol Toxicol. 2024;38(8): e23774.
Shi CJ, Xue ZH, Zeng WQ, Deng LQ, Pang FX, Zhang FW, et al. LncRNA-NEF suppressed oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer through epigenetically inactivating MEK/ERK signaling. Cancer Gene Ther. 2023;30(6):855–65.
Zhang L, Wu H, Zhang Y, Xiao X, Chu F, Zhang L. Induction of lncRNA NORAD accounts for hypoxia-induced chemoresistance and vasculogenic mimicry in colorectal cancer by sponging the miR-495-3p/ hypoxia-inducible factor-1α (HIF-1α). Bioengineered. 2022;13(1):950–62.
Wang W, Zhou Z, Dai X, Wang H, Jin J, Min K, et al. LncRNA-ENST00000543604 exerts a tumor-promoting effect via miRNA 564/AEG-1 or ZNF326/EMT and predicts the prognosis of and chemotherapeutic effect in colorectal cancer. Front Oncol. 2022;12: 960481.
Wu Z-H, Wang X-L, Tang H-M, Jiang T, Chen J, Lu S, et al. Long non-coding RNA HOTAIR is a powerful predictor of metastasis and poor prognosis and is associated with epithelial-mesenchymal transition in colon cancer. Oncol Rep. 2014;32(1):395–402.
Liu Y, Sun M, Xia R, Zhang E, Liu X, Zhang Z, et al. LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer. Cell Death Dis. 2015;6(7):e1802–e.
Jiang Y, Liu G, Ye W, Xie J, Shao C, Wang X, et al. ZEB2-AS1 accelerates epithelial/mesenchymal transition through miR-1205/CRKL pathway in colorectal cancer. Cancer Biother Radiopharm. 2020;35(2):153–62.
Long F, Li X, Pan J, Ye H, Di C, Huang Y, et al. The role of LncRNA NEAT1 in human cancer chemoresistance. Cancer Cell Int. 2024;24(1):236.
Jiang P, Xu H, Xu C, Chen A, Chen L, Zhou M, et al. NEAT1 contributes to the CSC-like traits of A549/CDDP cells via activating Wnt signaling pathway. Chemico-Biological Interactions. 2018;296:154–61.
Azizidoost S, Ghaedrahmati F, Anbiyaee O, Ahmad Ali R, Cheraghzadeh M, Farzaneh M. Emerging roles for lncRNA-NEAT1 in colorectal cancer. Cancer Cell Int. 2022;22(1):209.
Ye Z, Zhou M, Tian B, Wu B, Li J. Expression of lncRNA-CCAT1, E-cadherin and N-cadherin in colorectal cancer and its clinical significance. Int J Clin Exp Med. 2015;8(3):3707.
Yang C, Pan Y, Deng SP. Downregulation of LncRNA CCAT1 enhances 5-fluorouracil sensitivity in human colon cancer cells. BMC Mol Cell Biol. 2019;20:1–11.
Sun F, Liang W, Qian J. The identification of CRNDE, H19, UCA1 and HOTAIR as the key LncRNAs involved in oxaliplatin or Irinotecan resistance in the chemotherapy of colorectal cancer based on integrative bioinformatics analysis. Mol Med Rep. 2019;20(4):3583–96.
Selem NA, Youness RA, Gad MZ. What is beyond LncRNAs in breast cancer: a special focus on colon cancer-associated transcript-1 (CCAT-1). Non-coding RNA Research. 2021;6(4):174–86.
Ghafouri-Fard S, Abak A, Anamag FT, Shoorei H, Majidpoor J, Taheri M. The emerging role of non-coding RNAs in the regulation of PI3K/AKT pathway in the carcinogenesis process. Biomed Pharmacother. 2021;137: 111279.
Tsang S, Patel T, Yustein JT. Long non-coding RNAs regulation of therapeutic resistance. Cancer Drug Resist. 2019;2(3):550.
Poursheikhani A, Abbaszadegan MR, Kerachian MA. Mechanisms of long non-coding RNA function in colorectal cancer tumorigenesis. Asia-Pac J Clin Oncol. 2021;17(1):7–23.
.
Prime Directive: While you must use only the provided text, if you detect a clear and obvious factual contradiction or a statement that defies logic, omit the questionable statement and report on the remaining confirmed facts.
Handling Quotes: Use quotes from the source verbatim for impact. Since the original speaker must be anonymized, attribute quotes using general but descriptive terms (e.g., “a senior official stated,” “according to a company release,” “one analyst noted”).
Time-Sensitive Language: Update relative time references (e.g., “yesterday,” “next month”) to absolute, specific dates or context (e.g., “on Thursday,” “in July 2025”) to ensure the article remains accurate and evergreen.
5. Integrated Media & Links
Embeds: If
Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233–54.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
Van der Jeught K, Xu H-C, Li Y-J, Lu X-B, Ji G. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol. 2018;24(34):3834.
Shinji S, Yamada T, Matsuda A, Sonoda H, Ohta R, Iwai T, et al. Recent advances in the treatment of colorectal cancer: a review. J Nippon Med Sch. 2022;89(3):246–54.
Haider T, Pandey V, Banjare N, Gupta PN, Soni V. Drug resistance in cancer: mechanisms and tackling strategies. Pharmacol Rep. 2020;72(5):1125–51.
Sheikhnia F, Maghsoudi H, Majidinia M. The critical function of MicroRNAs in developing resistance against 5- fluorouracil in cancer cells. Mini Rev Med Chem. 2024;24(6):601–17.
Zhou J, Ji Q, Li Q. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. J Exp Clin Cancer Res. 2021;40:1–17.
Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016;8(1):57–84.
Sharifi-Azad M, Fathi M, Cho WC, Barzegari A, Dadashi H, Dadashpour M, et al. Recent advances in targeted drug delivery systems for resistant colorectal cancer. Cancer Cell Int. 2022;22(1):196.
Khosravi M, Poursaleh A, Ghasempour G, Farhad S, Najafi M. The effects of oxidative stress on the development of atherosclerosis. Biol Chem. 2019;400(6):711–32.
Basak D, Uddin MN, Hancock J. The role of oxidative stress and its counteractive utility in colorectal cancer (CRC). Cancers. 2020;12(11):3336.
Yang L, Fang C, Zhang R, Zhou S. Prognostic value of oxidative stress-related genes in colorectal cancer and its correlation with tumor immunity. BMC Genomics. 2024;25(1):8.
Briffa R, Langdon SP, Grech G, Harrison DJ. Acquired and intrinsic resistance to colorectal cancer treatment. Colorectal Cancer-Diagnosis. Screening and Management: Intech Open London; 2018. pp. 57–81.
To KK, Wu M, Tong CW, Yan W. Drug transporters in the development of multidrug resistance in colorectal cancer. Drug resistance in colorectal cancer: molecular mechanisms and therapeutic strategies. Elsevier; 2020. pp. 35–55.
Maali A, Sarfi M, Mirzakhani M, Goodarzi G, Maghsoudi H, Maniati M, et al. Peaceful existence of tumor cells with their non-malignant neighbors: the trade of tumor cells with tumor microenvironment. Curr Chem Biol. 2020;14(4):228–39.
Zafari N, Khosravi F, Rezaee Z, Esfandyari S, Bahiraei M, Bahramy A, et al. The role of the tumor microenvironment in colorectal cancer and the potential therapeutic approaches. J Clin Lab Anal. 2022;36(8): e24585.
Chen Y, Zheng X, Wu C. The role of the tumor microenvironment and treatment strategies in colorectal cancer. Front Immunol. 2021;12:792691.
Liu K, Gao L, Ma X, Huang J-J, Chen J, Zeng L, et al. Long non-coding RNAs regulate drug resistance in cancer. Mol Cancer. 2020;19(1):1–13.
Sheikhnia F, Fazilat A, Rashidi V, Azizzadeh B, Mohammadi M, Maghsoudi H, et al. Exploring the therapeutic potential of Quercetin in cancer treatment: targeting long non-coding RNAs. Pathology. 2024;260: 155374.
Mohammadi F, Nejatollahi M, Sheikhnia F, Ebrahimi Y, Mohammadi M, Rashidi V, et al. MiRNAs: main players of cancer drug resistance target ABC transporters. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2025. https://doi.org/10.1007/s00210-024-03719-y.
Alizadeh-Fanalou S, Khosravi M, Alian F, Rokhsartalb-Azar S, Nazarizadeh A, Karimi-Dehkordi M, et al. Dual role of microRNA-1297 in the suppression and progression of human malignancies. Biomed Pharmacother. 2021;141: 111863.
Tajik F, Alian F, Yousefi M, Azadfallah A, Hoseini A, Mohammadi F, et al. MicroRNA-372 acts as a double-edged sword in human cancers. Heliyon. 2023;9(5):e15991. https://doi.org/10.1016/j.heliyon.2023.e15991.
Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669–85.
Yau TO. Precision treatment in colorectal cancer: now and the future. JGH Open. 2019;3(5):361–9.
McNair AG, Whistance RN, Forsythe RO, Macefield R, Rees J, Pullyblank AM, et al. Core outcomes for colorectal cancer surgery: a consensus study. PLoS Med. 2016;13(8): e1002071.
Vennix S, Bakker OJ, Prins HA, Lips DJ. Re-interventions following laparoscopic surgery for colorectal cancer: data from 818 individuals from the Dutch surgical colorectal audit. Journal of Laparoendoscopic & Advanced Surgical Techniques. 2014;24(11):751–5.
Ammerata G, Filippo R, Laface C, Memeo R, Solaini L, Cavaliere D, et al. Hyperthermic intraperitoneal chemotherapy and colorectal cancer: from physiology to surgery. World J Clin Cases. 2022;10(30):10852.
McQuade M, Stojanovska R, Bornstein VC, Nurgali J. Colorectal cancer chemotherapy: the evolution of treatment and new approaches. Curr Med Chem. 2017;24(15):1537–57.
Xie Y-H, Chen Y-X, Fang J-Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5(1): 22.
Sakata S, Larson DW. Targeted therapy for colorectal cancer. Surg Oncol Clin N Am. 2022;31(2):255–64.
Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–75.
Golshani G, Zhang Y. Advances in immunotherapy for colorectal cancer: a review. Therapeutic Adv Gastroenterol. 2020;13:1756284820917527.
Boushey R, Williams LJ, Weiser M, Chen W. Management of anastomotic complications of colorectal surgery. 2017.
Köhne C. Current stages of adjuvant treatment of colon cancer. Ann Oncol. 2012;23:x71–6.
Sheikhnia F, Rashidi V, Maghsoudi H, Majidinia M. Potential anticancer properties and mechanisms of thymoquinone in colorectal cancer. Cancer Cell Int. 2023;23(1): 320.
Hossain MS, Karuniawati H, Jairoun AA, Urbi Z, Ooi DJ, John A, et al. Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers. 2022;14(7):1732.
Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2(2):141.
Fu J, Xu Y, Yang Y, Liu Y, Ma L, Zhang Y. Aspirin suppresses chemoresistance and enhances antitumor activity of 5-Fu in 5-Fu-resistant colorectal cancer by abolishing 5-Fu-induced NF-κB activation. Sci Rep. 2019;9(1):16937.
Wawro ME, Sobierajska K, Ciszewski WM, Niewiarowska J. Nonsteroidal anti-inflammatory drugs prevent vincristine-dependent cancer-associated fibroblasts formation. Int J Mol Sci. 2019;20(8): 1941.
Esra’a IK, Ismail WW, Mhaidat NM, Alqudah MA. Effect of metformin on irinotecan-induced cell cycle arrest in colorectal cancer cell lines HCT116 and SW480. Int J Health Sci. 2021;15(5):34.
Zhang P, Zhao S, Lu X, Shi Z, Liu H, Zhu B. Metformin enhances the sensitivity of colorectal cancer cells to cisplatin through ROS-mediated PI3K/Akt signaling pathway. Gene. 2020;745:144623.
Maghsoudi H, Sheikhnia F, Sitarek P, Hajmalek N, Hassani S, Rashidi V, et al. The potential preventive and therapeutic roles of NSAIDs in prostate cancer. Cancers. 2023;15(22):5435.
Hassani S, Maghsoudi H, Fattahi F, Malekinejad F, Hajmalek N, Sheikhnia F, et al. Flavonoids nanostructures promising therapeutic efficiencies in colorectal cancer. Int J Biol Macromol. 2023;241: 124508.
Wu S, Wen F, Li Y, Gao X, He S, Liu M, et al. PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma. Tumor Biol. 2016;37:8799–809.
Xia Z, Zhang L, Chen Q, Royal C, Yu Z, Liu Z, et al. Stable reversal of multidrug resistance in colon cancer cells by RNA interference targeting the MDR1 gene. Mol Med Rep. 2009;2(4):579–84.
Ma SC, Zhang JQ, Yan TH, Miao MX, Cao YM, Cao YB, et al. Novel strategies to reverse chemoresistance in colorectal cancer. Cancer Med. 2023;12(10):11073–96.
Singh D, Khan MA, Siddique HR. Emerging role of long non-coding RNAs in cancer chemoresistance: unravelling the multifaceted role and prospective therapeutic targeting. Mol Biol Rep. 2020;47(7):5569–85.
Mahato RK, Bhattacharya S, Khullar N, Sidhu IS, Reddy PH, Bhatti GK, et al. Targeting long non-coding RNAs in cancer therapy using CRISPR-Cas9 technology: a novel paradigm for precision oncology. J Biotechnol. 2024;379:98–119. https://doi.org/10.1016/j.jbiotec.2023.12.003.
Wang X, Zhao X, Zhong Y, Shen J, An W. Biomimetic exosomes: a new generation of drug delivery system. Front Bioeng Biotechnol. 2022;10:865682.
Chabria Y, Duffy GP, Lowery AJ, Dwyer RM. Hydrogels: 3d drug delivery systems for nanoparticles and extracellular vesicles. Biomedicines. 2021;9(11): 1694.
Sui H, Zhou S, Wang Y, Liu X, Zhou L, Yin P, et al. COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer. Carcinogenesis. 2011;32(5):667–75.
Kim S-H, Kim S-C, Ku J-L. Metformin increases chemo-sensitivity via gene downregulation encoding DNA replication proteins in 5-Fu resistant colorectal cancer cells. Oncotarget. 2017;8(34):56546.
Zhang C, Wang Y. Metformin attenuates cells stemness and epithelial–mesenchymal transition in colorectal cancer cells by inhibiting the Wnt3a/β–catenin pathway. Mol Med Rep. 2019;19(2):1203–9.
Liang Y, Hou L, Li L, Li L, Zhu L, Wang Y, et al. Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway. Oncogene. 2020;39(2):469–85.
Liang Y, Zhu D, Hou L, Wang Y, Huang X, Zhou C, et al. MiR-107 confers chemoresistance to colorectal cancer by targeting calcium-binding protein 39. Br J Cancer. 2020;122(5):705–14.
Yang Y, Ma L, Xu Y, Liu Y, Li W, Cai J, et al. Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins. Cell Death Dis. 2020;11(6):477.
Jiang L, Wang P, Sun Y-J, Wu Y-J. Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway. J Exp Clin Cancer Res. 2019;38(1):1–18.
Li S, Tian J, Zhang H, Zhou S, Wang X, Zhang L, et al. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer. Apoptosis. 2018;23:356–74.
Sakatani A, Sonohara F, Goel A. Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells. Carcinogenesis. 2019;40(3):422–31.
Mosca L, Pagano M, Borzacchiello L, Mele L, Russo A, Russo G, et al. S-adenosylmethionine increases the sensitivity of human colorectal cancer cells to 5-fluorouracil by inhibiting P-glycoprotein expression and NF-κB activation. Int J Mol Sci. 2021;22(17): 9286.
Pires AS, Marques CR, Encarnação JC, Abrantes AM, Marques IA, Laranjo M, et al. Ascorbic acid chemosensitizes colorectal cancer cells and synergistically inhibits tumor growth. Front Physiol. 2018;9:911.
Liu G, Hu X, Chakrabarty S. Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor‐dependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5‐FU. Int J Cancer. 2010;126(3):631–9.
Taghizadeh F, Tang MJ, Tai IT. Synergism between vitamin D and secreted protein acidic and rich in cysteine–induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy. Mol Cancer Ther. 2007;6(1):309–17.
Wang Z, Sun X, Feng Y, Wang Y, Zhang L, Wang Y, et al. Dihydromyricetin reverses MRP2-induced multidrug resistance by preventing NF-κB-Nrf2 signaling in colorectal cancer cell. Phytomedicine. 2021;82:153414.
Fan Y, Abulimiti P, Zhang H, Zhou Y, Zhu L. Mechanism of reversal of multidrug resistance by curcumin in human colorectal cancer cell line HCT-8/5-FU. Genet Mol Res. 2017;16(2): 16029414.
Lu Y, Zhang R, Zhang X, Zhang B, Yao Q. Curcumin may reverse 5-fluorouracil resistance on colonic cancer cells by regulating TET1-NKD-Wnt signal pathway to inhibit the EMT progress. Biomed Pharmacother. 2020;129: 110381.
Buhrmann C, Shayan P, Kraehe P, Popper B, Goel A, Shakibaei M. Resveratrol induces chemosensitization to 5-fluorouracil through up-regulation of intercellular junctions, epithelial-to-mesenchymal transition and apoptosis in colorectal cancer. Biochem Pharmacol. 2015;98(1):51–68.
Zhang R, Pan T, Xiang Y, Zhang M, Feng J, Liu S, et al. Β-elemene reverses the resistance of p53-deficient colorectal cancer cells to 5-fluorouracil by inducing pro-death autophagy and cyclin D3-dependent cycle arrest. Front Bioeng Biotechnol. 2020;8:378.
Li T, Si W, Zhu J, Yin L, Zhong C. Emodin reverses 5-Fu resistance in human colorectal cancer via downregulation of PI3K/Akt signaling pathway. Am J Transl Res. 2020;12(5):1851.
Hu T, Wang L, Zhang L, Lu L, Shen J, Chan RL, et al. Sensitivity of apoptosis-resistant colon cancer cells to Tanshinones is mediated by autophagic cell death and p53-independent cytotoxicity. Phytomedicine. 2015;22(5):536–44.
Zhang Y, Ge T, Xiang P, Zhou J, Tang S, Mao H, et al. Tanshinone IIA reverses oxaliplatin resistance in human colorectal cancer via Inhibition of erk/akt signaling pathway. OncoTargets Therapy. 2019;12:9725.
Lin S, Lei K, Du W, Yang L, Shi H, Gao Y, et al. Enhancement of oxaliplatin sensitivity in human colorectal cancer by hypericin mediated photodynamic therapy via ROS-related mechanism. Int J Biochem Cell Biol. 2016;71:24–34.
Sui H, Zhou LH, Zhang YL, Huang JP, Liu X, Ji Q, et al. Evodiamine suppresses ABCG2 mediated drug resistance by inhibiting p50/p65 NF-κB pathway in colorectal cancer. J Cell Biochem. 2016;117(6):1471–81.
Liu GW, Liu YH, Jiang GS, Ren WD. The reversal effect of ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism. Hum Cell. 2018;31(3):189–98.
Wang Z, Zhan Y, Xu J, Wang Y, Sun M, Chen J, et al. β-Sitosterol reverses multidrug resistance via BCRP suppression by inhibiting the p53-MDM2 interaction in colorectal cancer. J Agric Food Chem. 2020;68(12):3850–8.
Guo P, Wang S, Liang W, Wang W, Wang H, Zhao M, et al. Salvianolic acid B reverses multidrug resistance in HCT–8/VCR human colorectal cancer cells by increasing ROS levels. Mol Med Rep. 2017;15(2):724–30.
Al Bitar S, El-Sabban M, Doughan S, Abou-Kheir W. Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: updates and beyond. World J Gastroenterol. 2023;29(9):1395.
Ahmadi D, Zarei M, Rahimi M, Khazaie M, Asemi Z, Mir SM, et al. Preparation and in-vitro evaluation of pH-responsive cationic cyclodextrin coated magnetic nanoparticles for delivery of methotrexate to the Saos-2 bone cancer cells. J Drug Deliv Sci Technol. 2020;57:101584.
Kist M, Vucic D. Cell death pathways: intricate connections and disease implications. EMBO J. 2021;40(5): e106700.
Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011;30:1–14.
Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B, et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 2012;45(6):487–98.
Wang H, Liu H, Zheng Z-M, Zhang K-B, Wang T-P, Sribastav S-S, et al. Role of death receptor, mitochondrial and endoplasmic reticulum pathways in different stages of degenerative human lumbar disc. Apoptosis. 2011;16:990–1003.
Cavalcante GC, Schaan AP, Cabral GF, Santana-da-Silva MN, Pinto P, Vidal AF, et al. A cell’s fate: an overview of the molecular biology and genetics of apoptosis. Int J Mol Sci. 2019;20(17):4133.
Neophytou CM, Trougakos IP, Erin N, Papageorgis P. Apoptosis deregulation and the development of cancer multi-drug resistance. Cancers (Basel). 2021;13(17):4363.
Berindan-Neagoe I, Braicu C, Pileczki V, Petric RC, Miron N, Balacescu O, et al. 5-Fluorouracil potentiates the anti-cancer effect of oxaliplatin on Colo320 colorectal adenocarcinoma cells. J Gastrointestin Liver Dis. 2013;22(1):37–43.
Silke J, Vince J. IAPs and cell death. In: Nagata S, Nakano H, editor. Apoptotic and non-apoptotic cell death. Current topics in microbiology and immunology, vol. 403. Springer, Cham; 2016. https://doi.org/10.1007/82_2016_507.
Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov. 2012;11(2):109–24.
Meyer M. Pre-Clinical application of inhibitor of apoptosis protein (IAP) antagonists in colorectal cancer (CRC). Royal College of Surgeons in Ireland; 2022.
Knoll G, Ehrenschwender M. The non-peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis. FEBS Open Bio. 2021;11(3):714–23.
Enoch T, Norbury C. Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. Trends Biochem Sci. 1995;20(10):426–30.
Yao J, Huang A, Zheng X, Liu T, Lin Z, Zhang S, et al. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM–CHK2–P53 pathway. J Cancer Res Clin Oncol. 2017;143:419–31.
Xie Q, Wu M-Y, Zhang D-X, Yang Y-M, Wang B-S, Zhang J, et al. Synergistic anticancer effect of exogenous wild-type p53 gene combined with 5-FU in human colon cancer resistant to 5-FU in vivo. World J Gastroenterol. 2016;22(32): 7342.
Dominijanni A, Gmeiner WH. Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations. Cancer Drug Resist. 2018;1:48.
Kandioler D, Mittlböck M, Kappel S, Puhalla H, Herbst F, Langner C, et al. TP53 mutational status and prediction of benefit from adjuvant 5-fluorouracil in stage III colon cancer patients. EBioMedicine. 2015;2(8):825–30.
Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev. 2010;24(8):837–52.
Chan Wah Hak CM, Rullan A, Patin EC, Pedersen M, Melcher AA, Harrington KJ. Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy. Front Oncol. 2022;12: 971959.
Koirala M, DiPaola M. Overcoming cancer resistance: strategies and modalities for effective treatment. Biomedicines. 2024;12(8):1801.
Gurjao C, Liu D, Hofree M, AlDubayan SH, Wakiro I, Su M-J, et al. Intrinsic resistance to immune checkpoint blockade in a mismatch repair–deficient colorectal cancer. Cancer Immunol Res. 2019;7(8):1230–6.
Neboori HJ, Haffty BG, Wu H, Yang Q, Aly A, Goyal S, et al. Low p53 binding protein 1 (53BP1) expression is associated with increased local recurrence in breast cancer patients treated with breast-conserving surgery and radiotherapy. Int J Radiation Oncology* Biology* Phys. 2012;83(5):e677–83.
Ma J, Benitez JA, Li J, Miki S, de Albuquerque CP, Galatro T, et al. Inhibition of nuclear PTEN tyrosine phosphorylation enhances glioma radiation sensitivity through attenuated DNA repair. Cancer Cell. 2019;35(3):504–18. e7.
Najafi M, Farhood B, Mortezaee K. Cancer stem cells (CSCs) in cancer progression and therapy. J Cell Physiol. 2019;234(6):8381–95.
Fakhrioliaei A, Tanhaei S, Pakmehr S, Noori Shakir M, Qasim MT, Hariri M, et al. Potential role of Nrf2, HER2, and ALDH in cancer stem cells: a narrative review. J Membr Biol. 2024;257(1):3–16.
Ebrahimi N, Afshinpour M, Fakhr SS, Kalkhoran PG, Shadman-Manesh V, Adelian S, et al. Cancer stem cells in colorectal cancer: signaling pathways involved in stemness and therapy resistance. Crit Rev Oncol-Hematol. 2023;182: 103920.
Das PK, Islam F, Lam AK. The roles of cancer stem cells and therapy resistance in colorectal carcinoma. Cells. 2020;9(6):1392.
Phi LTH, Sari IN, Yang Y-G, Lee S-H, Jun N, Kim KS et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem cells international. 2018;2018.
Smith AG, Macleod KF. Autophagy, cancer stem cells and drug resistance. J Pathol. 2019;247(5):708–18.
Guo Q, Zhou Y, Xie T, Yuan Y, Li H, Shi W, et al. Tumor microenvironment of cancer stem cells: perspectives on cancer stem cell targeting. Genes Dis. 2024;11(3): 101043.
Desai N, Hasan U, Jeyashree K, Mani R, Chauhan M, Basu SM, et al. Biomaterial-based platforms for modulating immune components against cancer and cancer stem cells. Acta Biomater. 2023;161:1–36.
Vermeulen L, De Sousa E, Melo F, Van Der Heijden M, Cameron K, De Jong JH, Borovski T, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010;12(5):468–76.
Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 2014;14(3):342–56.
Lu H, Clauser KR, Tam WL, Fröse J, Ye X, Eaton EN, et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol. 2014;16(11):1105–17.
Zhou W, Ke SQ, Huang Z, Flavahan W, Fang X, Paul J, et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol. 2015;17(2):170–82.
Sansone P, Berishaj M, Rajasekhar VK, Ceccarelli C, Chang Q, Strillacci A, et al. Evolution of cancer stem-like cells in endocrine-resistant metastatic breast cancers is mediated by stromal microvesicles. Cancer Res. 2017;77(8):1927–41.
Shi X, Valizadeh A, Mir SM, Asemi Z, Karimian A, Majidina M, et al. MiRNA-29a reverses P-glycoprotein-mediated drug resistance and inhibits proliferation via up-regulation of PTEN in colon cancer cells. Eur J Pharmacol. 2020;880: 173138.
Nieto MA, Huang RY-J, Jackson RA, Thiery JP. EMT: 2016 Cell. 2016;166(1):21–45.
Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212–26.
Shibue T, Weinberg RA. EMT, CSCS, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611–29.
Roy S, Sunkara RR, Parmar MY, Shaikh S, Waghmare SK. EMT imparts cancer stemness and plasticity: new perspectives and therapeutic potential. Front Bioscience-Landmark. 2020;26(2):238–65.
Nobili S, Lapucci A, Landini I, Coronnello M, Roviello G, Mini E, editors. Role of ATP-binding cassette transporters in cancer initiation and progression. Seminars in cancer biology. Elsevier; 2020.
Silvestrini A, Meucci E, Martorana GE, Giardina B, Mordente A. Cancer stem cell and ATP-Binding cassette: which role in chemoresistance?? Advances in cancer stem cell biology. 2012:267–88.
Jiang Z-S, Sun Y-Z, Wang S-M, Ruan J-S. Epithelial-mesenchymal transition: potential regulator of ABC transporters in tumor progression. J Cancer. 2017;8(12):2319.
Saxena M, Stephens MA, Pathak H, Rangarajan A. Transcription factors that mediate epithelial–mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2011;2(7):e179–e.
Lindner D, editor. Editor animal models and the tumor microenvironment: studies of tumor–Host symbiosis. Seminars in oncology. Elsevier; 2014.
Li J, Liu H, Yu J, Yu H. Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells. Mol Med Rep. 2015;12(1):192–8.
Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D, et al. Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res. 2012;10(12):1597–606.
Cai J, Tian A-X, Wang Q-S, Kong P-Z, Du X, Li X-Q, et al. FOXF2 suppresses the FOXC2-mediated epithelial–mesenchymal transition and multidrug resistance of basal-like breast cancer. Cancer Lett. 2015;367(2):129–37.
Kaşıkcı E, Aydemir E, Bayrak ÖF, Şahin F. Inhibition of migration, invasion and drug resistance of pancreatic adenocarcinoma cells – role of snail, slug and twist and small molecule inhibitors. Onco Targets Ther. 2020;13:5763–77.
Lazarova D, Bordonaro M. ZEB1 mediates drug resistance and EMT in p300-deficient CRC. J Cancer. 2017;8(8):1453–9.
Bremnes RM, Dønnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol. 2011;6(1):209–17.
Guan J, Zhang H, Wen Z, Gu Y, Cheng Y, Sun Y, et al. Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells. Cancer Lett. 2014;345(1):132–9.
Sui H, Zhu L, Deng W, Li Q. Epithelial-mesenchymal transition and drug resistance: role, molecular mechanisms, and therapeutic strategies. Oncol Res Treat. 2014;37(10):584–9.
Jiao M, Nan K-J. Activation of PI3 kinase/Akt/HIF-1α pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma. Int J Oncol. 2012;40(2):461–8.
Kosuri K, Wu X, Wang L, Villalona-Calero M, Otterson G. An epigenetic mechanism for capecitabine resistance in mesothelioma. Biochem Biophys Res Commun. 2010;391(3):1465–70.
Alzahrani SM, Al Doghaither HA, Al-Ghafari AB, Pushparaj PN. 5–fluorouracil and capecitabine therapies for the treatment of colorectal cancer. Oncol Rep. 2023;50(4):175.
Kumar A, Singh AK, Singh H, Thareja S, Kumar P. Regulation of thymidylate synthase: an approach to overcome 5-FU resistance in colorectal cancer. Med Oncol. 2022;40(1):3.
Blondy S, David V, Verdier M, Mathonnet M, Perraud A, Christou N. 5-fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes. Cancer Sci. 2020;111(9):3142–54.
Kurasaka C, Nishizawa N, Ogino Y, Sato A. Trapping of 5-fluorodeoxyuridine monophosphate by thymidylate synthase confers resistance to 5-fluorouracil. ACS Omega. 2022;7(7):6046–52.
Kurasaka C, Ogino Y, Sato A. Molecular mechanisms and tumor biological aspects of 5-fluorouracil resistance in HCT116 human colorectal cancer cells. Int J Mol Sci. 2021;22(6): 2916.
Che J, Pan L, Yang X, Liu Z, Huang L, Wen C, et al. Thymidine phosphorylase expression and prognosis in colorectal cancer treated with 5–fluorouracil–based chemotherapy: A meta–analysis. Mol Clin Oncol. 2017;7(6):943–52.
Furukawa T, Tabata S, Yamamoto M, Kawahara K, Shinsato Y, Minami K, et al. Thymidine phosphorylase in cancer aggressiveness and chemoresistance. Pharmacol Res. 2018;132:15–20.
Saif MW, Syrigos KN, Katirtzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs. 2009;18(3):335–48.
Sharma V, Gupta SK, Verma M. Dihydropyrimidine dehydrogenase in the metabolism of the anticancer drugs. Cancer Chemother Pharmacol. 2019;84(6):1157–66.
Verma H, Narendra G, Raju B, Singh PK, Silakari O. Dihydropyrimidine dehydrogenase-mediated resistance to 5-fluorouracil: mechanistic investigation and solution. ACS Pharmacol Transl Sci. 2022;5(11):1017–33.
Maslarinou A, Manolopoulos VG, Ragia G. Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm? Front Pharmacol. 2023;14:1184523.
Cui Z, He S, Wen F, Lu L, Xu L, Wu H, et al. Dihydropyrimidine dehydrogenase (DPD) as a bridge between the immune microenvironment of colon cancers and 5-FU resistance. Frontiers in Bioscience-Landmark. 2023;28(4): 80.
Gmeiner WH, Okechukwu CC. Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects. Cancer Drug Resist. 2023;6(2):257.
Kciuk M, Marciniak B, Kontek R. Irinotecan—still an important player in cancer chemotherapy: a comprehensive overview. Int J Mol Sci. 2020;21(14): 4919.
Capello M, Lee M, Wang H, Babel I, Katz MH, Fleming JB, et al. Carboxylesterase 2 as a determinant of response to irinotecan and neoadjuvant FOLFIRINOX therapy in pancreatic ductal adenocarcinoma. J Natl Cancer Inst. 2015;107(8): djv132.
Xie F-W, Peng Y-H, Chen X, Chen X, Li J, Yu Z-Y, et al. Regulation and expression of aberrant methylation on Irinotecan metabolic genes CES2, UGT1A1 and GUSB in the in-vitro cultured colorectal cancer cells. Biomed Pharmacother. 2014;68(1):31–7.
Xiao D, Yang D, Guo L, Lu W, Charpentier M, Yan B. Regulation of carboxylesterase‐2 expression by p53 family proteins and enhanced anti‐cancer activities among 5‐fluorouracil, Irinotecan and Doxazolidine prodrug. Br J Pharmacol. 2013;168(8):1989–99.
Shaojun C, Li H, Haixin H, Guisheng L. Expression of topoisomerase 1 and carboxylesterase 2 correlates with Irinotecan treatment response in metastatic colorectal cancer. Cancer Biol Ther. 2018;19(3):153–9.
de Man FM, Goey AK, van Schaik RH, Mathijssen RH, Bins S. Individualization of Irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet. 2018;57:1229–54.
Paulík A, Grim J, Filip S. Predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer. Acta Medica (Hradec Kralove). 2012;55(4):153–9.
Tagawa K, Maruo Y, Mimura Y, Ikushiro S. Effects of common genetic variants of human uridine diphosphate glucuronosyltransferase subfamilies on irinotecan glucuronidation. Toxicol Mech Methods. 2023;33(3):197–205.
Li W, Zhang H, Assaraf YG, Zhao K, Xu X, Xie J, et al. Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies. Drug Resist Updat. 2016;27:14–29.
Lin L, Yee SW, Kim RB, Giacomini KM. Slc transporters as therapeutic targets: emerging opportunities. Nat Rev Drug Discov. 2015;14(8):543–60.
International Transporter Consortium; Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215–36. https://doi.org/10.1038/nrd3028.
Ceballos MP, Rigalli JP, Ceré LI, Semeniuk M, Catania VA, Ruiz ML. ABC transporters: regulation and association with multidrug resistance in hepatocellular carcinoma and colorectal carcinoma. Curr Med Chem. 2019;26(7):1224–50.
Sun L, Ke J, He Z, Chen Z, Huang Q, Ai W, et al. HES1 promotes colorectal cancer cell resistance to 5-Fu by inducing of EMT and ABC transporter proteins. J Cancer. 2017;8(14):2802.
Gao Q, Li X-x, Xu Y-m, Zhang J-z, Qin Y-q, Fang J. IRE1α-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells. Cancer Lett. 2020;476:67–74.
Wang JQ, Wu ZX, Yang Y, Teng QX, Li YD, Lei ZN, et al. ATP-binding cassette (ABC) transporters in cancer: A review of recent updates. J Evidence‐Based Med. 2021;14(3):232–56.
Liu X. ABC family transporters. In: Liu X, Pan G, editors. Drug transporters in drug disposition, effects and toxicity. Advances in experimental medicine and biology, vol 1141. Springer, Singapore; 2019. https://doi.org/10.1007/978-981-13-7647-4_2.
Zhou H, Lin C, Zhang Y, Zhang X, Zhang C, Zhang P, et al. Mir-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR 1/P‐gp expression. Cell Prolif. 2017;50(3): e12341.
Du J, He Y, Li P, Wu W, Chen Y, Ruan H. IL-8 regulates the doxorubicin resistance of colorectal cancer cells via modulation of multidrug resistance 1 (MDR1). Cancer Chemother Pharmacol. 2018;81:1111–9.
Wang T, Chen Z, Zhu Y, Pan Q, Liu Y, Qi X, et al. Inhibition of transient receptor potential channel 5 reverses 5-fluorouracil resistance in human colorectal cancer cells. J Biol Chem. 2015;290(1):448–56.
Westover D, Li F. New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies. J Exp Clin Cancer Res. 2015;34:1–9.
Guo J, Wang Q, Zhang Y, Sun W, Zhang S, Li Y, et al. Functional daidzein enhances the anticancer effect of topotecan and reverses BCRP-mediated drug resistance in breast cancer. Pharmacol Res. 2019;147: 104387.
Ozawa S, Miura T, Terashima J, Habano W. Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review. Cancer Drug Resist. 2021;4(4):946.
Lu JF, Pokharel D, Bebawy M. MRP1 and its role in anticancer drug resistance. Drug Metab Rev. 2015;47(4):406–19.
Cole SP. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future. Annu Rev Pharmacol Toxicol. 2014;54:95–117.
Blythe AJ, Fox AH, Bond CS. The ins and outs of LncRNA structure: how, why and what comes next? Biochim Et Biophys Acta (BBA)-Gene Regul Mech. 2016;1859(1):46–58.
Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics Proteomics Bioinf. 2016;14(1):42–54.
Mattick JS, Amaral PP, Carninci P, Carpenter S, Chang HY, Chen L-L, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023;24(6):430–47.
Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009;458(7235):223–7.
Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, et al. The GENCODE v7 catalog of human long noncoding rnas: analysis of their gene structure, evolution, and expression. Genome Res. 2012;22(9):1775–89.
Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011;25(18):1915–27.
Alvarez-Dominguez JR, Lodish HF. Emerging mechanisms of long noncoding RNA function during normal and malignant hematopoiesis. Blood. 2017;130(18):1965–75.
Zampetaki A, Albrecht A, Steinhofel K. Long non-coding RNA structure and function: is there a link?? Front Physiol. 2018;9: 1201.
Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43(6):904–14.
Ahmad P, Bensaoud C, Mekki I, Rehman MU, Kotsyfakis M. Long non-coding RNAs and their potential roles in the vector-host-pathogen triad. Life (Basel). 2021;11(1):56. https://doi.org/10.3390/life11010056.
Hu ZY, Wang XY, Guo WB, Xie LY, Huang YQ, Liu YP, et al. Long non-coding RNA MALAT1 increases AKAP-9 expression by promoting SRPK1-catalyzed SRSF1 phosphorylation in colorectal cancer cells. Oncotarget. 2016;7(10):11733–43.
He Y, Luo Y, Liang B, Ye L, Lu G, He W. Potential applications of MEG3 in cancer diagnosis and prognosis. Oncotarget. 2017;8(42):73282–95.
Cao Y, Shi H, Ren F, Jia Y, Zhang R. Long non-coding RNA CCAT1 promotes metastasis and poor prognosis in epithelial ovarian cancer. Exp Cell Res. 2017;359(1):185–94.
Dong X, Yang Z, Yang H, Li D, Qiu X. Long non-coding RNA MIR4435-2HG promotes colorectal cancer proliferation and metastasis through miR-206/YAP1 axis. Front Oncol. 2020;10: 160.
Yan S, Yue Y, Wang J, Li W, Sun M, Gu C, et al. LINC00668 promotes tumorigenesis and progression through sponging miR-188-5p and regulating USP47 in colorectal cancer. Eur J Pharmacol. 2019;858: 172464.
Ahadi A. Functional roles of LncRNAs in the pathogenesis and progression of cancer. Genes Dis. 2021;8(4):424–37.
Moayedi K, Orandi S, Ebrahimi R, Tanhapour M, Moradi M, Abbastabar M, et al. A novel approach to type 3 diabetes mechanism: the interplay between noncoding RNAs and insulin signaling pathway in Alzheimer’s disease. J Cell Physiol. 2022;237(7):2838–61.
Jin H, Du W, Huang W, Yan J, Tang Q, Chen Y, et al. LncRNA and breast cancer: progress from identifying mechanisms to challenges and opportunities of clinical treatment. Mol Ther. 2021;25:613–37.
Chen R, Li W-X, Sun Y, Duan Y, Li Q, Zhang A-X, et al. Comprehensive analysis of LncRNA and mRNA expression profiles in lung cancer. Clin Lab. 2017;63(2):313–20.
Jiang MC, Ni JJ, Cui WY, Wang BY, Zhuo W. Emerging roles of LncRNA in cancer and therapeutic opportunities. Am J Cancer Res. 2019;9(7):1354–66.
Sarfi M, Abbastabar M, Khalili E. Increased expression of urinary exosomal LnCRNA TUG-1 in early bladder cancer. Gene Rep. 2021;22: 101010.
Pardini B, Sabo AA, Birolo G, Calin GA. Noncoding RNAs in extracellular fluids as cancer biomarkers: the new frontier of liquid biopsies. Cancers. 2019;11(8):1170.
Wang WT, Sun YM, Huang W, He B, Zhao YN, Chen YQ. Genome-wide long non-coding RNA analysis identified circulating LncRNAs as novel non-invasive diagnostic biomarkers for gynecological disease. Sci Rep. 2016;6:23343.
Xu K, Jiang X, Ariston Gabriel AN, Li X, Wang Y, Xu S. Evolving landscape of long non-coding RNAs in cerebrospinal fluid: a key role from diagnosis to therapy in brain tumors. Front Cell Dev Biol. 2021;9:737670.
Luo Y, Chen JJ, Lv Q, Qin J, Huang YZ, Yu MH, et al. Long non-coding RNA NEAT1 promotes colorectal cancer progression by competitively binding miR-34a with SIRT1 and enhancing the Wnt/β-catenin signaling pathway. Cancer Lett. 2019;440–441:11–22.
Ye M, Zhao L, Zhang L, Wu S, Li Z, Qin Y, et al. LncRNA NALT1 promotes colorectal cancer progression via targeting PEG10 by sponging microRNA-574-5p. Cell Death Dis. 2022;13(11):960.
Zhu X, Bu F, Tan T, Luo Q, Zhu J, Lin K, et al. Long noncoding RNA RP11-757G1.5 sponges miR-139-5p and upregulates YAP1 thereby promoting the proliferation and liver, spleen metastasis of colorectal cancer. J Exp Clin Cancer Res. 2020;39(1):207.
Xu Y, Zhang X, Hu X, Zhou W, Zhang P, Zhang J, et al. The effects of LncRNA MALAT1 on proliferation, invasion and migration in colorectal cancer through regulating SOX9. Mol Med. 2018;24:1–15.
Zhang M, Li Y, Wang H, Yu W, Lin S, Guo J. LncRNA SNHG5 affects cell proliferation, metastasis and migration of colorectal cancer through regulating miR-132-3p/CREB5. Cancer Biol Ther. 2019;20(4):524–36.
Wang A-H, Fan W-J, Fu L, Wang X-T. LncRNA PCAT-1 regulated cell proliferation, invasion, migration and apoptosis in colorectal cancer through targeting miR-149-5p. Eur Rev Med Pharmacol Sci. 2019;23:19.
Zheng XY, Cao MZ, Ba Y, Li YF, Ye JL. Lncrna testis-specific transcript, Y-linked 15 (TTTY15) promotes proliferation, migration and invasion of colorectal cancer cells via regulating miR-29a-3p/DVL3 axis. Cancer Biomark. 2021;31(1):1–11.
Chen D, Sun Q, Zhang L, Zhou X, Cheng X, Zhou D, et al. The lncRNA HOXA11-AS functions as a competing endogenous RNA to regulate PADI2 expression by sponging miR-125a-5p in liver metastasis of colorectal cancer. Oncotarget. 2017;8(41):70642.
Xu J, Meng Q, Li X, Yang H, Xu J, Gao N, et al. Long noncoding RNA MIR17HG promotes colorectal cancer progression via miR-17-5p. Cancer Res. 2019;79(19):4882–95.
Chen D-l, Lu Y-x, Zhang J-x, Wei X-l, Wang F, Zeng Z-l, et al. Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a CeRNA for microRNA-215 to regulate ZEB2 expression. Theranostics. 2017;7(19):4836.
Zhang Y, Huang W, Yuan Y, Li J, Wu J, Yu J, et al. Long non-coding RNA H19 promotes colorectal cancer metastasis via binding to hnRNPA2B1. J Exp Clin Cancer Res. 2020;39(1):1–15.
Fang X, Xu Y, Li K, Liu P, Zhang H, Jiang Y et al. Exosomal lncRNA PCAT1 promotes tumor circulating cell-mediated colorectal cancer liver metastasis by regulating the activity of the miR-329-3p/Netrin-1-CD146 complex. Journal of Immunology Research. 2022;2022.
Zhan T, Cheng X, Zhu Q, Han Z, Zhu K, Tan J, et al. LncRNA LOC105369504 inhibits tumor proliferation and metastasis in colorectal cancer by regulating PSPC1. Cell Death Discov. 2023;9(1):89.
Yin DD, Liu ZJ, Zhang E, Kong R, Zhang ZH, Guo RH. Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. Tumour Biol. 2015;36(6):4851–9.
Amirmahani F, Asadi MH, Jannat Alipoor F. LncRNA MIAT promotes the proliferation and invasion of colorectal cancer via suppressing apoptosis and senescence. Middle East J Cancer. 2023;14(2):219–29.
Xu M, Xu X, Pan B, Chen X, Lin K, Zeng K, et al. LncRNA SATB2-AS1 inhibits tumor metastasis and affects the tumor immune cell microenvironment in colorectal cancer by regulating SATB2. Mol Cancer. 2019;18(1):135.
Zhang C, Wang L, Jin C, Zhou J, Peng C, Wang Y, et al. Long non-coding RNA Lnc-LALC facilitates colorectal cancer liver metastasis via epigenetically silencing LZTS1. Cell Death Dis. 2021;12(2):224.
Li J, Ji Y, Chen N, Wang H, Fang C, Yin X, et al. A specific upregulated long noncoding RNA in colorectal cancer promotes cancer progression. JCI Insight. 2022;7(15):e158855. https://doi.org/10.1172/jci.insight.158855.
Wang B, Chen W, Zhao Z, Sun Y, Huang Y. Lncrna-DANCR promotes growth and metastasis of colorectal cancer via activating epithelial-mesenchymal transition process. Transl Cancer Res. 2019;8(7):2517.
Xie J, Wang J-J, Li Y-J, Wu J, Gu X-J, Yang X-R. LncRNA GAS5 suppresses colorectal cancer progress by target miR-21/LIFR axis. Evidence‐Based Complement Altern Med. 2022;2022(1):3298939.
Corrà F, Agnoletto C, Minotti L, Baldassari F, Volinia S. The network of non-coding RNAs in cancer drug resistance. Front Oncol. 2018;8: 327.
Amiri R, Nabi PN, Fazilat A, Roshani F, Kararoudi AN, Hemmati-Dinarvand M, et al. Crosstalk between miRNAs and signaling pathways in the development of drug resistance in breast cancer. Horm Mol Biol Clin Investig. 2024. https://doi.org/10.1515/hmbci-2024-0066.
Bian Z, Jin L, Zhang J, Yin Y, Quan C, Hu Y, et al. Lncrna—UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p. Sci Rep. 2016;6(1):23892.
Jiang X, Li Q, Zhang S, Song C, Zheng P. Long noncoding RNA GIHCG induces cancer progression and chemoresistance and indicates poor prognosis in colorectal cancer. Onco Targets Ther. 2019;12:1059.
Qiao L, Liu X, Tang Y, Zhao Z, Zhang J, Liu H. Knockdown of long non-coding RNA prostate cancer-associated NcRNA transcript 1 inhibits multidrug resistance and c-Myc-dependent aggressiveness in colorectal cancer Caco-2 and HT-29 cells. Mol Cell Biochem. 2018;441:99–108.
Fan H, Zhu JH, Yao XQ. Knockdown of long non–coding RNA PVT1 reverses multidrug resistance in colorectal cancer cells. Mol Med Rep. 2018;17(6):8309–15.
Tang D, Yang Z, Long F, Luo L, Yang B, Zhu R, et al. Inhibition of MALAT1 reduces tumor growth and metastasis and promotes drug sensitivity in colorectal cancer. Cell Signal. 2019;57:21–8.
Li Y, Huang S, Li Y, Zhang W, He K, Zhao M, et al. Decreased expression of lncRNA SLC25A25-AS1 promotes proliferation, chemoresistance, and EMT in colorectal cancer cells. Tumor Biol. 2016;37:14205–15.
Lee H, Kim C, Ku J-L, Kim W, Yoon SK, Kuh H-J, et al. A long non-coding RNA SnaR contributes to 5-fluorouracil resistance in human colon cancer cells. Mol Cells. 2014;37(7):540.
Li J, Li X, Cen C, Ai X, Lin C, Hu G. The long non-coding RNA ENST00000547547 reduces 5-fluorouracil resistance of colorectal cancer cells via competitive binding to microRNA-31. Oncol Rep. 2018;39(1):217–26.
Bian Z, Zhang J, Li M, Feng Y, Yao S, Song M, et al. Long non-coding RNA LINC00152 promotes cell proliferation, metastasis, and confers 5-FU resistance in colorectal cancer by inhibiting miR-139-5p. Oncogenesis. 2017;6(11): 395.
Yue B, Cai D, Liu C, Fang C, Yan D. Linc00152 functions as a competing endogenous RNA to confer oxaliplatin resistance and holds prognostic values in colon cancer. Mol Ther. 2016;24(12):2064–77.
Li P, Zhang X, Wang H, Wang L, Liu T, Du L, et al. MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2. Mol Cancer Ther. 2017;16(4):739–51.
Ren J, Ding L, Zhang D, Shi G, Xu Q, Shen S, et al. Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal LncRNA H19. Theranostics. 2018;8(14):3932.
Wang H, Li H, Zhang L, Yang D. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis. Biomed Pharmacother. 2018;106:1607–15.
Li L, Shang J, Zhang Y, Liu S, Peng Y, Zhou Z, et al. MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis. Oncol Rep. 2017;38(3):1383–92.
Ping G, Xiong W, Zhang L, Li Y, Zhang Y, Zhao Y. Silencing long noncoding RNA PVT1 inhibits tumorigenesis and cisplatin resistance of colorectal cancer. Am J Transl Res. 2018;10(1):138.
Xiao Z, Qu Z, Chen Z, Fang Z, Zhou K, Huang Z, et al. LncRNA HOTAIR is a prognostic biomarker for the proliferation and chemoresistance of colorectal cancer via MiR-203a-3p-mediated Wnt/ss-catenin signaling pathway. Cell Physiol Biochem. 2018;46(3):1275–85.
Wu K-f, Liang W-C, Feng L, Pang J-x, Waye MM-Y, Zhang J-F, et al. H19 mediates methotrexate resistance in colorectal cancer through activating Wnt/β-catenin pathway. Exp Cell Res. 2017;350(2):312–7.
Li C, Gao Y, Li Y, Ding D. TUG1 mediates methotrexate resistance in colorectal cancer via miR-186/CPEB2 axis. Biochem Biophys Res Commun. 2017;491(2):552–7.
Zhu J, Zhang R, Yang D, Li J, Yan X, Jin K, et al. Knockdown of long non-coding RNA XIST inhibited doxorubicin resistance in colorectal cancer by upregulation of miR-124 and downregulation of SGK1. Cell Physiol Biochem. 2018;51(1):113–28.
Lu Y, Zhao X, Liu Q, Li C, Graves-Deal R, Cao Z, et al. LncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling. Nat Med. 2017;23(11):1331–41.
Doxtater KD, Tripathi MK. LncRNA UCA1 as a potential therapeutic target for drug resistance in colorectal cancer. Cancer Res. 2023;83(7Supplement):2854.
Yang Y-n, Zhang R, Du J-w, Yuan H-h, Li Y-j, Wei X-l, et al. Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer. Cancer Cell Int. 2018;18:1–11.
Ramli S, Sim MS, Guad RM, Gopinath SCB, Subramaniyan V, Fuloria S, et al. Long noncoding RNA UCA1 in Gastrointestinal cancers: molecular regulatory roles and patterns, mechanisms, and interactions. J Oncol. 2021;2021:1–15.
Amirinejad R, Rezaei M, Shirvani-Farsani Z. An update on long intergenic noncoding RNA p21: a regulatory molecule with various significant functions in cancer. Cell Biosci. 2020;10(1):82.
Silva-Fisher JM, Dang HX, White NM, Strand MS, Krasnick BA, Rozycki EB, et al. Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression. Nat Commun. 2020;11(1):2156.
Cabanski CR, White NM, Dang HX, Silva-Fisher JM, Rauck CE, Cicka D, et al. Pan-cancer transcriptome analysis reveals long noncoding RNAs with conserved function. RNA Biol. 2015;12(6):628–42.
White NM, Cabanski CR, Silva-Fisher JM, Dang HX, Govindan R, Maher CA. Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer. Genome Biol. 2014;15:1–16.
Zhang PF, Wu J, Wu Y, Huang W, Liu M, Dong ZR, et al. The lncRNA SCARNA2 mediates colorectal cancer chemoresistance through a conserved microRNA-342‐3p target sequence. J Cell Physiol. 2019;234(7):10157–65.
Weng W, Okugawa Y, Toden S, Toiyama Y, Kusunoki M, Goel A. FOXM1 and FOXQ1 are promising prognostic biomarkers and novel targets of tumor-suppressive miR-342 in human colorectal cancer. Clin Cancer Res. 2016;22(19):4947–57.
Lai X, Gupta SK, Schmitz U, Marquardt S, Knoll S, Spitschak A, et al. MiR-205-5p and miR-342-3p cooperate in the repression of the E2F1 transcription factor in the context of anticancer chemotherapy resistance. Theranostics. 2018;8(4):1106.
Ge X, Chen Y, Liao X, Liu D, Li F, Ruan H, et al. Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer. Med Oncol. 2013;30:1–6.
Qiao L, Liu X, Tang Y, Zhao Z, Zhang J, Feng Y. Down regulation of the long non-coding RNA PCAT-1 induced growth arrest and apoptosis of colorectal cancer cells. Life Sci. 2017;188:37–44.
Zhou Q, Hou Z, Zuo S, Zhou X, Feng Y, Sun Y, et al. LUCAT1 promotes colorectal cancer tumorigenesis by targeting the ribosomal protein L40-MDM 2‐p53 pathway through binding with UBA 52. Cancer Sci. 2019;110(4):1194–207.
Thorenoor N, Faltejskova-Vychytilova P, Hombach S, Mlcochova J, Kretz M, Svoboda M, et al. Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer. Oncotarget. 2016;7(1):622.
Shan TD, Tian ZB, Li Q, Jiang YP, Liu FG, Sun XG, et al. Long intergenic noncoding RNA 00908 promotes proliferation and inhibits apoptosis of colorectal cancer cells by regulating KLF5 expression. J Cell Physiol. 2021;236(2):889–99.
Zhang XT, Pan SX, Wang AH, Kong QY, Jiang KT, Yu ZB. Long non-coding RNA (lncRNA) X-inactive specific transcript (XIST) plays a critical role in predicting clinical prognosis and progression of colorectal cancer. Med Sci Monit. 2019;25:6429–35.
Xiao M, Liang Z, Yin Z. Long non–coding RNA ZFPM2–AS1 promotes colorectal cancer progression by sponging miR–137 to regulate TRIM24. Mol Med Rep. 2021;23(2):1.
Wang J, Zhu J, Dong M, Yu H, Dai X, Li K. Knockdown of tripartite motif containing 24 by lentivirus suppresses cell growth and induces apoptosis in human colorectal cancer cells. Oncol Res. 2014;22(1):39.
Xie W, Zhang Y, Wang B, Hu Y, Zhan B, Wei F, et al. Tripartite motif containing 24 regulates cell proliferation in colorectal cancer through YAP signaling. Cancer Med. 2020;9(17):6367–76.
Du T, Gao Q, Zhao Y, Gao J, Li J, Wang L, et al. Long non-coding RNA LINC02474 affects metastasis and apoptosis of colorectal cancer by inhibiting the expression of GZMB. Front Oncol. 2021;11: 651796.
Chiusolo V, Jacquemin G, Yonca Bassoy E, Vinet L, Liguori L, Walch M, et al. Granzyme B enters the mitochondria in a Sam50-, Tim22-and mtHsp70-dependent manner to induce apoptosis. Cell Death Differ. 2017;24(4):747–58.
Carrieri C, Cimatti L, Biagioli M, Beugnet A, Zucchelli S, Fedele S, et al. Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat. Nature. 2012;491(7424):454–7.
Hu J, Shan Y, Ma J, Pan Y, Zhou H, Jiang L, et al. LncRNA ST3Gal6-AS1/ST3Gal6 axis mediates colorectal cancer progression by regulating α‐2, 3 sialylation via PI3K/Akt signaling. Int J Cancer. 2019;145(2):450–60.
Zhang X, Tang N, Hadden TJ, Rishi AK, Akt. FoxO and regulation of apoptosis. Biochim Et Biophys Acta (BBA)-Molecular Cell Res. 2011;1813(11):1978–86.
Cheng K, Zhao Z, Wang G, Wang J, Zhu W. LncRNA GAS5 inhibits colorectal cancer cell proliferation via the miR–182–5p/FOXO3a axis. Oncol Rep. 2018;40(4):2371–80.
Cao M-Q, You A-B, Zhu X-D, Zhang W, Zhang Y-Y, Zhang S-Z, et al. miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a. J Hematol Oncol. 2018;11(1):1–12.
Zhang Y-H, Fu J, Zhang Z-J, Ge C-C, Yi Y. LncRNA-LINC00152 down-regulated by miR-376c-3p restricts viability and promotes apoptosis of colorectal cancer cells. Am J Transl Res. 2016;8(12):5286.
Chen Z, Cai X, Chang L, Xia Y, Wang L, Hou Y, et al. LINC00152 is a potential biomarker involved in the modulation of biological characteristics of residual colorectal cancer cells following chemoradiotherapy. Oncol Lett. 2018;15(4):4177–84.
Lian Y, Yan C, Xu H, Yang J, Yu Y, Zhou J, et al. A novel lncrna, LINC00460, affects cell proliferation and apoptosis by regulating KLF2 and CUL4A expression in colorectal cancer. Mol Ther Nucleic Acids. 2018;12:684–97.
Lepage C, Léger D, Bertrand J, Martin F, Beneytout J, Liagre B. Diosgenin induces death receptor-5 through activation of p38 pathway and promotes TRAIL-induced apoptosis in colon cancer cells. Cancer Lett. 2011;301(2):193–202.
Wang J, Huang F, Bai Z, Chi B, Wu J, Chen X. Curcumol inhibits growth and induces apoptosis of colorectal cancer LoVo cell line via IGF-1R and p38 MAPK pathway. Int J Mol Sci. 2015;16(8):19851–67.
Chiacchiera F, Grossi V, Cappellari M, Peserico A, Simonatto M, Germani A, et al. Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models. Cancer Lett. 2012;324(1):98–108.
Liang H, Zhao Q, Zhu Z, Zhang C, Zhang H. Long noncoding RNA LINC00958 suppresses apoptosis and radiosensitivity of colorectal cancer through targeting miR-422a. Cancer Cell Int. 2021;21:1–15.
Wei W-T, Nian X-X, Wang S-Y, Jiao H-L, Wang Y-X, Xiao Z-Y, et al. miR-422a inhibits cell proliferation in colorectal cancer by targeting AKT1 and MAPK1. Cancer Cell Int. 2017;17:1–12.
Zhu S, Mao J, Zhang X, Wang P, Zhou Y, Tong J, et al. CAF-derived exosomal lncRNA FAL1 promotes chemoresistance to oxaliplatin by regulating autophagy in colorectal cancer. Dig Liver Dis. 2024;56(2):330–42.
Mirza-Aghazadeh-Attari M, Ostadian C, Saei AA, Mihanfar A, Darband SG, Sadighparvar S, et al. DNA damage response and repair in ovarian cancer: potential targets for therapeutic strategies. DNA Repair. 2019;80:59–84.
Mihanfar A, Darband SG, Sadighparvar S, Kaviani M, Mirza-Aghazadeh-Attari M, Yousefi B, et al. In vitro and in vivo anticancer effects of syringic acid on colorectal cancer: possible mechanistic view. Chemico-Biological Interactions. 2021;337: 109337.
Sharma V, Khurana S, Kubben N, Abdelmohsen K, Oberdoerffer P, Gorospe M, et al. A BRCA 1-interacting lnc RNA regulates homologous recombination. EMBO Rep. 2015;16(11):1520–34.
Kaller M, Götz U, Hermeking H. Loss of p53-inducible long non-coding RNA LINC01021 increases chemosensitivity. Oncotarget. 2017;8(61):102783.
Ma S, Yang D, Liu Y, Wang Y, Lin T, Li Y, et al. LncRNA BANCR promotes tumorigenesis and enhances adriamycin resistance in colorectal cancer. Aging. 2018;10(8):2062.
Li Y, Yuan S, Liu J, Wang Y, Zhang Y, Chen X, et al. CSE1L silence inhibits the growth and metastasis in gastric cancer by repressing GPNMB via positively regulating transcription factor MITF. J Cell Physiol. 2020;235(3):2071–9.
Gao H, Song X, Kang T, Yan B, Feng L, Gao L, et al. Long noncoding RNA CRNDE functions as a competing endogenous RNA to promote metastasis and oxaliplatin resistance by sponging miR-136 in colorectal cancer. Onco Targets Ther. 2017;10:205–16. https://doi.org/10.2147/OTT.S116178.
Chaudhary R, Gryder B, Woods WS, Subramanian M, Jones MF, Li XL, et al. Prosurvival long noncoding RNA PINCR regulates a subset of p53 targets in human colorectal cancer cells by binding to matrin 3. Elife. 2017;6:e23244.
Shi L, Sun J, Kinomura A, Fukuto A, Horikoshi Y, Tashiro S. Matrin3 promotes homologous recombinational repair by regulation of RAD51. J Biochem. 2019;166(4):343–51.
Liu R, Zhang Q, Shen L, Chen S, He J, Wang D, et al. Long noncoding RNA lnc-RI regulates DNA damage repair and radiation sensitivity of CRC cells through NHEJ pathway. Cell Biol Toxicol. 2020;36:493–507.
Yao P, Wu Y, Zhao K, Li Y, Cao J, Xing C. The feedback loop of ANKHD1/lncRNA MALAT1/YAP1 strengthens the radioresistance of CRC by activating YAP1/AKT signaling. Cell Death Dis. 2022; 13: 103. Leukemia. 2018;32:2250-62.
Stanley L. Drug metabolism. Pharmacognosy: Elsevier; 2024. pp. 597–624.
Wang Y, Fang Z, Hong M, Yang D, Xie W. Long-noncoding RNAs (lncRNAs) in drug metabolism and disposition, implications in cancer chemo-resistance. Acta Pharm Sin B. 2020;10(1):105–12.
Liu LC, Wang YL, Lin PL, Zhang X, Cheng WC, Liu SH, et al. Long noncoding RNA HOTAIR promotes invasion of breast cancer cells through chondroitin sulfotransferase CHST15. Int J Cancer. 2019;145(9):2478–87.
Takahashi K, Yan IK, Wood J, Haga H, Patel T. Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Mol Cancer Res. 2014;12(10):1377–87.
Zhang XW, Bu P, Liu L, Zhang XZ, Li J. Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Biochem Biophys Res Commun. 2015;462(3):227–32.
Fang Z, Chen W, Yuan Z, Liu X, Jiang H. Lncrna-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation. Biomed Pharmacother. 2018;101:536–42.
Lan WG, Xu DH, Xu C, Ding CL, Ning FL, Zhou YL, et al. Silencing of long non-coding RNA ANRIL inhibits the development of multidrug resistance in gastric cancer cells. Oncol Rep. 2016;36(1):263–70.
Wang Y, Zhang D, Wu K, Zhao Q, Nie Y, Fan D. Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines. Mol Cell Biol. 2014;34(17):3182–93.
Hu H, Yang L, Li L, Zeng C. Long non-coding RNA KCNQ1OT1 modulates oxaliplatin resistance in hepatocellular carcinoma through miR-7-5p/ABCC1 axis. Biochem Biophys Res Commun. 2018;503(4):2400–6.
Chang L, Hu Z, Zhou Z, Zhang H. Linc00518 contributes to multidrug resistance through regulating the MiR-199a/MRP1 axis in breast cancer. Cell Physiol Biochem. 2018;48(1):16–28.
Wu X, Zheng Y, Han B, Dong X. Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361. Biomed Pharmacother. 2018;99:832–8.
Wang L, Bu P, Ai Y, Srinivasan T, Chen HJ, Xiang K, et al. A long non-coding RNA targets MicroRNA miR-34a to regulate colon cancer stem cell asymmetric division. Elife. 2016;5:e14620.
Sun J, Zhou H, Bao X, Wu Y, Jia H, Zhao H et al. lncRNA TUG1 facilitates colorectal cancer stem cell characteristics and chemoresistance by enhancing GATA6 protein stability. Stem cells international. 2021;2021.
Fu C, Li X, Han L, Xie M, Ouyang S. LncRNA PTPRG-AS1 maintains stem-cell-like features and promotes oxaliplatin resistance in colorectal cancer via regulating the miR-665 and STAT3 axis. Mol Cell Toxicol. 2024;20:35–45. https://doi.org/10.1007/s13273-022-00314-1.
Di Cecilia S, Zhang F, Sancho A, Li S, Aguiló F, Sun Y, et al. RBM5-AS1 is critical for self-renewal of colon cancer stem-like cells. Cancer Res. 2016;76(19):5615–27.
Yu Y, Nangia-Makker P, Farhana L, Majumdar AP. A novel mechanism of LncRNA and MiRNA interaction: CCAT2 regulates miR-145 expression by suppressing its maturation process in colon cancer cells. Mol Cancer. 2017;16(1):1–11.
Yu X, Mi L, Dong J, Zou J. Long intergenic non-protein-coding RNA 1567 (LINC01567) acts as a sponge against microRNA-93 in regulating the proliferation and tumorigenesis of human colon cancer stem cells. BMC Cancer. 2017;17(1):1–15.
Guo K, Gong W, Wang Q, Gu G, Zheng T, Li Y, et al. LINC01106 drives colorectal cancer growth and stemness through a positive feedback loop to regulate the Gli family factors. Cell Death Dis. 2020;11(10):869.
Zhou H, Xiong Y, Peng L, Wang R, Zhang H, Fu Z. LncRNA-cCSC1 modulates cancer stem cell properties in colorectal cancer via activation of the Hedgehog signaling pathway. J Cell Biochem. 2020;121(3):2510–24.
De Las Rivas J, Brozovic A, Izraely S, Casas-Pais A, Witz IP, Figueroa A. Cancer drug resistance induced by EMT: novel therapeutic strategies. Arch Toxicol. 2021;95(7):2279–97.
Cao H, Xu E, Liu H, Wan L, Lai M. Epithelial–mesenchymal transition in colorectal cancer metastasis: a system review. Pathol – Res Pract. 2015;211(8):557–69.
Liaghat M, Ferdousmakan S, Mortazavi SH, Yahyazadeh S, Irani A, Banihashemi S, et al. The impact of epithelial-mesenchymal transition (EMT) induced by metabolic processes and intracellular signaling pathways on chemo-resistance, metastasis, and recurrence in solid tumors. Cell Commun Signal. 2024;22(1):575.
Weng X, Ma T, Chen Q, Chen BW, Shan J, Chen W, et al. Decreased expression of H19/miR-675 ameliorates hypoxia-induced oxaliplatin resistance in colorectal cancer. Heliyon. 2024;10(5):e27027.
Li C-f, Li Y-c, Wang Y, Sun L-b. The effect of LncRNA H19/miR-194-5p axis on the epithelial-mesenchymal transition of colorectal adenocarcinoma. Cell Physiol Biochem. 2018;50(1):196–213.
Wang M, Han D, Yuan Z, Hu H, Zhao Z, Yang R, et al. Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy. Cell Death Dis. 2018;9(12):1149.
Park MS, Jeong SD, Shin CH, Cha S, Yu A, Kim EJ, et al. LINC02257 regulates malignant phenotypes of colorectal cancer via interacting with miR-1273 g-3p and YB1. Cell Death Dis. 2024;15(12):895.
Ding M, Wang W, Huo K, Song Y, Chen X, Xiang Z, et al. The role of LncRNA FEZF1-AS1 in colorectal cancer progression via the P53 signaling pathway. DNA Cell Biol. 2025;44(1):32–45.
Wu W, Li A, He H, Ye S, Zhou Z, Quan JH, et al. Long noncoding RNA LINC01550 inhibits colorectal cancer malignancy by suppressing the Wnt/β-catenin signaling pathway. J Biochem Mol Toxicol. 2024;38(8): e23774.
Shi CJ, Xue ZH, Zeng WQ, Deng LQ, Pang FX, Zhang FW, et al. LncRNA-NEF suppressed oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer through epigenetically inactivating MEK/ERK signaling. Cancer Gene Ther. 2023;30(6):855–65.
Zhang L, Wu H, Zhang Y, Xiao X, Chu F, Zhang L. Induction of lncRNA NORAD accounts for hypoxia-induced chemoresistance and vasculogenic mimicry in colorectal cancer by sponging the miR-495-3p/ hypoxia-inducible factor-1α (HIF-1α). Bioengineered. 2022;13(1):950–62.
Wang W, Zhou Z, Dai X, Wang H, Jin J, Min K, et al. LncRNA-ENST00000543604 exerts a tumor-promoting effect via miRNA 564/AEG-1 or ZNF326/EMT and predicts the prognosis of and chemotherapeutic effect in colorectal cancer. Front Oncol. 2022;12: 960481.
Wu Z-H, Wang X-L, Tang H-M, Jiang T, Chen J, Lu S, et al. Long non-coding RNA HOTAIR is a powerful predictor of metastasis and poor prognosis and is associated with epithelial-mesenchymal transition in colon cancer. Oncol Rep. 2014;32(1):395–402.
Liu Y, Sun M, Xia R, Zhang E, Liu X, Zhang Z, et al. LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer. Cell Death Dis. 2015;6(7):e1802–e.
Jiang Y, Liu G, Ye W, Xie J, Shao C, Wang X, et al. ZEB2-AS1 accelerates epithelial/mesenchymal transition through miR-1205/CRKL pathway in colorectal cancer. Cancer Biother Radiopharm. 2020;35(2):153–62.
Long F, Li X, Pan J, Ye H, Di C, Huang Y, et al. The role of LncRNA NEAT1 in human cancer chemoresistance. Cancer Cell Int. 2024;24(1):236.
Jiang P, Xu H, Xu C, Chen A, Chen L, Zhou M, et al. NEAT1 contributes to the CSC-like traits of A549/CDDP cells via activating Wnt signaling pathway. Chemico-Biological Interactions. 2018;296:154–61.
Azizidoost S, Ghaedrahmati F, Anbiyaee O, Ahmad Ali R, Cheraghzadeh M, Farzaneh M. Emerging roles for lncRNA-NEAT1 in colorectal cancer. Cancer Cell Int. 2022;22(1):209.
Ye Z, Zhou M, Tian B, Wu B, Li J. Expression of lncRNA-CCAT1, E-cadherin and N-cadherin in colorectal cancer and its clinical significance. Int J Clin Exp Med. 2015;8(3):3707.
Yang C, Pan Y, Deng SP. Downregulation of LncRNA CCAT1 enhances 5-fluorouracil sensitivity in human colon cancer cells. BMC Mol Cell Biol. 2019;20:1–11.
Sun F, Liang W, Qian J. The identification of CRNDE, H19, UCA1 and HOTAIR as the key LncRNAs involved in oxaliplatin or Irinotecan resistance in the chemotherapy of colorectal cancer based on integrative bioinformatics analysis. Mol Med Rep. 2019;20(4):3583–96.
Selem NA, Youness RA, Gad MZ. What is beyond LncRNAs in breast cancer: a special focus on colon cancer-associated transcript-1 (CCAT-1). Non-coding RNA Research. 2021;6(4):174–86.
Ghafouri-Fard S, Abak A, Anamag FT, Shoorei H, Majidpoor J, Taheri M. The emerging role of non-coding RNAs in the regulation of PI3K/AKT pathway in the carcinogenesis process. Biomed Pharmacother. 2021;137: 111279.
Tsang S, Patel T, Yustein JT. Long non-coding RNAs regulation of therapeutic resistance. Cancer Drug Resist. 2019;2(3):550.
Poursheikhani A, Abbaszadegan MR, Kerachian MA. Mechanisms of long non-coding RNA function in colorectal cancer tumorigenesis. Asia-Pac J Clin Oncol. 2021;17(1):7–23.
includes URLs from YouTube, X/Twitter, or Instagram, paste each URL on its own line. Precede it with a single, concise sentence that integrates it into the narrative.
Data Placeholders: If a chart or graph would be useful but the specific data points are missing, insert a placeholder comment in the text: “.
6. Final Output Rules
Deliverable: Generate only the final, complete article in Markdown.
Purity: Your response must begin directly with the H1 headline and end with the final sentence of the article. Do not include any of your own notes, instructions, or conversational text. The output must be perfectly clean and ready for a direct copy-paste into a CMS.
[/gpt3]
